UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No. __)

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.     )

Filed by the Registrant  x

Filed by a Party other than the Registranto

Check the appropriate box:

x

x

Preliminary Proxy Statement

o

¨

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

o

¨

Definitive Proxy Statement

o

¨

Definitive Additional Materials

o

¨

Soliciting Material under §240.14a-12

Pursuant to Sec. 240.14a-11(c) or Sec. 240.14a-12

Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund,

Tekla World Healthcare Fund

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Heathcare Opportunities Fund, Tekla World Healthcare Fund

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x

x

No fee required.

o

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1)

¨

Title of each class of securities to which transaction applies:

(2)

Aggregate number of securities to which transaction applies:

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)

Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

o

Fee paid previously with preliminary proxy materials.

o

Check box if any part of the fee is offset as provided¨

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 0-11(a)(2)Rules 14a6(i)(1) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)

Amount Previously Paid:

(2)

Form, Schedule or Registration Statement No.:

(3)

Filing Party:

(4)

Date Filed:

0-11

 



TEKLA HEALTHCARE INVESTORS
TEKLA LIFE SCIENCES INVESTORS
TEKLA HEALTHCARE OPPORTUNITIES FUND
TEKLA WORLD HEALTHCARE FUND

100 Federal Street, 19th Floor
Boston, Massachusetts 02110
(617) 772-8500

IMPORTANT SHAREHOLDER INFORMATION

We are pleased to enclose the Notice of Special Joint Meetings and Joint Proxy Statement for the Special Joint Meetings of Shareholders (with any adjournments or postponements thereof) of Tekla Healthcare Investors (“HQH”), Tekla Life Sciences Investors (“HQL”), Tekla Healthcare Opportunities Fund (“THQ”) and Tekla World Healthcare Fund (“THW”) (each a “Fund” and collectively, the “Funds”) to be held at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110. The first special meeting will be held at 9:00 a.m. ET on August 14, 2023 (the “First Meeting”) and the second special meeting will be held at 9:30 a.m. ET on August 14, 2023 (the “Second Meeting” and together with the First Meeting, the “Special Meetings”).

The Funds’ Boards of Trustees (each a “Board” and collectively, the “Boards”), including the Trustees who are not “interested persons” (the “Independent Trustees”) as defined in the Investment Company Act of 1940, as amended, are asking you to approve significant, and we believe, positive changes to the Funds.

Tekla Capital Management LLC (“Tekla”), the investment adviser to each of the Funds, has entered into a purchase agreement (the “Purchase Agreement”) with abrdn Inc. pursuant to which Tekla has agreed to sell certain assets to abrdn Inc. relating to Tekla’s advisory business for the Funds (the “Asset Transfer”). The completion of the Asset Transfer is subject to certain approvals by the shareholders of each Fund as well as other conditions set forth in the Purchase Agreement.

At the First Meeting, you will be asked to approve new investment advisory agreements between the Funds and abrdn Inc. (each a “New Advisory Agreement” and collectively, the “New Advisory Agreements”) (the “First Meeting Proposal”). Copies of the New Advisory Agreements are attached as Exhibit A to the enclosed joint proxy statement. The Funds’ investment management team, investment objectives, principal investment policies and investment advisory fees will not change as a result of the proposed change in investment adviser to abrdn Inc., an experienced manager and operator of U.S. registered closed-end funds.

In addition, at the Second Meeting, you will be asked to elect four new Trustees to serve as Trustees of the Funds (the “New Trustees”) (the “Second Meeting Proposal” and together with the First Meeting Proposal, the “Proposals”). The New Trustees would replace four of the Trustees currently serving on the Boards (the “Resigning Trustees”). Two existing Trustees would continue to serve on the Boards after completion of the Asset Transfer (each a “New Board” and collectively, the “New Boards”).

If (i) shareholders of all four of the Funds approve the New Advisory Agreements; (ii) shareholders of all four of the Funds elect the New Trustees; and (iii) the other conditions in the Purchase Agreement are satisfied or waived, abrdn Inc. will serve as investment adviser to the Funds (employing the same investment team currently employed by Tekla) and the New Trustees will replace the Resigning Trustees effective upon the completion of the Asset Transfer, which is expected to occur as soon as reasonably practicable following the affirmative vote of shareholders of the Funds, currently anticipated for the third quarter of 2023.

If (i) shareholders of one or more Funds do not approve the New Advisory Agreements; (ii) shareholders of one or more Funds do not elect the New Trustees; or (iii) the other conditions in the Purchase Agreement are not satisfied or waived, then the Asset Transfer will not be completed, the Purchase Agreement will terminate, Tekla will continue to serve as investment adviser to the Funds and all of the current Trustees will continue to serve as Trustees of the Funds.

i

The enclosed Notice of Special Joint Meetings outlines the items for you to consider and vote upon. The enclosed Joint Proxy Statement gives details about each proposal and should be carefully read and considered before you vote.

The Boards believe each Proposal is in the best interests of the Funds and their shareholders and unanimously recommend that you vote “FOR” each Proposal.

As a shareholder of record of one or more Funds as of the close of business on June 16, 2023, the record date, you are entitled to notice of, and to vote at, the Special Meetings; therefore, we are asking that you please take the time to cast your vote prior to the August 14, 2023 Special Meetings. If you have any questions regarding the proposals, please call the Funds’ proxy solicitor, Okapi Partners LLC, toll-free at (877) 285-5990. If you do not vote, you may receive a phone call from Okapi Partners LLC reminding you to vote your shares.

As always, we appreciate your support.

Sincerely,

Daniel R. Omstead, Ph.D.
President

[   ], 2023

ii

QUESTIONS AND ANSWERS
REGARDING THE JOINT PROXY STATEMENT AND
SPECIAL JOINT MEETINGS OF SHAREHOLDERS

While we strongly encourage you to read the full text of the enclosed Joint Proxy Statement, we are also providing you with a brief overview of the proposals (“Proposals”) to be considered at the Special Joint Meetings of Shareholders (with any adjournments or postponements thereof) of Tekla Healthcare Investors (“HQH”), Tekla Life Sciences Investors (“HQL”), Tekla Healthcare Opportunities Fund (“THQ”) and Tekla World Healthcare Fund (“THW”) (each a “Fund” and collectively, the “Funds”). Your vote is important.

Q. Why are you sending me this information?

A. You are receiving this Joint Proxy Statement because you own shares of one or more of the Funds and have the right to vote on the very important Proposals concerning your investment.

Q. What am I being asked to vote “FOR” in this Joint Proxy Statement?

A. At the first special meeting (the “First Meeting”) you will be asked to approve a new investment advisory agreement (each a “New Advisory Agreement” and collectively, the “New Advisory Agreements”) between each Fund and abrdn Inc. (the “First Meeting Proposal”).

At the second special meeting (the “Second Meeting” and together with the First Meeting, the “Special Meetings”) you will be asked to elect four new Trustees to serve as Trustees of each Fund (the “New Trustees”) (the “Second Meeting Proposal” and together with the First Meeting Proposal, the “Proposals”).

If (i) shareholders of all four of the Funds approve the New Advisory Agreements; (ii) shareholders of all four of the Funds elect the New Trustees; and (iii) the other conditions in the Purchase Agreement (defined below) are satisfied or waived, abrdn Inc. will serve as investment adviser to the Funds (employing the same investment team currently employed by Tekla Capital Management LLC (“Tekla”)) and the New Trustees will replace four of the Trustees currently serving on the Boards effective upon the completion of the Asset Transfer (defined below), which is expected to occur as soon as reasonably practicable following the affirmative vote of shareholders of the Funds, currently anticipated for the third quarter of 2023.

If (i) shareholders of one or more Funds do not approve the New Advisory Agreements; (ii) shareholders of one or more Funds do not elect the New Trustees; or (iii) the other conditions in the Purchase Agreement are not satisfied or waived, then the Asset Transfer will not be completed, the Purchase Agreement will terminate, Tekla will continue to serve as investment adviser to the Funds and all of the Trustees currently serving as Trustees of the Funds (the “Current Trustees”) will continue to serve as Trustees of the Funds.

Q. How does the Board of Trustees recommend that I vote?

A. The Boards of Trustees (each a “Board” collectively, the “Boards”) unanimously recommend that shareholders vote FOR the Proposals. If no instructions are indicated on your proxy, the representatives holding proxies will vote in accordance with the recommendations of the Boards.

Q. What changes are being proposed to the Funds’ investment adviser and why are the Boards recommending abrdn Inc.?

A. Tekla currently serves as the investment adviser to the Funds. On June 20, 2023, Tekla entered into a purchase agreement (the “Purchase Agreement”) with abrdn Inc. pursuant to which Tekla has agreed to sell certain assets to abrdn Inc. relating to Tekla’s advisory business for the Funds (the “Asset Transfer”). The Asset Transfer is subject to receipt of the necessary approvals of the New Advisory Agreements, election of the New Trustees and satisfaction or waiver of certain other conditions. More specifically, under the Purchase Agreement, in exchange for cash payment at the completion of the Asset Transfer and subsequent

iii

“earn out” payments tied to revenues following the Asset Transfer, Tekla has agreed to transfer to abrdn Inc., with certain exceptions: (i) all right, title and interest of Tekla and its affiliates in and to the books and records or documents to the extent solely used or held for use with respect to the Funds; (ii) the non-exclusive right to use each Fund’s performance information in abrdn Inc.’s performance information to the extent permitted by applicable law; (iii) all goodwill of Tekla’s business attributable to the Funds; and (iv) certain other contracts and rights of Tekla, including the contracts required for the operation of Tekla’s business attributable to the Funds (excluding the Tekla Advisory Agreements, as defined below).

Tekla recommended that the Boards consider and approve the New Advisory Agreements with abrdn Inc. with respect to each Fund upon the determination that it would be in the best interest of each Fund’s shareholders. At an in-person meeting held on June 26, 2023, the Trustees, including all of the Trustees who are not “interested persons” (the “Independent Trustees”) as defined in the Investment Company Act of 1940, as amended (the “1940 Act”), approved the New Advisory Agreement for each Fund and unanimously recommended that shareholders of each Fund approve the New Advisory Agreement for such Fund. abrdn Inc., its parent company, abrdn plc, and its affiliates are collectively referred to as “abrdn.” abrdn Inc. is an indirect wholly-owned subsidiary of abrdn plc. Tekla and abrdn Inc. are not affiliates of each other. The Joint Proxy Statement provides additional information about abrdn and the New Advisory Agreements.

The Funds are not a party to the Purchase Agreement; however, the completion of the Asset Transfer is subject to approval by the shareholders of all four of the Funds of both of the Proposals described in the enclosed Joint Proxy Statement and the satisfaction or waiver of certain other conditions in the Purchase Agreement.

If shareholders of all four of the Funds approve both Proposals and the other conditions in the Purchase Agreement are satisfied or waived, the New Advisory Agreements will become effective and abrdn Inc. will assume its responsibilities thereunder upon the completion of the Asset Transfer, which is expected to occur as soon as reasonably practicable following the affirmative vote of shareholders of the Funds, currently anticipated for the third quarter of 2023.

If (i) shareholders of one or more Funds do not approve the New Advisory Agreements; (ii) shareholders of one or more Funds do not elect the New Trustees; or (iii) the other conditions in the Purchase Agreement are not satisfied or waived, then the Asset Transfer will not be completed and the Purchase Agreement will terminate.

abrdn plc and its subsidiaries, including abrdn Inc., constitute one of the world’s largest asset management firms. abrdn Inc. has extensive experience in managing closed-end funds in markets directly relevant to the Funds. As of December 31, 2022, abrdn and its affiliates had approximately $452 billion in assets under management. Moreover, closed-end funds are an important element of the abrdn client base in the U.S. and globally. abrdn Inc. and its affiliates managed thirty-eight closed-end funds, totaling $29.8 billion in assets as of January 24, 2023. If the New Advisory Agreements are approved, the Funds would complement, rather than compete with, abrdn’s U.S. closed-end fund family. abrdn has substantial experience in assimilating closed-end funds into its family of funds.

It is currently anticipated that substantially all of members of the investment team currently managing the Funds at Tekla would continue to manage the Funds as full-time employees of abrdn, Inc. abrdn Inc. is also committed to its asset management business and, in particular, its larger closed-end fund platform, has knowledge of the closed-end fund marketplace, and has dedicated closed-end fund investor services professionals. For further details on the Boards’ decision to recommend abrdn Inc., please see “Board Consideration of the New Advisory Agreements” in the Joint Proxy Statement.

The Boards believe that approval of the New Advisory Agreements would be in the best interests of the Funds.

iv

Q. Will the approval of the New Advisory Agreements result in different terms that affect my shares?

A. No. The New Advisory Agreements will not affect your shares. You will still own the same shares in the applicable Fund(s) and your shares will have the same rights and preferences. The terms of the New Advisory Agreements are materially identical to the terms of the current investment advisory agreements between Tekla and the Funds (the “Tekla Advisory Agreements”), and the New Advisory Agreements will have the same advisory fee structures as are currently in effect, which will result in identical advisory fee rates. As a result, the advisory fees you pay as a shareholder will not increase as a result of the Asset Transfer.

The Funds’ Operating Expenses (as defined below) are expected to decrease following the Asset Transfer. abrdn will seek to achieve savings through scale and efficiency in the Funds’ operations (for instance, by driving better terms from fund service providers). In addition, at a minimum, abrdn Inc. has contractually agreed to limit, for a period of two years following completion of the Asset Transfer, the Operating Expenses of each Fund to an amount that is at least 0.02% less than the Operating Expenses of the Fund, as reported as a percentage of average net assets in the Fund’s annual report for the fiscal year ended September 30, 2022.

Fund2022 Operating Expenses1 as a
Percentage of Net Assets2
Operating Expense Limit
HQH1.19%1.17%
HQL1.38%1.36%
THQ1.46%1.44%
THW1.53%1.51%

1 Operating Expenses means aggregate expenses incurred by each Fund in any fiscal year, including but not limited to investment advisory fees (but excluding borrowing costs, taxes, brokerage commissions, and any non-routine expenses).

2 Reported in the Financial Highlights in the relevant Fund’s annual report to shareholders for the fiscal year ended September 30, 2022.

If shareholders of all four of the Funds approve both Proposals and the other conditions in the Purchase Agreement are satisfied or waived, abrdn Inc. will assume responsibility for management of the Funds’ investment portfolios as soon as reasonably practicable following the affirmative vote of shareholders of the Funds, currently anticipated for the third quarter of 2023. For further details, please see “How will the Asset Transfer affect the value of my investment?” below.

Q. Will the proposed new investment adviser change the Funds’ investment team or investment objectives and policies?

A. No. The Funds’ current investment team is currently expected to join abrdn Inc. as full-time employees and to continue managing the Funds after completion of the Asset Transfer. Further, the Funds’ investment objectives and fundamental and non-fundamental policies will not change as a result of the New Advisory Agreements.

Q. Why am I being asked to vote for new Trustees in the Second Meeting Proposal?

A. Section 16 of the 1940 Act requires that certain percentages of trustees on boards of registered investment companies must have been elected by shareholders under various circumstances. In addition, new trustees cannot be appointed by existing trustees to fill vacancies created by retirements, resignations or an expansion of a board unless, after those appointments, at least two thirds of the trustees have been elected by shareholders.

If the New Advisory Agreements take effect, the Funds will undergo certain changes in their day-to-day operations, although as noted above, the current investment team is expected to continue to manage the Funds as employees of abrdn Inc. rather than as employees of Tekla. Each of the New Trustees nominated in the Second Meeting Proposal already serves on boards of funds for which abrdn Inc. or its affiliates provide advisory services, and as such, these nominees have developed a certain level of familiarity with the investment philosophy, capabilities, personnel and ethics of abrdn Inc. and its affiliates. At the same time, two of the existing Trustees are expected to continue to serve as Trustees of the Funds after the completion of the Asset Transfer. The current Boards believe that having a mix of existing trustees and new trustees who are familiar with Tekla’s and abrdn Inc.’s respective investment philosophies and operations is important and will result in a more efficient transition.

The current Boards have determined that if the Asset Transfer is completed, it would be in the best interests of the Funds and their shareholders if the New Trustees are elected. The New Trustees are described in the Second Meeting Proposal.

v

If shareholders of all four of the Funds approve both Proposals and the other conditions in the Purchase Agreement are satisfied or waived, four of the Current Trustees would resign from their positions and the two continuing Trustees and four New Trustees would comprise the New Boards of the Funds. As a result, the total number of Trustees on each Board would remain at six. The entry into office of the New Trustees would be effective as of the completion of the Asset Transfer. If the Asset Transfer is completed, it is expected that the New Boards will elect a new slate of officers. The entry into office of the new officers of the Funds would be effective upon their election by the New Boards.

If the First Meeting Proposal is not approved by shareholders of all four of the Funds, none of the nominees in the Second Meeting Proposal will serve as Trustees of the Funds, even if elected by shareholders. In such an event, the Current Trustees would continue to serve. Similarly, if the Second Meeting Proposal is not approved by the shareholders of all four of the Funds, the New Advisory Agreements will not go into effect and Tekla will remain the Funds’ investment adviser, even if shareholders approve the New Advisory Agreements, unless the parties agree to waive or modify certain conditions of the Purchase Agreement. The completion of the Asset Transfer described in this Joint Proxy Statement is contingent upon both the First Meeting Proposal and the Second Meeting Proposal being approved by shareholders of all four of the Funds and the satisfaction or waiver of certain other conditions. If either of the Proposals are not approved by shareholders of one or more Funds or the conditions of the Purchase Agreement are not satisfied or waived, the Asset Transfer will not be completed, Tekla will continue to serve as the Funds’ investment adviser and the Current Trustees will continue to serve as Trustees of the Funds.

Q. Will the Proposals result in a change in the Funds’ service providers?

A. If shareholders of all four of the Funds approve both Proposals and the other conditions in the Purchase Agreement are satisfied or waived, abrdn Inc. will replace Tekla as the Funds’ investment adviser, although it will do so employing the current Tekla investment team as abrdn Inc. employees. Most of the Funds’ other significant service providers are expected to stay the same. For example, State Street Bank and Trust Company (“State Street”) will continue to serve as the Funds’ administrator and custodian. Computershare Inc. and its affiliates will continue to serve as the Funds’ transfer agent. It is expected, however, that KPMG LLP, which serves as auditor to the other U.S. closed-end funds advised by abrdn, will replace Deloitte & Touche LLP as auditor of the Funds.

Q. Will the Funds’ names change?

A. Yes. It is anticipated that, following the completion of the Asset Transfer, the Funds’ names will be changed as follows:

Current NameNew Name
Tekla Healthcare Investorsabrdn Healthcare Investors
Tekla Life Sciences Investorsabrdn Life Sciences Investors
Tekla Healthcare Opportunities Fundabrdn Healthcare Opportunities Fund
Tekla World Healthcare Fundabrdn World Healthcare Fund

The Funds’ ticker symbols are not expected to change as a result of the name changes.

Q. Will the fee rates payable under the New Advisory Agreements increase? Will total fund expenses increase?

A. No. If the Asset Transfer is completed, the New Management Agreement will provide for the same advisory fee as is currently in effect for each Fund.

vi

HQH and HQL

With respect to each of HQH and HQL, under the New Advisory Agreements and consistent with the Tekla Advisory Agreements, abrdn Inc. would be paid a fee computed monthly, equal when annualized to (i) 2.50% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for all other net assets, 0.98% of the average net assets up to and including $250 million, 0.88% of the average net assets for the next $250 million, 0.80% of the average net assets for the next $500 million and 0.70% of the average net assets in excess of $1 billion. The aggregate fee would not exceed a rate when annualized of 1.36% of the average net assets for any given month.

THQ and THW

With respect to each of THQ and THW, under the New Advisory Agreements and consistent with the Tekla Advisory Agreements, abrdn Inc. would be paid a fee, computed monthly, equal when annualized to 1.00% of the average daily value of the Fund’s managed assets. “Managed assets” for any month is equal to the total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund’s accrued liabilities (other than liabilities representing borrowings for investment purposes).

Total Fund Expenses; Proposed Operating Expense Limit

The Funds’ Operating Expenses (as defined below) are expected to decrease following the Asset Transfer. abrdn will seek to achieve savings through scale and efficiency in the Funds’ operations (for instance, by driving better terms from fund service providers). In addition, at a minimum, abrdn Inc. has contractually agreed to limit, for a period of two years following completion of the Asset Transfer, the aggregate expenses incurred by each Fund in any fiscal year, including but not limited to investment advisory fees (but excluding borrowing costs, taxes, brokerage commissions, and any non-routine expenses) (“Operating Expenses”), from exceeding the operating expense limit (the “Operating Expense Limit”) set forth in the table below.

Fund2022 Operating Expenses1 as a
Percentage of Net Assets2
Operating Expense Limit
HQH1.19%1.17%
HQL1.38%1.36%
THQ1.46%1.44%
THW1.53%1.51%

1 “Operating Expenses” is defined above.

2 Reported in the Financial Highlights in the relevant Fund’s annual report to shareholders for the fiscal year ended September 30, 2022.

As shown in the table above, each Fund’s Operating Expense Limit is equal to the Fund’s Operating Expenses as a percentage of average net assets as reported in the Fund’s annual report for the fiscal year ended September 30, 2022, minus 2 basis points (0.02%). The Operating Expense Limit shall be effective for two years from the completion of the Asset Transfer. Each Fund may repay any such reimbursement from abrdn Inc. within three years of the reimbursement, provided that the following requirements are met: the reimbursements do not cause the Funds to exceed the lesser of the applicable Operating Expense Limit in the contract at the time the fees were limited or expenses are paid or the applicable Operating Expense Limit in effect at the time the expenses are being recouped by abrdn Inc.

The Funds do not currently have expense limitation agreements in place.

Q. Will the Funds pay for this proxy solicitation?

A. No. Tekla and abrdn Inc. will bear all fees and expenses incurred by the Funds in connection with the Proposals (including, but not limited to, proxy and proxy solicitation costs, printing costs, expenses of holding additional Board and shareholder meetings and related legal fees) regardless of whether the Asset Transfer is completed. The Funds will bear no costs in connection with the Asset Transfer.

vii

Q. How do I vote my shares?

A. If your shares are held in “street name” by a broker or bank, you will receive information regarding how to instruct your bank or broker to cast your votes. If you are the shareholder of record, you may authorize a proxy to vote your shares by mail, phone, or internet or you may vote at the Special Meetings. To authorize a proxy to vote your shares by mail, please mark your vote for the First Meeting Proposal and the Second Meeting Proposal on the corresponding enclosed proxy card and sign, date and return the cards in the postage-paid envelope provided. If you choose to authorize a proxy to vote your shares by phone or internet, please refer to the instructions found on the proxy cards accompanying the Joint Proxy Statement. To authorize a proxy to vote your shares by phone or internet, you will need the “control number” that appears on the proxy cards.

Q. Whom should I call for additional information about the Joint Proxy Statement?

A. If you need any assistance or have any questions regarding the Proposals or how to vote your shares, please contact the Funds’ proxy solicitor, Okapi Partners LLC, toll-free (877) 285-5990 or Tekla@okapipartners.com.

viii

TEKLA HEALTHCARE INVESTORS

TEKLA LIFE SCIENCES INVESTORS

TEKLA HEALTHCARE OPPORTUNITIES FUND

TEKLA WORLD HEALTHCARE FUND

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

(617) 772-8500

NOTICE OF SPECIAL JOINT ANNUAL MEETINGMEETINGS OF SHAREHOLDERS

To the Shareholders of
TEKLA HEALTHCARE INVESTORS, TEKLA LIFE SCIENCES INVESTORS, TEKLA HEALTHCARE OPPORTUNITIES FUND AND TEKLA WORLD HEALTHCARE FUND:

An Annual Meeting

Two Special Joint Meetings of Shareholders of Tekla Healthcare Investors ("HQH"(“HQH”), Tekla Life Sciences Investors ("HQL"(“HQL”), Tekla Healthcare Opportunities Fund ("THQ"(“THQ”) and Tekla World Healthcare Fund ("THW"(“THW”) (each a "Fund", together“Fund” and collectively, the "Funds"“Funds”) will be held on Tuesday, June 14, 2016 at 10:00 a.m. at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110, for02110. The first special meeting will be held at 9:00 a.m. ET on August 14, 2023 (the “First Meeting”) and the following purposes:second special meeting will be held at 9:30 a.m. ET on August 14, 2023 (the “Second Meeting” and together with the First Meeting, the “Special Meetings”).

(1)  The election of

At the First Meeting, shareholders will be asked to vote to approve a new investment advisory agreement (each a “New Advisory Agreement” and collectively, the “New Advisory Agreements”) between each Fund and abrdn Inc. (the “First Meeting Proposal”).

At the Second Meeting, shareholders will be asked to vote to elect four new Trustees to serve as Trustees of each Fund;Fund (the “New Trustees”) (the “Second Meeting Proposal” and together with the First Meeting Proposal, the “Proposals”).

(2)  The ratification or rejection of the selection of Deloitte & Touche LLP as the independent registered public accountants of each Fund for the fiscal year ending September 30, 2016; and

(3)  Change the subclassification of HQH from "diversified" to "non-diversified" and eliminate the related fundamental investment restriction.

(4)  Change the subclassification of HQL from "diversified" to "non-diversified" and eliminate the related fundamental investment restriction.

(5)  (A)  Amend HQH's and HQL's fundamental investment restriction regarding issuing senior securities.

(B)  Remove HQH's and HQL's fundamental investment restriction regarding investments in other investment companies.

(C)  Remove HQH's fundamental investment restriction regarding short sales and purchasing securities on margin.

(6)  The transaction of such other business as may properly come before the Annual Meeting and any adjournment(s) or postponement(s) thereof.

If you have any questions about the proposals to be voted on, please call our solicitor, AST Fund Solutions, LLC, at (866)388-7535.

The Board of Trustees of each Fund unanimously recommends that shareholders vote FOR the approval of the New Investment Advisory Agreement and FOR the election of all nominees for electionof the New Trustees.

If (i) shareholders of all four of the Funds approve the New Advisory Agreements; (ii) shareholders of all four of the Funds elect the New Trustees; and (iii) the other conditions in the Purchase Agreement (as defined in the Joint Proxy Statement) are satisfied or waived, abrdn Inc. will serve as investment adviser to the Funds (employing the same investment team currently employed by Tekla) and the New Trustees will replace four of the Trustees currently serving on the Boards effective upon the completion of the Asset Transfer (as defined in the Joint Proxy Statement).

If (i) shareholders of one or more Funds do not approve the New Advisory Agreements; (ii) shareholders of one or more Funds do not elect the New Trustees; or (iii) the other conditions in the Purchase Agreement are not satisfied or waived, then Tekla will continue to serve as investment adviser to the Funds and all of the current Trustees will continue to serve as Trustees FORof the selection of Deloitte & Touche LLP as the independent registered accountants of each Fund, FOR the change to HQH from diversified to non-diversified, FOR change to HQL from diversified to non-diversified and FOR each change to the fundamental investment restrictions.Funds.



Although the AnnualSpecial Meetings are held together, for convenience in order to hear common presentations, each Fund'sFund’s shareholders take action at the Special Meetings independently of the other. Shareholders of record at the close of business on April 19, 2016June 16, 2023 will be entitled to vote at the Annual MeetingSpecial Meetings or at any adjournment(s) or postponement(s) thereof. We encourage you to check our website, www.teklacap.com, prior to the Special Meetings if you plan to attend.

Important Notice Regarding the Availability of Proxy Materials for the

Special Meetings To Be Held on August 14, 2023.

The proxy statement is available on the internet at www.OkapiPartners.com/TeklaSpecial.

ix

By Order of the Board of Trustees of each Fund,

Daniel R. Omstead, Ph.D.
President

April 20, 2016

[      ], 2023

Please complete, date and sign the Proxyproxy cards for the shares held by you and return the Proxyproxy cards in the envelope provided so that your vote can be recorded. No postage is required if the envelope is mailed in the United States. It is important that you return your signed Proxyproxy cards promptly, regardless of the size of your holdings, so that a quorum may be assured.

x




TEKLA HEALTHCARE INVESTORS

TEKLA LIFE SCIENCES INVESTORS

TEKLA HEALTHCARE OPPORTUNITIES FUND

TEKLA WORLD HEALTHCARE FUND

JOINT PROXY STATEMENT

Information Regarding the Special Meetings

This Joint Proxy Statement is furnished in connection with the solicitation by the Board of Trustees (each a "Board," together“Board” and collectively, the "Boards"“Boards”) of Tekla Healthcare Investors ("HQH"(“HQH”), Tekla Life Sciences Investors ("HQL"(“HQL”), Tekla Healthcare Opportunities Fund ("THQ"(“THQ”) and Tekla World Healthcare Fund ("THW"(“THW”) (each a "Fund", together“Fund” and collectively, the "Funds"“Funds”) of proxies to be voted at the Special Joint Annual MeetingMeetings of Shareholders of the Funds, to be held on June 14, 2016 (the "Annual Meeting"), and any adjournment(s) or postponement(s) thereof, for the purposes set forth in the accompanying Notice of Joint AnnualSpecial Meetings, dated [July 11], 2023. The first special meeting will be held at 9:00 a.m. ET on August 14, 2023 (the “First Meeting”) and the second special meeting will be held at 9:30 a.m. ET on August 14, 2023 (the “Second Meeting” and together with the First Meeting, dated April 20, 2016.the “Special Meetings”). This Joint Proxy Statement, the Notice of Special Joint Annual MeetingMeetings of Shareholders and the Proxy Card(s)proxy cards (each a “Proxy Card” and together, the “Proxy Cards”) are first being mailed to shareholders on or about April 20, 2016.[July 11], 2023.

General Voting Information

Only shareholders of record as of the close of business on the Record Date, June 16, 2023, will be entitled to receive notice of, and to vote at, the Special Meetings or any adjournment(s) or postponement(s) thereof. If the enclosed forms of Proxy Cards are properly executed and returned (or your vote is cast through the web site or over the telephone as indicated on the Proxy Cards) in time to be voted at the Special Meetings or any adjournment(s) or postponement(s) thereof, the proxies named therein will vote the shares represented by the proxy in accordance with the instructions marked thereon. If you return a signed Proxy Card without any voting instructions, your shares will be voted, with respect to the Fund(s) of which you are a shareholder, “FOR” the new investment advisory agreement(s) or “FOR ALL” of the new Trustee nominees, as applicable. The persons designated on the Proxy Cards as proxies will also be authorized to vote (or to withhold their votes) in their discretion on any other matters which properly come before the Special Meetings. They may also vote in their discretion to adjourn the Special Meetings. If you sign and return the Proxy Cards, you may still attend the Special Meetings to vote your shares. Please note that if your shares are held of record by a broker and you wish to vote in person at the Special Meetings, you should obtain a legal proxy from your broker and submit proof of your legal proxy reflecting your Fund holdings along with your name and email address to Tekla@okapipartners.com.

You may revoke your proxy at any time before the Special Meetings (i) by notifying the Secretary of the Funds at the address on the cover of the Proxy Statement; (ii) by submitting a later signed Proxy Card; or (iii) by participating in the Special Meetings and casting your vote. If your shares are held in the name of your broker, you will have to make arrangements with your broker to revoke any previously executed proxy. Shareholders do not have rights of appraisal with respect to any matter to be acted upon.

Unless revoked, all valid and executed proxies will be voted in accordance with the specifications thereon or, in the absence of such specifications, FOR each of the Proposals (defined below).

Each shareholder may cast one vote with respect to each of the Proposals (as defined below) for each full share, and a partial vote for each partial share, of the Fund that they owned of record on June 16, 2023 (the “Record Date”). Schedule 1 shows the number of shares of each Fund that were outstanding on the Record Date and Schedule 2 lists the shareholders who owned 5% or more of the outstanding shares of any Fund

Proposal 

Affected Funds

Proposal 1. The election of Trustees of each Fund.

All Funds

Proposal 2. The ratification or rejection of the selection of Deloitte & Touche LLP
as the independent registered public accountants of each Fund for the fiscal year
ending September 30, 2016.
All Funds

Proposal 3. Change the subclassification of HQH from diversified to non-diversified
and eliminate the related fundamental investment restrictions.
HQH
Proposal 4. Change the subclassification of HQL from diversified to non-diversified
and eliminate the related fundamental investment restrictions.
HQL
Proposal 5.A. Amend HQH's and HQL's fundamental investment restriction
regarding senior securities.
HQH and HQL
Proposal 5.B. Remove HQH's and HQL's fundamental investment restriction
regarding other investment companies.
HQH and HQL
Proposal 5.C. Remove HQH's fundamental investment restriction regarding short
sales and securities on margin.
HQH
1
 

 

on that date. It is expected that this Joint Proxy Statement and the accompanying Proxy Cards will be first mailed to shareholders on or about [July 11], 2023.

This proxy solicitation is being made largely by mail, but may include telephonic, electronic or oral communication by Okapi Partners LLC, a professional proxy solicitation firm engaged by the Funds, at a cost estimated to be between $249,000 and $499,000, depending on the services provided. Tekla and abrdn Inc. will bear all fees and expenses incurred by the Funds in connection with the Proposals (including, but not limited to, proxy and proxy solicitation costs, printing costs, expenses of holding additional Board and shareholder meetings and related legal fees) regardless of whether the Asset Transfer is completed. The BoardFunds will bear no costs in connection with the Asset Transfer. In addition, certain officers of the Funds and certain employees of Tekla, who will receive no compensation for their services other than their regular salaries, may solicit the return of proxies personally or by telephone or facsimile. Banks, brokerage houses, nominees and other fiduciaries will be requested to forward the proxy soliciting materials to the beneficial owners of the shares of the Funds. The Funds may reimburse brokerage houses, nominees and other fiduciaries for postage and reasonable expenses incurred by them in forwarding of proxy material to beneficial owners.

Tekla Capital Management LLC (“Tekla”) and abrdn Inc. have entered into a purchase agreement (the “Purchase Agreement”) pursuant to which Tekla has agreed to sell certain assets to abrdn Inc. relating to Tekla’s advisory business for the Funds (the “Asset Transfer”). The Asset Transfer is subject to receipt of the necessary approvals of the New Advisory Agreements, election of the New Trustees and satisfaction or waiver of certain other conditions. The Boards have considered and approved certain items relating to the Asset Transfer, which were presented to the Boards by representatives of Tekla and abrdn Inc., who together provided a detailed explanation of their reasons for seeking to enter into the Asset Transfer and their views of the benefits to the Funds, among other things. As described in further detail below, the Boards reviewed requested information provided from both Tekla and abrdn Inc. and voted to approve, and recommend that shareholders approve: (i) a new investment advisory agreement between each Fund and abrdn Inc. (each a “New Advisory Agreement” and collectively, the “New Advisory Agreements”) (the “First Meeting Proposal”); and (ii) the election of four new Trustees to serve as Trustees of each Fund recommends(the “New Trustees”) (the “Second Meeting Proposal” and together with the First Meeting Proposal, the “Proposals”). The New Trustees would replace four of the Trustees currently serving on the Boards (the “Resigning Trustees”). Shareholders will be asked to vote on the First Meeting Proposal at the First Meeting and on the Second Meeting Proposal at the Second Meeting. Two existing Trustees would continue to serve on the Boards after completion of the Asset Transfer.

If (i) shareholders of all four of the Funds approve the New Advisory Agreements; (ii) shareholders of all four of the Funds elect the New Trustees; and (iii) the other conditions in the Purchase Agreement are satisfied or waived, the New Advisory Agreements will be effective and the New Trustees will replace the Resigning Trustees effective upon the completion of the Asset Transfer, which is expected to occur as soon as reasonably practicable following the affirmative vote of shareholders of the Funds, currently anticipated for the third quarter of 2023.

If the First Meeting Proposal is not approved by shareholders of all four of the Funds, none of the nominees in the Second Meeting Proposal will serve as Trustees of the Funds, even if elected by shareholders. In such an event, the Trustees currently serving as Trustees of the Funds (the “Current Trustees”) would continue to serve. Similarly, if the Second Meeting Proposal is not approved by the shareholders of all four of the Funds, the New Advisory Agreements will not go into effect and Tekla will remain the Funds’ investment adviser, even if shareholders approve the New Advisory Agreements, unless the parties agree to waive or modify certain conditions of the Purchase Agreement. The completion of the Asset Transfer described in this Joint Proxy Statement is contingent upon both the First Meeting Proposal and the Second Meeting Proposal being approved by shareholders of all four of the Funds and the satisfaction or waiver of certain other conditions. If either of the Proposals are not approved by shareholders of one or more Funds or the conditions of the Purchase Agreement are not satisfied or waived, the Asset Transfer will not be completed, Tekla will continue to serve as the Funds’ investment adviser and the Current Trustees will continue to serve as Trustees of the Funds.

2

The Special Meetings may be adjourned by the chairman of the meeting whether or not a quorum is present. Any business that shareholderswould have been transacted at a Special Meeting may be transacted at any adjourned meeting. If a quorum is present at a Special Meeting with respect to any one or more proposals, the chairman of the meeting may, but shall not be required to, cause a vote FORto be taken with respect to any such proposal or proposals, which vote can be certified as final and effective notwithstanding the adjournment of the Special Meeting with respect to any other proposal or proposals.

Abstentions and Broker Non-Votes

Broker non-votes occur when a meeting has (1) a “routine” proposal, such as the election of all nomineesTrustees, where the applicable stock exchange permits brokers to vote their clients’ shares in their discretion, and (2) a “non-routine” proposal, where the applicable exchange does not permit brokers to vote their clients’ shares in their discretion. The shares that are considered to be present as a result of the broker discretionary vote on a routine proposal but that are not voted on a non-routine proposal are called “broker non-votes.” The First Meeting Proposal is considered a non-routine matter. The Second Meeting Proposal is considered a routine matter. As a result, the Funds do not anticipate that there will be any broker non-votes at the Special Meetings. Abstentions will be included for electionpurposes of determining whether a quorum is present for a Fund at the Special Meetings and will be treated as Trustees, FORvotes present at the selection of Deloitte & Touche LLPSpecial Meetings but will not be treated as votes cast. Therefore, abstentions will have the independent registered accountants of each Fund, FORsame effect as a vote against the change to HQH from diversified to non-diversified, FORFirst Meeting Proposal and will have no effect on the change to HQL from diversified to non-diversified and FOR each change to the fundamental investment restrictions.Second Meeting Proposal.

Each Fund will furnish, without charge, a copy of its Annual Report, or the most recent Semi-Annual Report succeeding the Annual Report, if any, to a shareholder upon request. Requests may be sent to the Fund at 100 Federal Street, 19th Floor, Boston, MA 02110 or be made by calling (617) 772-8500.

FIRST MEETING PROPOSAL

TO APPROVE A NEW INVESTMENT ADVISORY AGREEMENT BETWEEN EACH FUND AND ABRDN INC.

Background

The Boards have considered and approved certain items relating to the Asset Transfer, which were presented to the Boards by representatives of Tekla and abrdn Inc., who together provided a detailed explanation of their reasons for seeking to enter into the Purchase Agreement and their views of the benefits to the Funds, among other things. As described in further detail below under the section titled “Board Consideration of the New Advisory Agreements,” the Boards met with representatives of Tekla and abrdn Inc. and reviewed requested information provided from both parties prior to approving the New Advisory Agreements and recommending that shareholders approve the New Advisory Agreements.

The Asset Transfer will be completed only if (i) shareholders of all four of the Funds approve the New Advisory Agreements; (ii) shareholders of all four of the Funds elect the New Trustees; and (iii) the other conditions in the Purchase Agreement are satisfied or waived. If (i) shareholders of one or more Funds do not approve the New Advisory Agreements; (ii) shareholders of one or more Funds do not elect the New Trustees; or (iii) the other conditions in the Purchase Agreement are not satisfied or waived, then the Asset Transfer will not be completed, Tekla will continue to serve as investment adviser to the Funds and the New Advisory Agreements will not go into effect.


3

Benefits of the New Advisory Agreements

Potential benefits of the New Advisory Agreements to shareholders of the Funds include: (i) the opportunity to be part of a large and broad closed-end fund platform from a global and independent organization with a focus on continuing and expanding its asset management business in general and its U.S. registered closed-end fund business in particular; and (ii) lower Operating Expenses (as defined below) for at least two years from the date of the completion of the Asset Transfer. As of December 31, 2022, abrdn plc, the parent company to abrdn Inc., and its affiliates (“abrdn”) had approximately $452 billion in assets under management. Moreover, closed-end funds are an important element of the abrdn client base in the U.S. and globally. abrdn Inc. and its affiliates managed thirty-eight closed-end funds, totaling $29.8 billion in assets as of January 24, 2023. abrdn Inc. has a complementary closed-end fund family into which the Funds can be transitioned. abrdn Inc.’s U.S. closed-end fund business has been developed primarily from targeted acquisition (such as the Asset Transfer) as opposed to development through initial public offering and secondary market fundraising. abrdn Inc., however, is resourced to support all areas of administration, marketing, operations, legal, compliance, company secretarial and risk management.

The advisory fees of the Funds will not increase as a result of the New Advisory Agreements. In fact, the Funds’ Operating Expenses (as defined below) are expected to decrease following the Asset Transfer. abrdn will seek to achieve savings through scale and efficiency in the Funds’ operations (for instance, by driving better terms from fund service providers). In addition, abrdn Inc. has contractually agreed to limit, for a period of two years following completion of the Asset Transfer, the aggregate expenses incurred by each Fund in any fiscal year, including but not limited to investment advisory fees (but excluding borrowing costs, taxes, brokerage commissions, and any non-routine expenses) (“Operating Expenses”), from exceeding the operating expense limit (the “Operating Expense Limit”) set forth in the table below.

Fund2022 Operating Expenses1 as a
Percentage of Net Assets2
Operating Expense Limit
HQH1.19%1.17%
HQL1.38%1.36%
THQ1.46%1.44%
THW1.53%1.51%

Proposal 1
ELECTION OF TRUSTEES
Operating Expenses” is defined above. 

2 Reported in the Financial Highlights in the relevant Fund’s annual report to shareholders for the fiscal year ended September 30, 2022.

As shown in the table above, each Fund’s Operating Expense Limit is equal to the Fund’s Operating Expenses as a percentage of average net assets as reported in the Fund’s annual report for the fiscal year ended September 30, 2022, minus 2 basis points (.02%).

The Funds’ current investment team is currently expected to join abrdn Inc. as full-time employees and to continue managing the Funds after completion of the Asset Transfer. Further, the Funds’ investment objectives and fundamental and non-fundamental policies will not change as a result of the New Advisory Agreements.

Terms of the Asset Transfer

On June 20, 2023, Tekla and abrdn Inc., entered into the Purchase Agreement pursuant to which Tekla has agreed to sell certain assets to abrdn Inc. relating to Tekla’s advisory business for the Funds subject to receipt of the necessary approvals of the New Advisory Agreements and the election of the New Trustees and satisfaction or waiver of certain other conditions. More specifically, under the Purchase Agreement, in exchange for cash payment at the completion of the Asset Transfer and subsequent “earn out” payments tied to certain revenues following the Asset Transfer, Tekla has agreed to transfer to abrdn Inc., with certain exceptions: (i) all right, title and interest of Tekla and its affiliates in and to the books and records or documents to the extent solely used or held for use with respect to the Funds; (ii) the non-exclusive right to

4

use each Fund’s performance information in abrdn Inc.’s performance information to the extent permitted by applicable law; (iii) all goodwill of Tekla’s business attributable to the Funds; and (iv) certain other contracts and rights of Tekla, including the contracts required for the operation of Tekla’s business attributable to the Funds (excluding the Tekla Advisory Agreements). If shareholders of all four of the Funds approve both Proposals and the other conditions in the Purchase Agreement are satisfied or waived, the New Advisory Agreements would go into effect as soon as reasonably practicable following the affirmative vote of shareholders of the Funds, currently anticipated for the third quarter of 2023.

As further discussed below, abrdn Inc. has agreed with Tekla that, for a minimum of two years subsequent to the completion of the Asset Transfer, it will use reasonable best efforts to ensure that no “unfair burden,” as defined in Section 15(f) of the Investment Company Act of 1940 (the “1940 Act”), is imposed on the Funds. In addition, abrdn Inc. has contractually agreed to limit, for a period of two years following completion of the Asset Transfer, each Fund’s Operating Expenses from exceeding the Operating Expense Limit. As noted above, each Fund’s Operating Expense Limit is equal to the Fund’s Operating Expenses as a percentage of average net assets as reported in the Fund’s annual report for the fiscal year ended September 30, 2022, minus 2 basis points (0.02%) (subject to certain exclusions noted previously). The Operating Expense Limit shall be effective for two years from the completion of the Asset Transfer. Each Fund may repay any such reimbursement from abrdn Inc. within three years of the reimbursement, provided that the following requirements are met: the reimbursements do not cause the Funds to exceed the lesser of the applicable operating expense limitation in the contract at the time the fees were limited or expenses are paid or the applicable operating expense limitation in effect at the time the expenses are being recouped by abrdn Inc. The Funds do not currently have expense limitation agreements in place.

Furthermore, during the three-year period after the completion of the Asset Transfer, abrdn Inc. will use reasonable best efforts to ensure that at least 75% of the Board will be comprised of persons who are not “interested persons” of either abrdn Inc. or Tekla.

Information Pertaining to Tekla

Tekla, located at 100 Federal Street, 19th Floor, Boston, MA 02110, currently serves as each Fund’s investment adviser pursuant to an investment advisory agreement between such Fund and Tekla (the “Tekla Advisory Agreements”). As of June 16, 2023, Tekla manages approximately $3.1 billion in assets.

Each Fund'sFund pays Tekla an annual investment advisory fee. HQH and HQL pay Tekla a monthly fee at the rate when annualized of (i) 2.50% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for all other net assets, 0.98% of the average net assets up to and including $250 million, 0.88% of the average net assets for the next $250 million, 0.80% of the average net assets for the next $500 million and 0.70% of the average net assets in excess of $1 billion. The aggregate fee would not exceed a rate when annualized of 1.36% of the average net assets for any given month. THQ and THW pay Tekla a fee, computed monthly, equal when annualized to 1.00% of the average daily value of the Fund’s managed assets. “Managed assets” for any month is equal to the total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund’s accrued liabilities (other than liabilities representing borrowings for investment purposes).

The Funds paid the following amounts in investment advisory fees under the Tekla Advisory Agreements during the fiscal years ended September 30, 2022, 2021, and 2020:

5

Fund202220212020
HQH$9,976,451$10,783,984$9,186,956
HQL$4,656,417$5,267,605$4,476,344
THQ$11,745,209$11,671,518$10,515,219
THW$6,532,081$6,283,994$5,475,071

Each Fund has entered into a Services Agreement with Tekla, pursuant to which, each Fund reimbursed Tekla in the following amounts during the year ended September 30, 2022 for certain services related to a portion of the payment of salary and provision of benefits to the Funds’ Chief Compliance Officer. The Services Agreement will not be needed if the Asset Transfer is completed. Consistent with the approach taken with respect to other closed-end funds managed by abrdn, abrdn, and not the Funds, shall be responsible for the salary and benefits of the Funds’ Chief Compliance Officer, who is employed by abrdn Inc.

FundAmount Paid under Services Agreement
HQH$139,755
HQL$65,401
THQ$111,837
THW$54,976

Information Pertaining to abrdn Inc.

abrdn Inc. is located at 1900 Market Street, Suite 200, Philadelphia, PA 19103. abrdn Inc. is an indirect wholly-owned subsidiary of abrdn plc, which manages or administers approximately $452 billion in assets as of December 31, 2022. The registered offices of abrdn plc are located at 10 Queen’s Terrace, Aberdeen, Scotland AB10 1YG. abrdn Inc., its parent company abrdn plc, and its affiliates are collectively referred to as “abrdn.”

Information Pertaining to the Current and Proposed Portfolio Manager

Daniel R. Omstead, Ph.D., Jason Akus, M.D./M.B.A., Timothy Gasperoni, M.B.A., Ph.D., Ashton Wilson, Christopher Abbott, Robert Benson, Kelly Girskis, Ph.D., Richard Goss, Jack Liu, M.B.A, Ph.D., Christopher Seitz, M.B.A., Loretta Tse, Ph.D. and Graham Attipoe, M.B.A., M.D. are members of a team that analyzes investments on behalf of the Funds. Dr. Omstead exercises ultimate decision-making authority with respect to investments.

The Funds’ current investment team is currently expected to join abrdn Inc. as full-time employees and to continue managing the Funds after completion of the Asset Transfer. Further, the Funds’ investment objectives and fundamental and non-fundamental policies will not change as a result of the New Advisory Agreements.

Valuation Procedures

Currently, Tekla uses valuation procedures approved by the Funds’ Current Boards (“Current Valuation Procedures”). Upon completion of the Asset Transfer, the Funds’ assets will be valued pursuant to the valuation procedures for funds advised by abrdn Inc. as approved by the Boards after the new Trustees begin their term. The valuation procedures for funds advised by abrdn Inc. and the Funds’ current valuation procedures differ modestly from the Current Valuation Procedures. abrdn’s U.S. Registered Funds Valuation and Liquidity Procedures value foreign equity securities that trade on a market that closes prior to a fund’s valuation time by applying daily valuation factors to the last quoted sale price. The abrdn funds currently value foreign equity securities that trade on a market that

6

closes prior to the funds’ valuation times at the last quoted sale price and only will update this price if there are intervening events resulting in market volatility that significantly affect the value of any such foreign securities after the close of trading on the relevant foreign market. The impact of this difference on the Funds upon transition to abrdn as investment adviser is uncertain and could be positive or negative depending on market conditions on the day that the Funds’ adopt abrdn’s procedures and could be material.

abrdn’s U.S. Registered Funds Valuation and Liquidity Procedures will generally value forward foreign currency contracts based on the daily spot exchange rates and the forward exchange rate points (e.g. 1-month, 3-month). The Current Valuation Procedures value forward foreign currency contracts on the basis of the value of the underlying currencies at the prevailing currency exchange rate. If the Asset Transfer is completed, the prevailing currency exchange rate shall be determined within one hour of when the most recently available exchange rate information has been received based on information obtained from a bank or banks that a sub-committee of the Funds’ Valuation Committee (the “Sub-Committee”) deems appropriate. Forward foreign currency contracts are held only in the Tekla World Healthcare Fund and as of March 31, 2023 the difference in valuation is a decrease of $108,000 or 2 basis points.

Directors/Principal Officers of abrdn Inc.

The name, address and principal occupation of the principal executive officers and each director of abrdn Inc. are set out in the table below. No current officer or Trustee of the Funds is also an officer, employee or director of abrdn Inc. No Independent Trustee of the Funds owns any securities of, or has any other material direct or indirect interest in, abrdn Inc. or any of its affiliates. However, employees of abrdn Inc. or its affiliates may receive, as a portion of their bonus, deferred shares of and/or stock options for abrdn plc, which vest upon the occurrence of certain events.

Name and Principal
Business Address*
Principal Occupation
Joseph AndolinaDirector, Vice President and Chief Compliance Officer of abrdn Inc., and Chief Risk Officer - Americas at abrdn
Alan GoodsonDirector and Vice President of abrdn Inc., and Executive Director, Product & Client Solutions - Americas at abrdn
Jennifer NicholsDirector and Vice President of abrdn Inc., and Co-Head of Legal and Head of Legal Americas at abrdn
James O’ConnorDirector and Vice President of abrdn Inc., and Head of the Americas at abrdn
Marika ToozeDirector and Vice President of abrdn Inc., and Head of Human Resources - Americas at abrdn
Jaclyn MatsickTreasurer of abrdn Inc., and Head of Finance - Americas at abrdn

* The address of the principal executive officers and each director is 1900 Market Street, Suite 200, Philadelphia, PA 19103.

Information Pertaining to the Custodian, Administrator and Transfer Agent

Each Fund’s portfolio securities and cash are held under a custodian contract by State Street Bank and Trust Company (“State Street”), whose principal business address is One Congress Street, Suite 1, Boston, MA

7

02114-2016. State Street is also the administrator of each Fund and also performs certain accounting related functions for each Fund, including calculation of net asset value and net income.

Computershare Inc. serves as dividend disbursing agent. Computershare Trust Company, N.A., a fully owned subsidiary of Computershare Inc., serves as (1) the plan agent for each Fund’s dividend reinvestment plan and (2) the transfer agent and registrar for shares of each fund. Computershare Trust Company, N.A. and Computershare Inc. have their principal business at 150 Royall Street, Canton, MA 02021.

If the Asset Transfer is consummated, State Street will continue to serve as the Funds’ administrator and custodian and Computershare Inc. and its affiliates, will continue to serve as the Funds’ transfer agent, dividend disbursing agent, and registrar.

Information Relating to Affiliated Brokerage

The Funds did not pay any affiliated brokerage fees during the fiscal year ended September 30, 2022.

Required Vote

Approval of the First Meeting Proposal with respect to each Fund will require the affirmative vote of a “majority of the outstanding voting securities” of the Fund as defined in the 1940 Act. This means the lesser of (1) 67% or more of the shares of the Fund present at the First Meeting if more than 50% of the outstanding shares of the Fund are present or represented by proxy, or (2) more than 50% of the outstanding shares of the Fund.

Board Approval and Recommendation

At an in-person meeting held on June 26, 2023, the Trustees, including all of the Independent Trustees, unanimously approved the New Advisory Agreement for each Fund and unanimously recommended that shareholders of each Fund approve the New Advisory Agreement for such Fund. Previously, on June 8, 2023, the Current Trustees received an in-person presentation from senior members of abrdn Inc. concerning its organization, the rationale for the Asset Transfer and its plans for the Funds. The current Independent Trustees also met separately on several occasions, with only their own legal counsel present, to discuss the Asset Transfer. A summary of the Trustees’ considerations is provided below in the section entitled “Board Consideration of the New Advisory Agreements.”

EACH FUND’S BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE NEW ADVISORY AGREEMENTS

Comparison of the Tekla Investment Advisory Agreements and New Advisory Agreements

It is proposed that abrdn Inc. provide investment advisory services to the Funds pursuant to the proposed New Advisory Agreements. If shareholders of all four of the Funds approve both Proposals and the other conditions in the Purchase Agreement are satisfied or waived such that the Asset Transfer is completed, the New Advisory Agreements would go into effect as soon as reasonably practicable following the affirmative vote of shareholders of the Funds, currently anticipated for the third quarter of 2023, with an initial two-year term, and would be subject to annual approval thereafter in accordance with the 1940 Act. The continuation of the Tekla Advisory Agreements was last considered and approved by the Boards on March 16, 2023. The Tekla Advisory Agreements for HQH, HQL, THQ and THW were last submitted for shareholder approval, for HQH and HQL, by the Funds’ public shareholders on June 25, 2002 in connection with a change of control of the Funds’ investment adviser, and for THQ and THW, by Tekla as the Funds’ sole initial shareholder on the following dates, prior to such Fund’s initial public offering: THQ: June 2, 2014; and THW: June 19, 2015.

8

The terms of the New Advisory Agreements are identical to those of the Tekla Advisory Agreements in all material respects. The only differences between the New Advisory Agreements and the Tekla Advisory Agreements are: (i) the names of the parties and dates; (ii) with respect to HQH and HQL only, the New Advisory Agreements do not include reference to a licensing agreement between Tekla and Tekla’s predecessor which is no longer relevant; (iii) with respect to HQH and HQL only, the New Advisory Agreements include the updated name of the Financial Industry Regulatory Authority; (iv) with respect to HQH and HQL only, the use of different terminology to describe certain of the same services to be provided to the Funds by abrdn Inc. and provided to the Funds by Tekla; and (v) with respect to HQH and HQL only, the New Advisory Agreements provide that the agreements will remain in effect for an initial two-year term and continuously thereafter so long as such continuance is approved at least annually by each Fund’s New Board, including a majority of the Independent Trustees. The changes to the HQH and HQL agreements were made, in each case, to bring them up-to-date and for consistency with the newer agreements for each of THQ and THW.

Copies of the New Advisory Agreements are attached as Exhibit A to this Joint Proxy Statement and the description of terms in this section is qualified in its entirety by reference to Exhibit A.

Investment Advisory Services. Under the New Advisory Agreements, abrdn Inc. would provide the same services to the Funds as Tekla under the Tekla Advisory Agreements. The New Advisory Agreements, in line with the Tekla Advisory Agreements, provide that abrdn Inc. will: (a) act in strict conformity with each Fund’s Declaration of Trust, the 1940 Act and the Investment Advisers Act of 1940; (b) manage each Fund’s portfolio in accordance with each Fund’s investment objective and policies as stated in the Fund’s prospectus; (c) make investment decisions for each Fund; (d) place purchase and sale orders for portfolio transactions for each Fund; (e) supply each Fund with office facilities (which may be in the adviser’s own offices), statistical and research data, data processing services, clerical, internal executive and administrative services, and stationery and office supplies; (f) supply or direct and supervise a third-party administrator and/or custodian in the provision to each Fund of accounting and bookkeeping services, the calculation of the net asset value of shares of each Fund, and the management of each Fund’s administrative affairs; and (g) prepare or supervise and direct a third-party administrator and/or custodian in the preparation of reports to shareholders of each Fund, tax returns and reports to and filings with the SEC and state Blue Sky authorities. With respect to HQH and HQL only, item (f) is described as “internal auditing services, and other clerical services in connection therewith” in the Tekla Advisory Agreements but relates to the same services that abrdn Inc. would provide under the New Advisory Agreements.

Consistent with the Tekla Advisory Agreements, each New Advisory Agreement further provides that abrdn Inc. will provide investment research and supervision of the Fund’s investments and conduct a continual program of investment, evaluation and, if appropriate, sale and reinvestment of each Fund’s assets. In addition, the New Advisory Agreements provide that abrdn Inc. will furnish each Fund with whatever statistical information the Fund may reasonably request with respect to the securities that the Fund may hold or contemplate purchasing.

Brokerage. The New Advisory Agreements require abrdn Inc. to use its best efforts to obtain the best price and execution for the Funds, as Tekla is required to do under the Tekla Advisory Agreements.

9

Compensation. With respect to each of HQH and HQL, under the New Advisory Agreements and consistent with the Tekla Advisory Agreements, abrdn Inc. would be paid a fee computed monthly, equal when annualized to (i) 2.50% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for all other net assets, 0.98% of the average net assets up to and including $250 million, 0.88% of the average net assets for the next $250 million, 0.80% of the average net assets for the next $500 million and 0.70% of the average net assets in excess of $1 billion. The aggregate fee would not exceed a rate when annualized of 1.36% of the average net assets for any given month.

With respect to each of THQ and THW, under the New Advisory Agreements and consistent with the Tekla Advisory Agreements, abrdn Inc. would be paid a fee, computed monthly, equal when annualized to 1.00% of the average daily value of the Fund’s managed assets. “Managed assets” for any month is equal to the total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund’s accrued liabilities (other than liabilities representing borrowings for investment purposes).

Expenses. Under the New Advisory Agreements, abrdn Inc. will bear all expenses in connection with the performance of its services, as Tekla does under the Tekla Advisory Agreements.

Non-Liability of the Investment Adviser. Under the New Advisory Agreements, abrdn Inc. shall not be held responsible for any loss incurred by any act or omission of any broker. abrdn Inc. shall also not be liable to the Funds and their shareholders for any error or judgment or for any loss suffered by the Funds in connection with rendering services under the New Advisory Agreements subject to certain exceptions. The Tekla Advisory Agreements include the same non-liability provisions with respect to Tekla.

Effective Period and Termination. If the New Advisory Agreements take effect, they will remain in effect for an initial two-year term and continuously thereafter so long as their continuance is approved annually by the New Boards, including a majority of the Independent Trustees. The New Advisory Agreements shall automatically terminate, without the payment of any penalty, in the event of assignment. Either party to the New Advisory Agreements may terminate the agreements by not less than thirty, but no more than sixty days’, written notice delivered to the other party. The New Advisory Agreements would automatically terminate if their continuance is not approved.

The Tekla Advisory Agreements for THQ and THW contain the same effective period and termination provisions but the effective period and termination provisions in the Tekla Advisory Agreements for HQH and HQL are different in certain respects. Unlike the New Advisory Agreements, the Tekla Advisory Agreements for HQH and HQL do not provide that the agreements shall remain in effect for an initial two-year term but, consistent with the New Advisory Agreements, the Tekla Advisory Agreements would remain in effect so long as their continuance is approved annually by the Boards, including a majority of the Independent Trustees. Under the Tekla Advisory Agreements for HQH and HQL, consistent with the New Advisory Agreements, either party may terminate the agreements by not less than thirty, but no more than sixty days’, written notice to the other party.

Amendments. Consistent with the Tekla Advisory Agreements, the New Advisory Agreements may not be amended without Board and shareholder approval.

BOARD CONSIDERATION OF THE NEW ADVISORY AGREEMENTS

At an in-person meeting held on June 26, 2023, the Current Trustees, including all of the Independent Trustees voting separately, unanimously determined, with respect to each Fund, that the terms of the New Advisory Agreement are fair and reasonable and approved the New Advisory Agreement as being in the best interests of such Fund and its shareholders. In making their determinations, the Boards considered materials that were specifically prepared by abrdn Inc. and Tekla regarding the Asset Transfer and the New Advisory Agreements, including information with respect to abrdn Inc. that was provided in response to a number of questions and supplemental information requests from counsel to the Independent Trustees and the Funds. In addition, prior to the June 26, 2023 Board meeting, the Trustees met with representatives of abrdn and Tekla and with the New Trustee nominees. The Independent Trustees of the Funds also met separately with their independent counsel to consider and discuss the New Advisory Agreement with respect to each Fund. The Trustees considered that the key members of the investment team currently managing the Funds at Tekla had entered into employment agreements with abrdn Inc. prior to Tekla and abrdn Inc. signing the Purchase Agreement and that substantially all of members of the investment team currently managing the Funds at Tekla are expected join abrdn Inc. as full-time employees and continue to manage the Funds under the New Advisory Agreements. In their deliberations, the Independent Trustees had the opportunity to meet privately on several occasions without representatives of abrdn or Tekla present and were represented throughout the process by counsel to the Independent Trustees and the Funds.

10

In approving the New Advisory Agreements, the Boards considered, among other things, the nature, extent, and quality of the services to be provided by abrdn Inc., the investment performance of the Funds and abrdn Inc., the costs of services to be provided by abrdn Inc. and profits expected to be realized by abrdn Inc. with respect to the Funds. The Trustees also considered whether the proposed fee levels reflect any economies of scale for the benefit of Fund shareholders and the extent to which economies of scale would be realized as the Funds grow. The Boards also evaluated the financial strength of abrdn Inc. and abrdn Inc.’s ability to manage the Funds, noting that substantially all of the members of the investment team currently managing the Funds at Tekla are expected to continue to do so under the New Advisory Agreements. Counsel to the Independent Trustees and the Funds provided the Independent Trustees with a memorandum regarding the statutory and regulatory requirements for approval and disclosure of investment advisory agreements. With respect to each Fund, the Board, including the Independent Trustees, evaluated all of the foregoing and, considering all factors together, determined in the exercise of its business judgment that the approval of the New Advisory Agreement is in the best interests of the Fund and its shareholders. The following provides more detail on certain factors considered by the Trustees and the Boards’ conclusions with respect to each such factor.

Nature, extent and quality of the services. The Trustees received and considered various information regarding the nature, extent and quality of the advisory services to be provided by abrdn Inc. to the Funds under the New Advisory Agreements. abrdn Inc. provided detailed responses to requests submitted by counsel to the Independent Trustees and the Funds. Prior to the June 26, 2023 meeting, the Trustees also received an in-person presentation from senior personnel across various departments of abrdn. The Trustees considered the information provided with respect to the resources that would be dedicated to the Funds and further considered that substantially all of the members of the investment team currently managing the Funds are expected to continue to do so under the New Advisory Agreements. Further, the Trustees noted that abrdn Inc. has advised the Trustees that in transitioning the management of the Funds, abrdn Inc. would be focused on minimizing any disruption to the Funds and their shareholders. The Trustees considered that abrdn Inc. is a very large asset manager and has extensive experience in managing closed-end funds. The Trustees noted that closed-end funds are an important element of the abrdn client base in the U.S. and globally and further noted that abrdn Inc. has substantial experience in assimilating closed-end funds into its family of funds.

The Trustees considered that as of December 31, 2022, abrdn had approximately $452 billion in assets under management and that abrdn Inc. manage 13 U.S. closed-end funds and 25 non-U.S. closed-end funds, totaling $29.8 billion in assets as of January 24, 2023. They also considered that while abrdn Inc. does not currently manage any healthcare or biotech strategies, substantially all of the members of the investment team currently managing the Funds at Tekla are expected to join abrdn Inc. as full-time employees and continue to manage the Funds under the New Advisory Agreements and abrdn Inc. had expressed its commitment to integrating this team into its organization and to expanding its expertise in the healthcare and biotech sectors more generally. The Trustees further considered that abrdn Inc. is committed to its asset management business and, in particular, its closed-end fund platform, has knowledge of the closed-end fund marketplace and has dedicated closed-end fund investor services professionals.

11

The Trustees noted abrdn Inc.’s and Tekla’s representation that, if abrdn Inc. were approved as the Funds’ investment adviser, there would be no expected diminution in the nature, quality and extent of services provided to the Funds and their shareholders, including administrative, regulatory and compliance services. The Trustees further considered certain differences in the valuation policies of abrdn Inc. and Tekla.

Based on the foregoing and other relevant information reviewed, the Trustees concluded that, overall, they were satisfied with assurances from abrdn Inc. as to the expected nature, extent and quality of the services to be provided to the Funds under the New Advisory Agreements.

Investment performance. The Trustees considered and reviewed the investment performance record of abrdn Inc. in managing other closed-end funds. The Trustees noted that abrdn Inc. does not currently manage any healthcare or biotech strategies. The Boards also considered the information received and reviewed throughout the year and in connection with its recent annual approval of the Tekla Advisory Agreements regarding the Funds’ performance, as well as the investment strategy and the investment team, both of which are expected to remain unchanged under the New Advisory Agreements. Furthermore, the Trustees considered that the Funds’ investment objectives, fundamental and non-fundamental policies are not expected to change as a result of the New Advisory Agreements.

Fees and Expenses. The Trustees considered that, with respect to each Fund, the advisory fee schedule would be the same under the New Advisory Agreement as under the Tekla Advisory Agreement. The Trustees considered the various services to be provided by abrdn Inc. to the Funds under the New Advisory Agreements and reviewed comparisons of the Funds’ proposed expense ratios to: (i) those of a peer group of other investment companies identified by an independent service provider engaged by the Independent Trustees in connection with their most recent renewal of the Tekla Advisory Agreements in March of 2023; and (ii) the Funds’ current expenses and expense ratios under the Tekla Advisory Agreements. The Trustees noted that abrdn Inc.’s proposed fees are within the range of fees presented in the comparative information and noted that, particularly in the case of HQH and HQL, the Funds may maintain a meaningful allocation to venture and restricted securities, a portfolio management service that can warrant higher management fees than those proposed to be charged by abrdn Inc. to the Funds. The Trustees considered, among other things, that the Funds’ Operating Expenses (as defined herein) are expected to decrease as a result of expense limitation agreements abrdn Inc. has agreed to impose, which will be in effect for at least two years from the date that abrdn Inc. begins managing the Funds and that the services to be provided by abrdn Inc. under the New Advisory Agreements are at least comparable to the services provided to the Funds under the Tekla Advisory Agreements.

Economies of Scale. The Trustees noted that while the Funds, as closed-end funds, generally would not present the opportunity for economies of scale by themselves, abrdn’s large platform presented new opportunities for the Funds to receive the benefits of economies of scale through abrdn’s relationships with service providers and other operational efficiencies. With respect to THQ and THW, the Trustees noted that the New Advisory Agreements, like the Tekla Advisory Agreements, do not provide for breakpoints that might reduce the effective fee rate paid by a Fund to the extent such Fund’s net assets should increase. With respect to HQH and HQL, the Trustees noted that, consistent with the Tekla Advisory Agreements for such Funds, the advisory fee schedules in the New Advisory Agreements provide for breakpoints that would reduce the effective fee to the extent a Fund’s net assets should increase, allowing such Fund to share in the benefits of any economies of scale that would inure to abrdn as the Fund’s assets increase. The Trustees considered that, given the closed-end structure of HQH, HQL and THQ and the fact that, absent a rights offering or other secondary offering, any significant growth in assets generally will occur through appreciation in the value of the Funds’ investment portfolio. The Trustees noted that although THW also has a closed-end structure involving the same limitations on growth, the Fund had commenced an at-the-market offering in January 2023, and the New Board would have an opportunity to evaluate any economies of scale generated by this offering in connection with future renewals of the New Advisory Agreement.

12

The Trustees also noted abrdn Inc.’s representation that it would attempt to achieve economies of scale through relationships with brokers, administrative systems and other efficiencies. The Trustees considered the ways in which abrdn Inc. may be able to achieve economies of scale for the Funds but noted that there can be no assurances that economies of scale will be achieved by abrdn Inc. Under the circumstances, the Board concluded that, with respect to each Fund, the proposed advisory fees are not excessive and that the advisory fee structure for the Fund is appropriate.

Fall-Out Benefits and Other Factors. The Trustees also considered information regarding potential “fall-out” or ancillary benefits that would be received by abrdn as a result of its relationship with the Funds. The Boards received and considered information regarding the extent to which abrdn might derive other ancillary benefits from fund operations, including the potential for procuring additional business as a result of the prestige and visibility associated with its role as investment adviser to the Funds. The Boards concluded that, to the extent abrdn derives other benefits from its relationship with the Funds, those benefits are not so significant as to render abrdn Inc.’s fees excessive.

The Trustees also considered that Tekla has a financial interest under the Purchase Agreement in having the Boards and shareholders approve the New Advisory Agreements.

Costs of Services Provided and Profitability. In evaluating the costs of the services to be provided by abrdn Inc. under the New Advisory Agreements and the expected profitability to abrdn Inc. from its proposed relationship with the Funds, the Trustees once again considered, among other things, that there would be no increase in advisory fee rate under the New Advisory Agreements. The Trustees further noted the pro forma nature of the profitability information presented and that it was not possible to predict with certainty how abrdn Inc.’s profitability actually would be affected by becoming the investment adviser to the Funds, but that they had been satisfied, based on their review of the projected profitability of abrdn Inc., that the profitability from its relationship with the Funds would not be excessive.

Based on the information provided to and evaluated by the Trustees, the Trustees concluded that, with respect to each Fund, the fees proposed to be charged by abrdn Inc. under the New Advisory Agreement are fair and reasonable in light of the quality and nature of the services proposed to be provided by abrdn Inc. and that the proposed profitability of abrdn Inc.’s relationship with the Fund will not be excessive.

Conclusion. In their deliberations, the Trustees did not identify any single item that was all-important or controlling and each Trustee may have attributed different weights to various factors. After an evaluation of the above-described factors and based on their deliberations and analysis of the information provided, the Trustees concluded that, with respect to each Fund, approval of the New Advisory Agreement is in the best interests of the Fund and its shareholders. Accordingly, the Trustees, including the Independent Trustees voting separately, unanimously approved the New Advisory Agreement with respect to each Fund and recommended that shareholders of each Fund vote FOR approval of the New Advisory Agreement.

Section 15(f) of the 1940 Act

Section 15(f) of the 1940 Act provides a safe harbor for an investment adviser of a registered investment company (or any affiliated persons of the investment adviser) to receive any amount or benefit in connection with a sale of securities or other interest in the investment adviser, provided that two conditions are satisfied. Tekla will receive compensation in connection with the Asset Transfer.

First, an “unfair burden” may not be imposed on the investment company as a result of the sale, or any express or implied terms, conditions or understandings applicable to the sale. The term “unfair burden,” as defined in the 1940 Act, includes any arrangement during the two-year period after the sale whereby the investment adviser (or predecessor or successor adviser), or any “interested person” of the adviser (as defined in the 1940 Act), receives or is entitled to receive any compensation, directly or indirectly, from the investment company or its security holders (other than fees for bona fide investment advisory or other services), or from any person in connection with the purchase or sale of securities or other property to, from or on behalf of the investment company (other than ordinary fees for bona fide principal underwriting services).

13

Second, during the three-year period after the sale, at least 75% of the members of the investment company’s board of directors cannot be “interested persons” (as defined in the 1940 Act) of the investment adviser or its predecessor.

The Trustees have not been advised by Tekla or abrdn Inc. of any circumstances arising from the Asset Transfer that might result in the imposition of an “unfair burden” on the Funds as defined in Section 15(f) of the 1940 Act. Moreover, abrdn Inc. has committed that for two years after the consummation of the Asset Transfer, it will use reasonable best efforts to ensure that no unfair burden is imposed on the Funds. abrdn Inc. has also agreed that for a minimum of three years subsequent to the consummation of the Asset Transfer, it will use reasonable best efforts to ensure that at least 75% of the Board of each Fund will be comprised of persons who are not “interested persons” of either abrdn Inc. or Tekla.

SECOND MEETING PROPOSAL

TO ELECT FOUR NEW TRUSTEES TO EACH FUND’S BOARD

Background

Each Fund’s Board is responsible for the overall management of the respective Fund, including general supervision and review of the Fund’s investment activities. Each Board, in turn, elects the officers of the respective Fund who are responsible for administering the Funds’ day-to-day operations. Among other things, each Board generally oversees the portfolio management of the respective Fund and reviews and approves the Fund’s investment advisory agreements and other principal contracts.

At an in-person meeting held on June 26, 2023, the current Boards, in reviewing the New Advisory Agreements, noted that the Funds would likely undergo certain changes in their day-to-day operations, although as noted above, the current investment team is expected to continue to manage the Funds as employees of abrdn Inc. rather than Tekla and most of the Funds’ other significant service providers will also continue in their current roles. In this context, four new highly experienced and qualified Trustees were proposed for the current Boards’ consideration, to serve the Funds only if the Asset Transfer were to be completed (which, as discussed above, is subject to approval of both Proposals by shareholders of all four Funds and certain other conditions). The New Trustee nominees are Rose DiMartino, C. William Maher, Todd Reit and Stephen Bird. Each of the New Trustees already serves on boards of funds for which abrdn Inc. or its affiliates provide advisory services, and as such, these nominees have developed a certain level of familiarity with the investment philosophy, capabilities, personnel and ethics of abrdn Inc. and its affiliates. Each of the New Trustees, except Stephen Bird, would serve as an Independent Trustee of the Funds.

The current Boards noted these factors as consistent with good governance and that the election of the New Trustees was in the best interests of the Funds. The current Boards also noted that it is expected that two of the existing Trustees, Jeffrey A. Bailey and Kathleen L. Goetz, would continue to serve as Trustees of the Funds after the completion of the Asset Transfer. The current Boards believe that having a mix of existing and new trustees who are familiar with Tekla’s and abrdn Inc.’s respective investment philosophies and operations is important and will result in a more efficient transition.

The current Boards requested and received information about the New Trustees in advance of the June 26, 2023 meeting. The Current Trustees also met personally with each of the New Trustees to assess their experience and backgrounds. The current Boards believe that each New Trustee’s experience, qualifications, attributes and skills on an individual basis and in combination with those of other continuing and New Trustees lead to the conclusion that each New Trustee should serve in such capacity. Among the attributes or skills common to all New Trustees are their ability to review critically and to evaluate, question and discuss information provided to them, to interact effectively with the other Trustees, the Fund’s investment adviser, the administrator and other

14

service providers, counsel and independent registered public accounting firm, and to exercise effective and independent business judgment in the performance of their duties as Trustees. Each New Trustee’s ability to perform the duties of a trustee effectively has been attained and enhanced through the New Trustee’s education, professional training and other life experiences, such as business, consulting or public service positions and through experience from service as a board member of other abrdn funds, public companies, non-profit entities or other organizations.

The Governance and Nominating Committee of each Fund’s Board also considered the New Trustees’ background, experience and their familiarity with the abrdn fund complex, their willingness to serve and the proposed structure of the Boards, including that Jeffrey A. Bailey and Kathleen Goetz, would continue to serve as Trustees of the Funds after the completion of the Asset Transfer. Upon the recommendation of the Governance and Nominating Committee, at the June 26, 2023 meeting, each Fund’s Board, including all of the Independent Trustees, considered and approved the New Trustees and recommended that shareholders elect the New Trustees.

If (i) shareholders of all four of the Funds approve the New Advisory Agreements; (ii) shareholders of all four of the Funds elect the New Trustees; and (iii) certain other conditions are satisfied such that the Asset Transfer is completed, four of the Current Trustees would resign from their positions and the two continuing Trustees (the “Continuing Current Independent Trustees”) and four New Trustees would comprise the New Boards of the Funds. As a result, the total number of Trustees on the Boards would remain at six. Further, five of the six Trustees would be Independent Trustees, as is the case currently. The entry into office of the New Trustees would be effective as of the completion of the Asset Transfer. If the Asset Transfer is completed, it is expected that the New Boards will elect a new slate of officers. Information relating to the new slate of officers expected to be elected into office by the New Boards is set forth in Schedule 4 to this Joint Proxy Statement. The entry into office of the new officers of the Funds would be effective upon their election by the New Boards.

Each Fund’s Declaration of Trust, as amended to date (the “Declaration of Trust”), provides that its Board shall be divided into three classes (each a “Class”) with staggered terms. For HQH and HQL, theTrustees of each Class of each Fund are elected for three-year terms. The term of office of theeach Class Cof Trustees expires on the date of the 2016 Annual Meeting and the term of office of the Class A and Class B Trusteesfor each Fund will expire one and two years, respectively, thereafter. Trustees chosen to succeedin the Class C Trustees whose terms are expiring will be elected for a three-year term. For THQ,year indicated in the term of office of the Class B Trustees expires on the date of the 2016 Annual Meeting and the term of office of the Class C and Class A Trustees will expire one and two years, respectively, thereafter. Trustees chosen to succeed the Class B Trustees whose terms are expiring will be elected for a three-year term. For THW, the term of office of the Class A Trustees expires on the date of the 2016 Annual Meeting and the term of office of the Class B and Class C Trustees will expire one and two years, respectively, thereafter. Trustees chosen to succeed the Class A Trustees whose terms are expiring will be elected for a three-year term.following chart:

FundClass AClass BClass C
HQH202620242025
HQL202620242025
THQ202420252026
THW202520262024

Each Fund'sFund’s Declaration of Trust provides that a majority of its Trustees shall fix the number of the entire Board of Trustees and that such number shall be at least three and no greater than fifteen. Each Fund'sFund’s Board has fixed the number of Trustees at seven. Proxies will be voted forsix. Each nominee has consented to serve as a New Trustee if elected at the election of the following nominees for HQH, HQL, THQ and THW.Second Meeting. In the event that a nominee is unable to serve for any reason when the election occurs, the accompanying Proxy Card will be voted for such other person or persons as the applicable Fund'sFund’s Board may recommend.

HQH

Class C Nominees to Serve until 2019

Michael W. Bonney

Oleg M. Pohotsky

William S. Reardon, CPA

HQL

Class C Nominees to Serve until 2019

Michael W. Bonney

Rakesh K. Jain, Ph.D.

Uwe E. Reinhardt, Ph.D.

THQ

Class B Nominees to Serve until 2019

Rakesh K. Jain, Ph.D.

Daniel R. Omstead, Ph.D.

Lucinda H. Stebbins, CPA

THW

Class A Nominees to Serve until 2019

Oleg M. Pohotsky

William S. Reardon, CPA

 


Each of the following Trustees is presently serving as a Trustee and has consented to continue to so serve in the class andProxies will be voted for the term specified below.

HQH

Class A Trustees to Serve until 2017

Rakesh K. Jain, Ph.D.

Lucinda H. Stebbins, CPA

Class B Trustees to Serve until 2018

Daniel R. Omstead, Ph.D.

Uwe E. Reinhardt, Ph.D.

HQL

Class A Trustees to Serve until 2017

Oleg M. Pohotsky

William S. Reardon, CPA

Class B Trustees to Serve until 2018

Daniel R. Omstead, Ph.D.

Lucinda H. Stebbins, CPA

THQ

Class C Trustees to Serve until 2017

Michael W. Bonney

Uwe E. Reinhardt, Ph.D.

Class A Trustees to Serve until 2018

Oleg M. Pohotsky

William S. Reardon, CPA

THW

Class B Trustees to Serve until 2017

Rakesh K. Jain, Ph.D.

Daniel R. Omstead, Ph.D.

Lucinda H. Stebbins, CPA

Class C Trustees to Serve until 2018

Michael W. Bonney

Uwe E. Reinhardt, Ph.D.

The Boards believe that each Trustee's experience, qualifications, attributes and skills on an individual basis and in combination with those of other Trustees lead to the conclusion that each Trustee should serve in such capacity. Among the attributes or skills common to all Trustees are their ability to review critically and to evaluate, question and discuss information provided to them, to interact effectively with the other Trustees, the Fund's investment adviser, the administrator and other service providers, counsel and independent registered public accounting firm, and to exercise effective and independent business judgment in the performance of their duties as Trustees. Each Trustee's ability to perform the duties of a trustee effectively has been attained and enhanced through the Trustee's education, professional training and other life experiences, such as business, consulting or public service positions and through experience from service as a member of each Fund's Board, public companies, or non-profit entities or other organizations.

Michael W. Bonney: Mr. Bonney has been a Partner at Third Rock Ventures since 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of each Fund. Mr. Bonney is also a Director of Celgene Corporation, Global Blood Therapeutics and Alnylam Pharmaceuticals, Inc. and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College.


Rakesh K. Jain, Ph.D.: Dr. Rakesh Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital, providing each Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain co-founded XTuit Pharmaceuticals, Inc. in 2012, where he also serves as a board member. He serves on the Governance and Nominating Committee of each Fund. Prior to joining Harvard, he was professor of chemical engineering at Columbia University and Carnegie Mellon University. Dr. Jain is regarded as a pioneer in the fields of tumor biology, drug delivery, in vivo imaging and bioengineering. Dr. Jain has authored more than 600 publications. He serves on advisory panels to government, industry and academia, and has served or continues to serve on editorial advisory boards of twenty journals, including Journal of Clinical Oncology and Nature Reviews Clinical Oncology. He has received more than 70 major awards and lectureships, including the United States National Medal of Science, a Guggenheim Fellowship, the Humboldt Senior Scientist Award, the National Cancer Institute's Research Career Development Award and Outstanding Investigator Grant, the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards, the Distinguished Service Award from Nature Biotechnology and the Innovator Award from the DoD Breast Cancer Program. He is a member of all three branches of US National Academies – the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences and is a member of the American Academy of Arts and Sciences.

Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH, HQL, THQ and THW. Dr. Omstead is also President of HQH, HQL, THQ and THW and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restricted/venture portfolios within HQH, HQL, THQ and THW. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of several portfolio companies including Dynex Corporation, EBI Life Sciences, Inc., Euthymics Biosciences, Inc., GenomDx Biosciences Inc., IlluminOss Medical, Inc., Insightra Medical, Inc., Neurovance, Inc. and Veniti, Inc. Dr. Omstead is also an observer of the Board of Directors of AlterG, Inc. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck & Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies. Dr. Omstead holds Ph.D. and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University. He is an emeritus member of the Board of Directors of a non-profit agency that provides emergency shelter, housing and supportive services to homeless and low-income individuals and families in the Boston area. Dr. Omstead is also an Overseer at the Joslin Diabetes Center.

Oleg M. Pohotsky: Mr. Pohotsky is a corporate finance and investment professional with over forty years of diversified experience gained both in industry and in financial markets. Mr. Pohotsky serves as Chairman of the Board of Trustees of each Fund and also serves as Chairman of each Fund's Valuation Committee and serves on each Fund's Audit Committee. He has over 45 years of cumulative board experience in the full range of organization types: publicly-traded, privately-held, venture-backed and non-profit. He has also served as a director of a healthcare services company listed on the


Nasdaq NMS where he was a member of the audit committee. In his various directorships he has also served on investment, compensation, personnel and executive committees. His career spanned over twenty years in the investment industry, both as an investment banker and as a venture capital and private equity investor, and included serving as chairman of the valuation and fairness opinion committee of a NYSE-member firm. Mr. Pohotsky also currently serves on the Board of Directors of Avangardco Investments Holdings, an LSE-listed agribusiness enterprise based in Ukraine, on the board of directorselection of the New America High Income Fund, Inc., a closed end fund investing in high yield securities on a leveraged basis and on the Board of Advisors of Kaufman & Co., LLC, a Boston-based boutique investment banking firm, and is affiliated with GovernanceMetrics International, Inc. as a Senior Advisor. He providesTrustees for each Fund with valuable experience in valuation and the financial industry. Mr. Pohotsky holds a BSChE degree from Clarkson University, a JD degree from the University of Miami and MBA from the Harvard Business School. He has also been awarded an honorary doctorate by Clarkson University.

William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides each Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. Until 2002, Mr. Reardon was a business assurance partner in PwC's Boston office and leader of the Life Sciences Industry Practice for New England and the Eastern U.S., working closely with many of the Firm's public clients in SEC-registered equity, convertible and R&D limited partnership offerings and many initial public offerings. He serves on the Valuation and Audit Committees of each Fund. From 1998-2000 he served on the Board of the Emerging Companies Section of the Biotechnology Industry Organization ("BIO") and from 2000 to 2002 he served on the Board of Directors of the Massachusetts Biotechnology Council ("MBC"). During his professional career, he was a frequent speaker at BIO conferences and MBC Industry meetings on issues affecting biotechnology companies. He currently also serves as a board member and audit committee chair of two development-stage public companies, Synta Pharmaceuticals and Idera Pharmaceuticals. Mr. Reardon is member of the American Institute of CPAs and the Massachusetts Society of CPAs, with an MBA from Harvard Business School and a BA in East Asian History from Harvard College.

Uwe E. Reinhardt, Ph.D.: Dr. Reinhardt is the James Madison Professor of Political Economy at Princeton University, teaching economics and public affairs since 1968, and has been a member of the Institute of Medicine of the National Academy of Sciences since 1978. He serves on the Audit Committee of each Fund. Dr. Reinhardt is recognized as one of the nation's leading authorities on health care economics, a prominent scholar in health care economics and a frequent speaker and author on subjects ranging from the war in Iraq to the future of Medicare. Dr. Reinhardt provides each Fund with valuable insights in healthcare economics and reform. He is a past president of the Association of Health Services Research. From 1986 to 1995 he served as a commissioner on the Physician Payment Review Committee, established in 1986 by Congress to advise it on issues related to the payment of physicians. He is a senior associate of the Judge Institute for Management of Cambridge University, UK, and a trustee of Duke University and the Duke University Health System. Dr. Reinhardt is or was a member of numerous editorial boards, among them the Journal of Health Economics, the Milbank Memorial Quarterly, Health Affairs, the New England Journal of Medicine, and the Journal of the American Medical Association. Dr. Reinhardt received his Ph.D. from Yale University.


Lucinda H. Stebbins, CPA: Ms. Stebbins brings to each Fund over thirty years experience working in the fund industry, providing valuable perspectives on a variety of technical and industry matters. She serves as Chairman of the Audit Committee and serves on the Governance and Nominating Committee of each Fund. She started her career with the investment management firm of Scudder, Stevens and Clark, which was later merged into the U.S. operations of Zurich Financial Services, and then finally acquired by Deutsche Bank. She served as a Senior Vice President at Scudder Investments and subsequently as a Director at Deutsche Asset Management and was an officer of approximately 200 funds in these complexes. Ms. Stebbins' expertise is in the accounting, tax, and regulatory sides of the fund business, and she continued through 2015 to act as an independent consultant to the fund industry. Prior to joining Scudder, she was a Senior Manager at Price Waterhouse and is a member of the Massachusetts Society of CPAs. She also serves on the Board of Solstice Home Care, Inc., served on the Board of Bald Peak Land Company and has been on a number of non-profit Boards. She holds an MBA degree from Babson College and a BA in economics from Wellesley College.

The Trustees and their principal occupation for at least the last five years are set forth in the following table. The table below.shows the applicable Class and expiration year with respect to each Fund.

Name, Age
and AddressNew Trustee
HQHHQLTHQTHW
Stephen BirdClass A (expires 2026)Class B (expires 2024)Class C (expires 2026)Class A (expires 2025)

 Position(s) Held
with HQH, HQL,
THQ and THW
Term of
Office and
Length of
Time Served
Principal
Occupations(s)
During Past 5 Years
Number of
Portfolios
in Fund
Complex
Overseen by
Director or
Nominee for
Director
Other
Directorships
Held by Director
or Nominee
for Director

INDEPENDENT TRUSTEES AND NOMINEES

Michael W. Bonney (57)
100 Federal Street,
19th Floor,
Boston MA 02110

Trustee of HQH, HQL, THQ and THW; Member of each Fund's Valuation and Governance and Nominating Committees.

3 years for HQH and HQL (since 2011); 3 years for THQ (since 2014); 3 years for THW (since 2015).

Partner, Third Rock Ventures (since 2016); Chief Executive Officer and Director, Cubist Pharmaceuticals, Inc. (2012-2015); President, Chief Executive Officer and Director, Cubist Pharmaceuticals, Inc. (2003-2012).

4

Director, Celgene Corporation (since 2015); Director, Global Blood Therapeutics (since 2016); Revolution Medicine (since 2016); Director, Alnylam Pharmaceuticals, Inc. (since 2014); Director, NPS Pharmaceuticals, Inc. (2005-2015); Chairman of the Board of Trustees, Bates College (since 2010); Trustee, Bates College (since 2002); Board member of the Pharmaceutical Research and Manufacturers of America (PhRMA) (2009-2014).

15
 

Rose DiMartinoClass B (expires 2024)Class C (expires 2025)Class B (expires 2025)Class B (expires 2026)
C. William MaherClass B (expires 2024)Class A (expires 2026)Class B (expires 2025)Class C (expires 2024)
Todd ReitClass C (expires 2025)Class C (expires 2025)Class A (expires 2024)Class B (expires 2026)

As noted above, two of the existing Trustees, Jeffrey A. Bailey and Kathleen Goetz, would continue to serve as Trustees of the Funds after the completion of Asset Transfer. The table shows their applicable Class and expiration year with respect to each Fund.

Continuing Current Independent TrusteeHQHHQLTHQTHW
Jeffrey A. BaileyClass A (expires 2026)Class B (expires 2024)Class C (expires 2026)Class C (expires 2024)
Kathleen L. GoetzClass C (expires 2025)Class A (expires 2026)Class A (expires 2024)Class A (expires 2025)

Required Vote

Each Fund’s Declaration of Trust states that Trustees shall be elected by a plurality of each Fund’s shares voting at the Second Meeting. Plurality voting means the nominee for each seat receiving the greatest number of votes will be elected.

For information on the New Trustee nominees, please see the “Information on the New Trustees” section below in this Joint Proxy Statement.

EACH FUND’S BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR”

EACH OF THE NEW TRUSTEE NOMINEES

Name, Age
and Address
Position(s) Held
with HQH, HQL,
THQ and THW
Term of
Office and
Length of
Time Served
Principal
Occupations(s)
During Past 5 Years
Number of
Portfolios
in Fund
Complex
Overseen by
Director or
Nominee for
Director
Other
Directorships
Held by Director
or Nominee
for Director
Rakesh K. Jain, Ph.D. (65)
100 Federal Street,
19th Floor,
Boston MA 02110

Trustee of HQH, HQL, THQ and THW; Member of each Fund's Governance and Nominating and Qualified Legal Compliance Committees.

3 years for HQH and HQL (since 2007); 2 years for THQ (since 2014); 2 years for THW (since 2015).

Director, Steele Lab of Tumor Biology at Massachusetts General Hospital (since 1991); A.W. Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School (since 1991).

4

Ad hoc Consultant/Scientific Advisory Board Member for pharmaceutical/biotech companies (various times since 2002); Ad hoc Consultant, Gershon Lehman Group (since 2004); Director, Co-Founder, XTuit Pharmaceuticals, Inc. (Since 2012).

Oleg M.
Pohotsky (69)
100 Federal Street,
19th Floor,
Boston MA 02110

Trustee, HQH, HQL, THQ and THW; Chairman, HQH, HQL (since 2012); Chairman, THQ (since 2014); Member of each Fund's Audit, Valuation and Qualified Legal Compliance Committees.

3 years for HQH and HQL (since 2000); 3 years for THQ (since 2014); 1 year for THW (since 2015).

Consultant and Managing Partner, Right Bank Partners (since 2002) (Corporate governance and strategy advisory).

4

Adviser, Board of Advisers, Kaufman & Co. LLC (since 2008); Director, Avangardco Investments Holdings (since 2011); Director, New America High Income Fund, Inc. (since 2013).

William S. Reardon, CPA (69)
100 Federal Street,
19th Floor,
Boston MA 02110

Trustee, HQH, HQL, THQ and THW; Member of each Fund's Valuation, Audit and Qualified Legal Compliance Committees.

3 years for HQH and HQL (since 2010); 3 years for THQ (since 2014); 1 year for THW (since 2015).

Independent Consultant (since 2002).

4

Director, Idera Pharmaceuticals, Inc. (since 2002); Director, Synta Pharmaceuticals Corp. (since 2004).

16
 


INFORMATION ON THE NEW TRUSTEE NOMINEES

New Trustee Nominees

Name, Age
Address1,
Year of
Birth
and Address
Position(s) HeldExpected
Position
with the
Funds
with HQH, HQL,
THQ and THW
Term of
Office and
Length of
Time Served
Principal
Occupations(s)
Occupation(s) Held During Past 5
Five Years
Number
of Funds
in the
Post-Asset
Transfer
abrdn
Fund
Complex
Overseen*
Portfolios
in Fund
Complex
Overseen by
Director or
Nominee for
Director
Other
Directorships
Held by Director
Nominee
or Nominee
for Director
Uwe E. Reinhardt, Ph.D. (78)

Rose DiMartino
100 Federal Street,Year of Birth: 1952

TrusteeMs. DiMartino served as partner and senior counsel within the asset management practice group at the law firm of Willkie Farr & Gallagher LLP from 1991 to 2019.7None
C. William Maher
19th Floor,Year of Birth: 1961
TrusteeMr. Maher is a Co-founder of Asymmetric Capital Management LLC from May 2018 to September 2020. Formerly Chief Executive Officer of Santa Barbara Tax Products Group from October 2014 to April 2016.7None
Todd Reit
Boston MA 02110Year of Birth: 1968
TrusteeMr. Reit is a Managing Member of Cross Brook Partners LLC, a real estate investment and management company since 2017. Mr. Reit is also Director and Financial Officer of Shelter Our Soldiers, a charity to support military veterans, since 2016. Mr. Reit was formerly a Managing Director and Global Head of Asset Management Investment Banking for UBS AG, where he was responsible for overseeing all the bank’s asset management client relationships globally, including all corporate security transactions, mergers and acquisitions. Mr. Reit retired from UBS in 2017 after an over 25-year career at the company and its predecessor company, PaineWebber Incorporated (merged with UBS AG in 2000).9None

 

Trustee, HQH, HQL, THQ and THW; Member of each Fund's Audit Committee.

3 years for HQH (since 1988); 3 years for HQL (since 1992); 3 years for THQ (since 2014); 3 years for THW (since 2015).

Professor of Economics, Princeton University (since 1968).

4

Director, Boston Scientific Corporation (2002-2015); Director, Amerigroup, Inc. (2002-2012).

Lucinda H. Stebbins, CPA (70)
100 Federal Street,
19th Floor,
Boston MA 02110

Trustee, HQH, HQL, THQ and THW; Member of each Fund's Audit and Governance and Nominating Committees.

3 years for HQH and HQL (since 2006); 2 years for THQ (since 2014); 2 years for THW (since 2015).

Independent Consultant, Deutsche Bank (2004-2015).

4

Director, Bald Peak Land Company (2008-2014); Director, Solstice Home Care, Inc. (since 2014).

17
 


Interested New Trustee Nominee

Stephen Bird
Year of Birth: 1967**
TrusteeMr. Bird joined the Board of abrdn plc in July 2020 as Chief Executive-Designate and was formally appointed Chief Executive Officer in September 2020. Previously, Mr. Bird served as chief executive officer of global consumer banking at Citigroup from 2015, retiring from the role in November 2019. His responsibilities encompassed all consumer and commercial banking businesses in 19 countries, including retail banking and wealth management, credit cards, mortgages, and operations and technology supporting these businesses. Prior to this, Mr. Bird was chief executive for all of Citigroup’s Asia Pacific business lines across 17 markets in the region, including India and China. Mr. Bird joined Citigroup in 1998, and during his 21 years with the company he held a number of leadership roles in banking, operations and technology across its Asian and Latin American businesses. Before this, he held management positions in the UK at GE Capital—where he was director of UK operations from 1996 to 1998—and at British Steel.31None

1 The address of each Trustee is abrdn Inc., 1900 Market Street, Suite 200, Philadelphia PA 19103

* As of the date of this Proxy Statement, the “abrdn Fund Complex” consists of: abrdn Income Credit Strategies Fund, abrdn Asia-Pacific Income Fund, Inc., abrdn Global Income Fund, Inc., abrdn Australia Equity Fund, Inc., abrdn Emerging Markets Equity Income Fund, Inc., abrdn Japan Equity Fund, Inc., The India Fund, Inc., abrdn Global Dynamic Dividend Fund, abrdn Total Dynamic Dividend Fund, abrdn Global Premier Properties Fund, abrdn Global Infrastructure Income Fund, abrdn Funds (which consists of 19 portfolios) and abrdn ETFs (which consists of 3 portfolios).

** Would be deemed to be an Interested Trustee of the Funds because of his position held with abrdn.

Continuing Current Independent Trustees

Name, Age
Address1,
Year of
Birth
and Address
Position(s) HeldExpected
Position
with the
Funds
with HQH, HQL,
THQ and THW
Term of
Office and
Length of
Time Served
Principal
Occupations(s)
Occupation(s) Held During Past 5
Five Years
Number
of Funds
in the
Post-Asset
Transfer abrdn
Fund
Complex
Overseen*
Portfolios
in Fund
Complex
Overseen by
Director or
Nominee for
Director
Other
Directorships
Held by Director
Trustee
or Nominee
for Director

INTERESTED TRUSTEEJeffrey A. Bailey

Year of Birth: 1962

TrusteeCEO, IlluminOss Inc. (2018-2020); Board Chairman, Aileron Therapeutics Inc. (since 2017); Director, Madison Vaccines, Inc. (since 2018); Director and CEO, BioDelivery Systems, Inc. (2020-2022).4None
Daniel R. Omstead, Ph.D.* (62)
100 Federal Street,
19th Floor,
Boston, MA 02110

Trustee, HQH, HQL, THQ and THW; President, HQH and HQL (since 2001); President THQ (since 2014); President THW (since 2015); MemberKathleen L. Goetz

Year of each Fund's Valuation Committee.Birth: 1966

Trustee

3 years for HQHVice President and HQL (since 2003)Head of Sales, Novartis Pharmaceuticals (2017-2019); 2 years for THQ (since 2014)Executive Director of Strategic Account Management, Novartis Pharmaceuticals (2015-2016); 2 years for THW (since 2015)Independent Consultant (2020-current).

4

President, HQH and HQL (since 2001); President, THQ (since 2014); President THW (since 2015); President, Chief Executive Officer and Managing Member, Tekla Capital Management LLC (since 2002).

4

Celladon Corporation (2012-2014); Concentric Medical, Inc. (2008-2012); Dynex Corporation (since 2011); EBI Life Sciences, Inc. (since 2015); Euthymics Biosciences, Inc. (since 2015); GenomeDx Biosciences Inc. (since 2016); IlluminOss Medical, Inc. (since 2011); Insightra Medical, Inc. (since 2015); Magellan Diagnostics, Inc. (2006-2016); Neurovance, Inc. (since 2015); Palyon Medical Corporation (2009-2015); Tibion Corporation (2011-2013) and Veniti, Inc. (since 2015).

None

 

1 The address of each Trustee is abrdn Inc., 1900 Market Street, Suite 200, Philadelphia PA 19103

* Trustee considered to be an "interested person" within the meaningAs of the Investment Company Actdate of 1940, as amended (the "1940 Act")this Proxy Statement, the “abrdn Fund Complex” consists of: abrdn Income Credit Strategies Fund, abrdn Asia-Pacific Income Fund, Inc., through position or affiliation with the Adviser.abrdn Global Income Fund, Inc., abrdn Australia Equity Fund, Inc., abrdn Emerging Markets Equity Income Fund, Inc., abrdn Japan Equity Fund, Inc., The India Fund, Inc., abrdn Global Dynamic Dividend Fund, abrdn Total Dynamic Dividend Fund, abrdn Global Premier Properties Fund, abrdn Global Infrastructure Income Fund, abrdn Funds (which consists of 19 portfolios) and abrdn ETFs (which consists of 3 portfolios).


The following table sets forth,shows the ownership of shares of each New Trustee nominee in each Fund and in all of the other funds in abrdn Family of Investment Companies as of October 31, 2022. “Beneficial ownership” is determined in accordance with Rule 16a-1(a)(2) under the 1934 Act.

18

Name of New Trustee NomineeDollar Range of Equity
Securities of the Funds*
Aggregate Dollar Range of Equity
Securities* in all Registered
Investment Companies Overseen by
Trustee in the abrdn Family of
Investment Companies**
Interested Trustee Nominee
Stephen BirdNoneOver $100,000
Independent Trustee Nominees
Rose DiMartinoNone$10,001-$50,000
C. William MaherNone$50,001-$100,000
Todd ReitNone$10,001-$50,000

* The ranges for equity securities ownership by each Trustee are: none; $1-$10,000; $10,001-$50,000; $50,001-$100,000; or over $100,000.

** “abrdn Family of Investment Companies” means those registered investment companies that are advised by abrdn and that hold themselves out to investors as related companies for purposes of investment and investor services.

The following table shows the aggregate dollar rangeownership of equity securities owned by such Trusteeshares of the Continuing Current Independent Trustees in HQH, HQL, THQ and THWeach Fund and in all of the aggregateother funds in HQH, HQL, THQ and THWabrdn Family of Investment Companies as of MarchDecember 31, 2016. The information as to beneficial ownership2022. “Beneficial ownership” is based upon statements furnished by each Trustee.determined in accordance with Rule 16a-1(a)(2) under the 1934 Act.

Name of Continuing Current
Independent Trustee
or Nominee
Dollar Range of Equity
Securities of the Funds*
Equity Securities
in HQH
Dollar Range of
Equity Securities
in HQL
Dollar Range of
Equity Securities
in THQ
Dollar Range of
Equity Securities
in THW
Aggregate Dollar
Range of Equity
Securities* in Allall Registered
FundsInvestment Companies Overseen by
by Trustee in the Post-Asset Transfer
abrdn Family of Investment
Companies**
Fund Complex
Independent
Trustees
Michael W.
Bonney
Jeffrey A. Bailey$10,001-$50,000$10,001-$50,000
Kathleen L. Goetz$10,001-$50,000$50,001-$100,000

Over $100,000

Over $100,000

Rakesh K.
Jain, Ph.D.

None

None

None

None

None

Oleg M.
Pohotsky
$1-$10,000$1-$10,000

None

None

$10,001-$50,000
William S.
Reardon
$10,001-$50,000$10,001-$50,000

None

None

$50,001-$100,000
Uwe E.
Reinhardt, Ph.D.
$50,001-$100,000$50,001-$100,000

None

None

Over $100,000

Lucinda H.
Stebbins, CPA

Over $100,000

Over $100,000

$10,001-$50,000

None

Over $100,000

Interested
Trustee
Daniel R.
Omstead, Ph.D.

Over $100,000

Over $100,000

Over $100,000

Over $100,000

Over $100,000

Although Trustees

* The ranges for equity securities ownership by each Trustee are: none; $1-$10,000; $10,001-$50,000; $50,001-$100,000; or over $100,000.

** “abrdn Family of Investment Companies” means those registered investment companies that are encouragedadvised by abrdn and that hold themselves out to attend the annual meetingsinvestors as related companies for purposes of shareholders to the extent they are able,investment and investor services. 

As of May 31, 2023, none of the Funds has a formal policy with regard to Board members' attendance at annual meetingsIndependent New Trustee nominees or any of shareholders. Last year, sixthe Continuing Current Independent Trustees then in office attended the 2015 annual meetingowned any shares of shareholders of HQH, HQL and THQ.

Shareholders wishing to send communications to the Boardabrdn Inc. or of any Fund may communicateperson directly or indirectly controlling, controlled by or under common control with members of the Board by submitting a written communication directed to the Board in care of Tekla Capital Management LLC, 100 Federal Street, 19th Floor, Boston, MA 02110.abrdn Inc.

Trustees –

Board Leadership Structure and Oversight ResponsibilitiesFunctions

Overall responsibility for general oversight

Board of Trustees.If the Asset Transfer is completed, the total number of Trustees on each Fund’s Board would remain at six. Five of the six Trustees would be independent. The Current Trustees and the New Trustees believe that the proposed size of each Fund restsNew Board is conducive to Board interaction, dialogue, and debate, resulting in an effective decision-making body. Each New Board will be comprised of Trustees with a variety of professional backgrounds. The Current Trustees and the Board.New Trustees believe that the skill sets of the New Trustees are complementary and add to the overall effectiveness of the Boards.

In addition to four regularly scheduled meetings per year, the Boards expect to hold special meetings either in person or virtually to discuss specific matters that may require consideration prior to the next regular meeting. As discussed below, the Boards have established several standing committees to assist the Boards in performing their oversight responsibilities, and each such committee would have a chairperson. The Boards may also designate working groups or ad hoc committees as it deems appropriate.

During the Funds’ fiscal years ended September 30, 2022, each current Board held five meetings. Each of the incumbent Trustees attended 100% of the aggregate number of meetings of the Board of each Fund is comprised of seven individuals, six of whom are not "interested persons"during the period for which he or she served as a Trustee. Each of the Fund as defined in the 1940 Act ("Independent Trustees"). The Chairmancontinuing Trustees attended 100% of the Board is an Independent Trustee. The Chairman presides ataggregate number of meetings of the Trustees, participatesCommittees of the Boards on which such Trustee served during the period that he or she has served.

Board Chair. The Boards expect to appoint Todd Reit, an Independent Trustee, to serve in the role of Chair (replacing the current Chair, Mr. Bailey, who will continue as an Independent Trustee). The Chair’s primary role would be to participate in the preparation of the agenda for meetings of the Board,Boards and actsthe identification of information to be presented to the Boards with respect to matters to be acted upon by the Boards. The Chair would also preside at all meetings of the Boards and between meetings generally act as a liaison betweenwith the Funds’ service providers, officers, legal counsel, and the other Trustees. The Chair would also be expected to perform such other functions as may be requested by the Boards from time to time.

19

The Boards also believe that having a Chair who is an Independent Trustee and having a super-majority of Independent Trustees would be appropriate and in the Fund's management between best interest of the Funds’ shareholders. Nevertheless, the Boards also believe that having an interested person serve on the Boards would likely bring to the Trustees’ deliberations corporate and financial viewpoints that generally are, in the Boards’ view, crucial elements in its decision-making process. The leadership structure of the New Boards may be changed at any time and in the discretion of the Boards, including in response to changes in circumstances or the characteristics of the Funds.

Board meetings. Except for any duties specified herein,Committees

If the designation as Chairman does not impose any obligations or standards greater than or different from other Trustees.Asset Transfer is completed, it is anticipated that each Board will maintain but reconstitute the following standing committees of the Board:


Audit Committee. The BoardAudit Committee is expected to be composed entirely of each Fund holds regular quarterly meetings each year to consider and address matters involving the Fund. The Board also may hold special meetings to address matters arising between regular meetings. The Independent Trustees who also meet outside the presencestandards of management in executive session at least quarterly and have engaged independent legal counsel to assist them in performing their oversight responsibilities.

The Board of each Fund has established Audit, Governance and Nominating, Valuation and Qualified Legal Compliance Committees to assist the Boardindependence for audit committee members set forth in the oversightlisting standards of the managementNew York Stock Exchange (“NYSE”); its members are expected to be C. William Maher, Todd Reit, Jeffrey A. Bailey, Kathleen L. Goetz and affairsRose DiMartino. C. William Maher is expected to be determined by the New Boards to be an “audit committee financial expert” as that term is defined under Item 407 of Regulation S-K. The Audit Committee will make recommendations to the New Boards concerning the selection of the Fund. All of the members of these Committees are Independent Trustees, except for Dr. Omstead, who serves on the Valuation Committee. From time to time the Board may establish additional committees or informal working groups to deal with specific matters.

Each Fund is subject to a number of risks including investment, compliance, operational and valuation risks. Although the Adviser and the officers of each Fund are responsible for managing these risks on a day-to-day basis, the Board of each Fund has adopted, and periodically reviews, policies and procedures designed to address these risks. As part of its regular oversight, the Board of each Fund, directly or through a Committee, interacts with the Fund's Chief Compliance Officer, the Fund'sFunds’ independent registered public accounting firm based on discussion and review of any necessary disclosures pertaining to the Fund's legal counsel. These interactions include discussingaccounting firm’s independence, review with such independent registered public accounting firm the Fund's risk managementscope and controls withresults of the Funds’ annual audit and consider any comments that the independent registered public accounting firm engaged bymay have regarding the Fund, reviewing valuation policies and procedures and the valuations of specific restricted securities, and receiving periodic reports from the Fund's Chief Compliance Officer regarding compliance matters relating to the Fund and its major service providers, including resultsFunds’ financial statements, accounting records or internal controls.

Each Fund’s current Audit Committee consists of the implementationfollowing current Independent Trustees: Thomas M. Kent (Chair), Kathleen L. Goetz and testingW. Mark Watson. Each current Audit Committee member also meets the standards of independence for audit committee members set forth in the listing standards of the Fund's and such providers' compliance programs. The Board's oversight function is facilitated by management reporting processes designed to provide information to theNYSE. Each Fund’s current Board regarding the identification, assessment, and management of critical risks and the controls and policies and procedures used to mitigate those risks. The Board reviews its role in supervising the Fund's risk management from time to time and may change the manner in which it fulfills its oversight responsibilities at its discretion at any time.

The Board of each Fund has determined that its leadership structure is appropriate for the Fund because it enables the Board to exercise informed and independent judgment over matters under its purview, allocates responsibility among committees in a manner that fosters effective oversight and allows the Board to devote appropriate resources to specific issues in a flexible manner as they arise. The Board periodically reviews its leadership structure as well as its overall structure, composition, and functioning and may make changes at its discretion at any time.

Standing Committees

Audit Committee. Each Fund has an Audit Committee comprised solely of Independent Trustees who are "independent" as defined in the New York Stock Exchange ("NYSE") Listing Standards. The Board of each Fund has adopted a formal written charter for the Audit Committee. TheEach current Audit Committee charter is available at http://www.teklacap.com/hqh-reports.html. The principal purpose of each Fund's Audit Committee is to assist the Board in fulfilling its responsibility to oversee management's conduct of the Fund's financial reporting process, including reviewing the financial reports and other financial information provided by the Fund, the Fund's systems of internal accounting and financial controls and the annual independent audit process.

Each Audit Committee's role is one of oversight, and it is recognized that each Fund's management is responsible for preparing each Fund's financial statements and that each Fund's independent registered public accountant is responsible for auditing those financial statements. Although each Audit Committee


member must be financially literate and one member must have accounting or financial management expertise (as determined by the Board in its business judgment), Audit Committee members are not professionally engaged in the practice of accounting or auditing and are not experts in the fields of accounting or auditing, including with respect to auditor independence. Audit Committee members rely, without independent verification, on the information provided to them and on the representations made by management and each Fund's independent registered public accountants.

The members of each Fund's Audit Committee are Mr. Pohotsky, Mr. Reardon, Dr. Reinhardt and Ms. Stebbins. Ms. Stebbins is the Chairman of each Fund's Audit Committee. The Audit Committee of each of HQH, HQL and THQ held four meetings during the fiscal year ended September 30, 2015. 2022.

Governance and Nominating Committee. The AuditGovernance and Nominating Committee is expected to be composed entirely of THWIndependent Trustees; its members are expected to be Todd Reit, Jeffrey A. Bailey, Kathleen L. Goetz, Rose DiMartino and C. William Maher, all of whom meet the independence requirements set forth in the listing standards of the NYSE. The Governance and Nominating Committee will be responsible for overseeing the New Boards’ governance and related Trustee practices, including selecting and recommending candidates to fill vacancies on the New Boards. The Governance and Nominating Committee will consider Trustee candidates recommended by shareholders of the Funds.

The current Governance and Nominating Committee consists of: Jeffrey A. Bailey, Dr. Rakesh K. Jain (Chair) and Thomas M. Kent, all of whom meet the independence requirements set forth in the listing standards of the NYSE. Each Fund’s current Board has adopted a formal written charter for the Governance and Nominating Committee, a copy of which is included as Exhibit C to this Joint Proxy Statement. Each current Governance and Nominating Committee held twofive meetings during the fiscal year ended September 30, 2015.2022.

Governance and Nominating Committee. Each Fund has a Governance and Nominating Committee comprised solely of Independent Trustees who are "independent" as defined in the NYSE Listing Standards. The Committee charter is not available on the Fund's website but the written charter is included as Exhibit A to this Proxy Statement dated April 20, 2016.

The principal missions of the Governance and Nominating Committee of each Fund are to (i) review, evaluate, and enhance the effectiveness of the Board in its role in governing the Fund and overseeing the management of the Fund and (ii) to promote the effective participation of qualified individuals on the Board, on committees of the Board, and as executive officers of the Fund. The Committee shall consider the Corporate Governance Guidelines that have been approved by the Board in fulfilling its missions.

The Committee of each Fund reviews, discusses and makes recommendations to the Board relating to those issues that pertain to the effectiveness of the Board in carrying out its responsibilities in governing the Fund and overseeing the Fund's management. The Committee makes nominations for Trustees and officers of the Fund and for membership on all committees of the Board and submits such nominations to the full Board for consideration.

Each Fund'sFund’s By-Laws require that each prospective trustee candidate have a college degree or equivalent business experience and provide a list of minimum qualifications for trustees, which include expertise, experience or relationships relevant to the business of the Fund. Each Fund'sFund’s By-Laws also require that a candidate not be serving in any of various positions with another investment company (as defined in the 1940 Act) that focuses its investments in the healthcare and/or life sciences industries, unless such investment company is managed by the Fund'sFund’s investment adviser or an affiliate, or in various positions with the investment adviser, sponsor or equivalent of such an investment company. Each current Governance and Nominating Committee may also take into account other factors when considering and evaluating potential trustee candidates, including but not limited to: (i) availability and commitment to attend meetings and perform responsibilities of the Board; (ii) relevant industry and related experience; (iii) educational background; (iv) financial expertise; (v) the candidate'scandidate’s ability, judgment and expertise; and (vi) the overall diversity of the Board'sBoard’s composition.

The Committee of

20

While each Fund may identify prospective trustees from any reasonable source, including, but not limited to, the consultation of third-party trustee search services. The Committee will consider potential trustee candidates recommended by shareholders, provided that the proposed candidates (i) satisfy any minimum qualifications of the Fund for its trustees; (ii) are not "interested persons" (as that term is defined in Section 2(a)(19) of the 1940 Act) of the Fund or the Adviser; and (iii) are "independent" as defined in the NYSE Listing Standards. In order to be evaluated by the Committee, trustee candidates recommended by shareholders must also meet certain eligibility requirements as


set out in the Committees' charter. Other than those eligibility requirements, the Committee shall not evaluate shareholder trustee nominees in a different manner than other nominees. The standard of the Committee is to treat all equally qualified nominees in the same manner.

All recommendations by shareholders must be received by a Fund by the deadline for submission of any shareholder proposals which would be included in the Fund's proxy statement for the next annual meeting of the Fund. Each shareholder or shareholder group must meet the requirements stated in the Committee's charter in order to recommend a candidate. A shareholder or shareholder group may not submit more than one candidate per year. When recommending a trustee candidate, shareholders must include in their notice to the Fund's Secretary: (i) the shareholder's contact information; (ii) the trustee candidate's contact information and the number of Fund shares owned by the proposed candidate; (iii) all information regarding the candidate that would be required to be disclosed in solicitations of proxies for elections of trustees required by Regulation 14A of the Securities Act of 1934, as amended (the "Exchange Act"); and (iv) a notarized letter executed by the trustee candidate, stating his or her intention to be a nominee and be named in the Fund's proxy statement, if nominated by the Board, and to serve as a trustee, if so elected. Once a recommendation has been timely received in proper form, the candidate will be asked to complete an eligibility questionnaire to assist the Fund in assessing the candidate's qualifications as a potential Independent Trustee and as someone who is "independent" under the NYSE Listing Standards. The Committee will make such determinations in its sole discretion and such determinations shall be final.

The members of each Fund's Committee are Mr. Bonney, Dr. Jain and Ms. Stebbins. Mr. Bonney is the Chairman of the Committee. The Governance and Nominating Committees of each of HQH, HQL and THQ held two meetings during the fiscal year ended September 30, 2015. Thecurrent Governance and Nominating Committee is solely responsible for the selection and nomination of THW held one meeting during the fiscal year ended September 30, 2015.New Trustees, the Committee will also review and consider Trustee nominations made by management and by Fund shareholders who have sent nominations (which include the biographical information and the qualifications of the proposed nominee) to the Funds, as the Trustees deem appropriate.

Valuation Committee.Committee. Each Fund's Board has delegated to the Fund'sThe Valuation Committee generalis expected to be composed entirely of Independent Trustees; its members are expected to be Jeffrey A. Bailey, Kathleen L. Goetz and C. William Maher, all of whom meet the independence requirements set forth in the listing standards of the NYSE. Each Fund’s Valuation Committee will have the responsibility for determining, subject to New Board ratification, in accordance with the Fund'sFund’s valuation procedures, the value of assets held by the Fund on any day on which the net asset value per share is determined. The Valuation Committee may appoint and has appointed, a Sub-Committee made up of employees and officers of the Adviser to deal with day to day valuation decisions,abrdn Inc., subject to oversight by the Valuation Committee. The Valuation Committee shall meet as often as necessary to ensure that each action taken by the Sub-Committee is reviewed within a calendar quarter of the occurrence. In connection with its review, the Valuation Committee shall ratify or revise the pricing methodologies authorized by the Sub-Committee since the last meeting of the Valuation Committee. The Valuation Committee is charged with the responsibility of determining the fair value of the Fund'sFund’s securities or other assets in situations set forth in the Fund'sFund’s valuation procedures.

The members of each Fund'sFund’s current Valuation Committee are Mr. Bonney,Jeffrey A. Bailey (Chair), Kathleen L. Goetz, Dr. Daniel R. Omstead Mr. Pohotsky and Mr. Reardon. Mr. Pohotsky is the Chairman of each Fund'sW. Mark Watson. Each current Valuation Committee. The Valuation Committees of each of HQH, HQL and THQCommittee held four meetings during the fiscal year ended September 30, 2015. The Valuation2022.

Other Current Committee of THW held one meeting during the fiscal year ended September 30, 2015.Funds

Qualified Legal Compliance Committee.Committee. Each Fund has a Qualified Legal Compliance Committee ("QLCC"(“QLCC”) comprised solely of Independent Trustees. The current Board of each Fund has adopted a written charter for the QLCC. The principal purpose of the Fund'sFund’s QLCC is to review and respond to reports of Evidence of a Material Violation (as defined in the QLCC charter). Reporting Evidence of a Material Violation is required under the Standards of Professional Conduct for Attorneys adopted by the U.S. Securities and Exchange


Commission (the "SEC"“SEC”) under the Sarbanes-Oxley Act of 2002 (the "Standards"“Standards”). Under the Standards, if an attorney appearing and practicing before the SEC in the representation of an issuer, such as the Fund, becomes aware of Evidence of a Material Violation by the issuer or by any officer, trustee, employee or agent of the issuer, the Standards provide for the attorney to report such evidence to the issuer'sissuer’s QLCC forthwith. In discharging its role, the QLCC is granted the power to investigate any Evidence of a Material Violation brought to its attention with full access to all books, records, facilities and personnel of the Fund and the power to retain outside counsel, auditors or other experts for this purpose.

The members of each Fund'sFund’s current QLCC are Dr. Rakesh K. Jain Mr. Pohotsky and Mr. Reardon. Mr. Reardon is the Chairman of each Fund's QLCC.Thomas M. Kent (Chair). Each Fund'sFund’s QLCC had no cause to meet during the fiscal year ended September 30, 2015.2022.

The New Boards do not currently anticipate continuing the QLCC but are expected instead to appoint a chief legal officer to serve in lieu of such committee.

The New Boards may establish additional committees as they deem necessary or convenient.

21

New Trustee Nominee and Continuing Current Independent Trustee Qualifications

Below is a brief summary of the qualifications of each New Trustee nominee and Continuing Current Independent Trustee as of the date of this Joint Proxy Statement.

Attendance.New Trustee Nominees

DuringStephen Bird. Mr. Bird joined the fiscal year ended September 30, 2015, HQH's and HQL's Boards each held six meetings, THQ's Board of Trusteesabrdn plc (formerly, Standard Life Aberdeen plc) in July 2020 as Chief Executive-Designate and was formally appointed Chief Executive Officer in September 2020. Previously, Mr. Bird served as chief executive officer of global consumer banking at Citigroup from 2015, retiring from the role in November 2019. His responsibilities encompassed all consumer and commercial banking businesses in 19 countries, including retail banking and wealth management, credit cards, mortgages, and operations and technology supporting these businesses. Prior to this, Mr. Bird was chief executive for all of Citigroup’s Asia Pacific business lines across 17 markets in the region, including India and China. Mr. Bird joined Citigroup in 1998, and during his 21 years with the company he held five meetingsa number of leadership roles in banking, operations and THW's Boardtechnology across its Asian and Latin American businesses. Before this, he held management positions in the UK at GE Capital – where he was director of Trustees held three meetings; HQH, HQLUK operations from 1996 to 1998 – and THQ'sat British Steel. Mr. Bird serves as an interested Director/Trustee on a number of abrdn-advised funds, including abrdn’s U.S. closed-end funds.

Rose DiMartino. Ms. DiMartino was previously a Partner (1991 – 2017) and Senior Counsel (2017 – 2019) in the asset management department at the law firm of Willkie Farr & Gallagher LLP. Ms. DiMartino has over 30 years of experience counseling registered investment companies and their advisers in all aspects of fund organization and operation. Ms. DiMartino is a Trustee of abrdn ETFs. In the healthcare and biotech field, Ms. DiMartino served as legal counsel to the Gabelli Healthcare and Wellness Trust, a closed-end fund, from its launch in 2007 until her retirement in 2019, handling its SEC registration, the adoption of discount-management mechanisms and capital-raising strategies. Ms. DiMartino also advised the board on various governance, disclosure and legal and regulatory matters.

C. William Maher. Mr. Maher is a Co-founder of Asymmetric Capital Management LLC from May 2018 to September 2020. Formerly Chief Executive Officer of Santa Barbara Tax Products Group from October 2014 to April 2016. Prior to that Mr. Maher served as Chief Financial Officer of Santa Barbara Tax Products Group from 2010 to 2014. Mr. Maher serves as the Audit Committees each held four meetingsChair and THW's Audit Committee held two meetings; HQHDirector of abrdn Emerging Markets Equity Income Fund, Inc. and HQL's Governanceas a Director of abrdn Japan Equity Fund, Inc. Earlier in Mr. Maher’s career, he was responsible for the Fund Administration Group, overseeing finance/accounting and Nominating Committees each held two meetingscompliance for the Invesco Global Healthcare Fund.

Todd Reit. Mr. Reit is a Managing Member of Cross Brook Partners LLC, a real estate investment and THQmanagement company, since 2017. Mr. Reit is also Director and THW's GovernanceFinancial Officer of Shelter Our Soldiers, a charity to support military veterans, since 2016. Mr. Reit was formerly a Managing Director and Nominating Committees each held one meeting; HQH, HQLGlobal Head of Asset Management Investment Banking for UBS AG, where he was responsible for overseeing all the bank’s asset management client relationships globally, including all corporate security transactions, mergers and THQ's Valuation Committees each held four meetingsacquisitions. Mr. Reit retired from UBS in 2017 after an over 25-year career at the company and THW's Valuation Committee held one meeting.its predecessor company, PaineWebber Incorporated (merged with UBS AG in 2000).

Each Mr. Reit serves as a Trustee of the Trustees attended at least 100%abrdn Global Infrastructure Income Fund, abrdn Global Dynamic Dividend Fund, abrdn Total Dynamic Dividend Fund and abrdn Global Premier Properties Fund. Mr. Reit began his career in healthcare investing banking and worked on the IPOs of multiple bio-tech and healthcare companies. Mr. Reit also led the aggregate numberIPO for the Invesco Global Health Science Fund in 1992 and was the sole advisor to its follow-on rights offering in 1999.

Continuing Current Independent Trustees

Jeffrey A. Bailey. Mr. Bailey is a seasoned operational healthcare executive with over 30 years of meetings ofleadership experience within the Boards of HQH, HQLhealthcare industry. Mr. Bailey has extensive business development and THWtransactional expertise, with diverse leadership experiences in commercial and each of the Trustees attended at least 80% of the aggregate number of meetingssupply chain management, finance, business development and product development for various pharmaceutical medical device companies. He serves as Chairman of the Board of THWTrustees and also on the Valuation Committee and on the Governance and Nominating Committee of the Fund. Most recently, Mr. Bailey served as chief executive officer and director of BioDelivery Sciences, a biotechnology company, from 2020-2022. He served as president and chief executive officer of IlluminOss Medical, Inc., a medical device company, from 2018 to 2020. From 2015 until 2017, Mr. Bailey served as chief executive officer of Neurovance, Inc., a biotechnology company. Previously, from 2013 through 2015, Mr. Bailey served as president and chief executive officer and as a director of Lantheus Medical Imaging, Inc., a public medical diagnostic company. Prior to 2013, Mr. Bailey held various leadership positions with several public and private pharmaceutical and medical device companies, including president and general manager at Novartis Pharmaceuticals, a multinational pharmaceutical company, and a 22-year career with Johnson & Johnson, a multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company. Mr. Bailey also has extensive board member experience, having previously served on boards of directors for eight companies. Mr. Bailey currently serves as a director for Aileron Therapeutics, Inc. and Madison Vaccines, Inc. Mr. Bailey holds a BA in business administration from Rutgers University.

Kathleen Goetz. Ms. Goetz brings to the Fund over 30 years of healthcare business and leadership experience. She brings extensive knowledge of healthcare markets, with leadership experience across product development, operational effectiveness, organizational governance and design, and marketing and sales strategy. She currently acts as a consultant and an advisor within the pharmaceutical, biotech, and medical technology sectors. Ms. Goetz was Vice President Head of Sales at Novartis Pharmaceuticals, a global healthcare company until 2019. During her 28 years with Novartis, Ms. Goetz held positions of increasing responsibility, leading marketing, sales and reimbursement teams through various stages of commercialization from pre-launch planning through to loss of exclusivity across diverse therapeutic areas. Other key roles during her time at Novartis also include National Executive Director of Strategic Accounts, Integrated Market Planning and Marketing Director, providing her with valuable experience leading organizational transformation, resourcing, forecasting, and analytics. She continues to act as a mentor to future leaders and as a champion for diversity through her past work as an Executive Leadership Development mentor and a former Novartis Pharmaceuticals Women in Leadership Chair. Ms. Goetz has won numerous healthcare and business leadership awards and recognition throughout her career, including being recognized with the Healthcare Women’s Business Association Rising Star Award. She serves on the Audit Committee and Valuation Committee of the Fund. Ms. Goetz holds a Business Finance degree from Iowa State University.

22

New Boards’ Role in Risk Oversight

The Funds are subject to a number of risks, including, among others, investment, compliance, operational and valuation risks. Risk oversight will form part of the New Boards’ general oversight of the Funds and will be addressed as part of various Board and Committee activities. The New Boards will adopt, and periodically review, policies and procedures designed to address these risks. Different processes, procedures and controls will be employed with respect to different types of risks. Day-to-day risk management functions will be subsumed within the responsibilities of abrdn Inc., who will carry out the Funds’ investment management and business affairs and other service providers in connection with the services they will provide to the Funds. abrdn Inc. and other service providers have their own, independent interest in risk management, and their policies and methods of risk management will depend on their functions and business models. As part of their regular oversight of the Funds, the New Boards, directly and/or through a Committee, will interact with and review reports from, among others, abrdn Inc. and the CommitteesFunds’ other service providers (including the Funds’ transfer agent), the Funds’ Chief Compliance Officer, the Funds’ independent registered public accounting firm, legal counsel to the Funds, and internal auditors, as appropriate, relating to the operations of the Funds. The New Boards also will require abrdn Inc. to report to the New Boards on other matters relating to risk management on a regular and as-needed basis. The New Boards recognize that it may not be possible to identify all of the risks that may affect the Funds or to develop processes and controls to eliminate or mitigate their occurrence or effects. The New Boards may, at any time and in their discretion, change the manner in which they conduct risk oversight.

Board Compensation

None of eachthe New Trustee nominees have served as a Trustee of the Funds. Therefore, none of the New Trustee nominees have received any compensation from the Funds. Each New Trustee, with the exception of Stephen Bird, will be paid by the Funds for his or her services as an Independent Trustee. If the New Trustee nominees are elected and take office, the Boards may establish a new compensation schedule for their Independent Trustees. The new compensation schedule for the Independent Trustees may take into account their services provided to other funds in the abrdn Fund on which such Trustee served during the fiscal year-ended September 30, 2015.Complex, if any. The Funds will not pay any compensation to an Interested Trustee.

Compensation of Trustees and Officers

For the fiscal year ended September 30, 2015,2022, each Fund paid an annual fee of $15,000$17,500 (the annual fee was $16,250 from January 1, 2021 through December 31, 2021) to its Independent Trustees and the Chairman of the Board receivesreceived an additional annual fee of $5,000. Additionally, each Fund paid each Independent Trustee $1,000 for each Board and $750 for each Committee meeting attended in person and(from January 1, 2021 through December 31, 2021 each Fund paid $250 for each Board and Committee meeting attended by telephone.telephone). The Chairman of the Board, the Chairman of the Audit Committee, and the Chairman of the Valuation Committee of each Fund each received an additional annual fee of $2,500. The Chairman ofand the Governance and Nominating Committee of each Fund each received an additional annual fee of $1,250.$2,000. Independent Trustees are also reimbursed for travel expenses incurred in connection with attending such meetings. For the fiscal year ended September 30, 2015,2022, the Independent Trustees as a group received $2,082$2,098 from HQH, $897$898 from HQL, $428$2,037 from THQ and $136$1,140 from THW for reimbursed expenses. No Fund directly paid any additional compensation to the Trustees for the fiscal year ended September 30, 2015.

Each Fund has entered into a Services Agreement (the "Agreement") with the Adviser.Tekla. Pursuant to the terms of the Services Agreement, each Fund reimburses the AdviserTekla for a portion of the payment of salary and provision of benefits to each Fund'sFund’s Chief Compliance Officer. During the fiscal year ended September 30, 2015 these payments amounted to $95,789 for HQH, $39,935 for HQL, $79,201 for THQ and $7,137 for THW.Current Trustees and officers of each Fund who hold positions with the AdviserTekla receive indirect compensation from the investment advisory fee paid to the AdviserTekla by each Fund. The Services Agreement will not be needed if the Asset Transfer is completed. Consistent with the approach taken with respect to other closed-end funds managed by abrdn, abrdn, and not the Funds, shall be responsible for the salary and benefits of the Funds’ Chief Compliance Officer, who is employed by abrdn Inc.

23

The following table sets forth information regarding compensation of the Trustees and Executive Officer by each Fund for the fiscal year ended September 30, 2015,2022, but does not include expenses.reimbursed expenses as described above.


Name of Person,
Position

Aggregate

Compensation

from Each Fund

Pension or
Retirement
Benefits
Accrued as
part of
Each
Fund’s
Expenses
Estimated
Annual
Benefits
upon
Retirement
Total
Compensation
from All
Funds in
Tekla Fund
Complex Paid
to Trustees
Independent Trustees*HQHHQLTHQTHW   
Jeffrey A. Bailey$30,021$30,021$30,021$30,021N/AN/A$120,083
Kathleen L. Goetz$23,979$23,979$23,979$23,979N/AN/A$95,917
Rakesh K. Jain, Ph.D.$28,104$28,104$28,104$28,104N/AN/A$112,417
Thomas M. Kent$29,938$29,938$29,938$29,938N/AN/A$119,750
W. Mark Watson$11,083$11,083$11,083$11,083N/AN/A$44,333
Interested Trustee
Daniel R. Omstead, Ph.D.$0$0$0$0N/AN/A$0
Executive Officer
Laura Woodward$139,755$65,401$111,837$54,976N/AN/AN/A

Compensation Table** Kathleen L. Goetz was appointed as a Trustee effective December 9, 2021. W. Mark Watson was appointed as a Trustee effective June 9, 2022.

Name of Person, Position

 Aggregate
Compensation
from each Fund
 Pension or
Retirement
Benefits Accrued
as part of each
Fund's Expenses
 Estimated
Annual
Benefits upon
Retirement
 Total
Compensation
from All Funds
in Fund Complex
Paid to Trustees
 

Independent Trustees

 

HQH

 

HQL

 

THQ

 

THW

       

Michael W. Bonney

 

$

25,375

  

$

25,375

  

$

23,105

  

$

23,750

   

N/A

   

N/A

  

$

97,605

  

Rakesh K. Jain, Ph.D.

 

$

20,938

  

$

20,938

  

$

19,542

  

$

19,500

   

N/A

   

N/A

  

$

80,918

  

Oleg M. Pohotsky

 

$

33,125

  

$

33,125

  

$

27,460

  

$

32,500

   

N/A

   

N/A

  

$

126,210

  

William S. Reardon, CPA

 

$

26,000

  

$

26,000

  

$

24,418

  

$

25,000

   

N/A

   

N/A

  

$

101,418

  

Uwe E. Reinhardt, Ph.D.

 

$

19,375

  

$

19,375

  

$

18,834

  

$

20,000

   

N/A

   

N/A

  

$

77,584

  

Lucinda H. Stebbins, CPA

 

$

25,438

  

$

25,438

  

$

22,584

  

$

25,000

   

N/A

   

N/A

  

$

98,460

  

Interested Trustees

               

Daniel R. Omstead, Ph.D.

 

$

0

  

$

0

  

$

0

  

$

0

   

N/A

   

N/A

  

$

0

  

 *

Officers

Information relating to the current officers of the Funds is set forth in Schedule 3 to this Joint Proxy Statement. The table includesBoards elect the Funds’ officers, who are responsible for administering the Funds’ day-to-day operations. If the Asset Transfer is completed, it is expected that the New Boards will elect a new slate of officers. The Funds will not pay any compensation paid by HQH, HQL and THQ forto the fiscal year ended September 30, 2015. As THW has not completed a full yearnew officers. Information relating to the new slate of operation, information provided for THW estimates paymentsofficers expected to be made forelected into office by the fiscal year ending September 30, 2016.

Executive Officers

SetNew Boards is set forth belowin Schedule 4 to this Joint Proxy Statement. This information is information for at leastsubject to change. To the last five years with respect toknowledge of the executiveFunds’ management, as of June 16, 2023, the Current Trustees, New Trustees, the current officers and the expected new officers owned, as a group, less than 1% of the outstanding shares of each Fund who do not also serve as Trustees. Each officer has been elected by the Board of each Fund and serves at the pleasure of the Board.Fund.

Laura Woodward, CPA (47), 100 Federal Street, 19th Floor, Boston MA 02110: Chief Compliance Officer, HQH and HQL and Tekla Capital Management LLC (since 2009), of THQ (since 2014) and of THW (since 2015); Secretary and Treasurer, HQH, HQL (since 2009), of THQ (since 2014) and of THW (since 2015); Senior Manager, PricewaterhouseCoopers LLP (prior to 2009).

Required Vote

Each Fund's Declaration of Trust states that the Trustees shall be elected by a plurality of each Fund's shares voting at the Annual Meeting. The Trustees recommend a vote FOR all nominees.

INFORMATION PERTAINING TO THE ADVISER

The Adviser is a limited liability company organized under the laws of Delaware. Under each Fund's Investment Advisory Agreement, the Adviser is responsible for the management of the Fund's assets, subject to the supervision of the Board. The Adviser manages the investments of each Fund in accordance with its investment objective and policies. The Adviser is also obligated to supervise and perform certain administrative and management services and is obligated to provide the office space, facilities, equipment and personnel necessary to perform its duties. Except for a portion of the salary of each Funds' Chief Compliance Officer, the salaries of all officers of each Fund and all personnel of each Fund or of the Adviser performing services relating to research, statistical or investment activities, and of all Trustees who are "interested persons" of the Fund or of the Adviser (as defined in the 1940 Act), are paid by the Adviser. The Adviser is located at 100 Federal Street, 19th Floor, Boston, MA 02110.

Daniel R. Omstead Ph.D. serves as President and Chief Executive Officer of the Adviser. The address for Dr. Omstead is c/o the Adviser at 100 Federal Street, 19th Floor, Boston, MA 02110.


REPORT OF THE AUDIT COMMITTEE OF EACH FUND

Each Fund'sFund’s Audit Committee reviewed and discussed the Fund'sFund’s audited financial statements with management for the Fund'sFund’s fiscal year ended September 30, 2015,2022, and discussed with the Fund'sFund’s independent registered public accountants, Deloitte & Touche LLP (“Deloitte”), the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board ("PCAOB"(“PCAOB”) Standard No. 16, as modified or supplemented.and the SEC. Each Fund'sFund’s Audit Committee received written disclosures and the letter from Deloitte & Touche LLP required by applicable requirements of the PCAOB Ethics and Independence Rule 3526 regarding Deloitte & Touche'sDeloitte’s communications with the Audit Committee concerning independence and discussed with Deloitte & Touche LLP its independence. Based on its review and discussions with management and Deloitte, & Touche LLP, the Fund'sFund’s Audit Committee recommended to the Board that the Fund'sFund’s audited financial statements for the Fund'sFund’s fiscal year ended September 30, 2015,2022, be included in the Fund'sFund’s Annual Report filed with the SEC.

SUBMITTED BY THE AUDIT COMMITTEE OF EACH FUND

24

Oleg M. Pohotsky
William S. Reardon
Uwe E. Reinhardt
Lucinda Stebbins

Proposal 2
RATIFICATION OR REJECTION OF SELECTION OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTANTS

Each Fund'sAs of the date of each Fund’s last annual report dated September 30, 2022, the members of each Audit Committee has approvedare Thomas M. Kent, CPA, Kathleen L. Goetz, W. Mark Watson and none of the appointmentmembers are considered to be “interested persons” under the 1940 Act.

Representatives of Deloitte & Toucheare not expected to attend the Special Meetings. It is expected that the New Boards will appoint KPMG LLP as auditor of the independent registered public accountantsFunds for the fiscal year ending September 30, 2016, and a majority of the Board of each Fund, including a majority of the Independent Trustees, subsequently ratified the appointment.2023.

Accounting services to be performed by Deloitte & Touche LLP for each Fund will consist of the examination of the annual financial statements of the Fund, consultation on financial, accounting and reporting matters, review and consultation regarding various filings with the SEC and attendance at some meetings of the Board. Deloitte & Touche LLP also will perform non-audit services consisting of review of income tax returns of each Fund.

A representative of Deloitte & Touche LLP is expected to participate in the Joint Annual Meeting and to be available for questioning and have an opportunity to make a statement.

The following tables set forth the aggregate fees billed for professional services rendered by Deloitte & Touche LLP to each Fund during each Fund'sFund’s two most recent fiscal years:

Fund

 

Fiscal year

 

Audit Fees

 

Audit-Related Fees

 

Tax Fees

 

All Other Fees

 

HQH

  

2015

  

$

108,010

  

$

0

  

$

4,650

  

$

0

  
   

2014

  

$

109,000

  

$

0

  

$

4,650

  

$

0

  

HQL

  

2015

  

$

108,010

  

$

0

  

$

4,650

  

$

0

  
   

2014

  

$

109,000

  

$

0

  

$

4,650

  

$

0

  

THQ

  

2015

  

$

36,000

  

$

0

  

$

4,650

  

$

0

  
   

2014

  

$

36,000

  

$

0

  

$

4,650

  

$

0

  

Fund

 

Fiscal year

 

Audit Fees

 

Audit-Related Fees

 

Tax Fees

 

All Other Fees

 

THW

  

2015

  

$

39,000

  

$

0

  

$

4,650

  

$

0

  

  

2014

   

n/a

  

n/a

   

n/a

  

n/a

  

FundFiscal YearAudit FeesAudit-Related FeesTax FeesAll Other Fees
HQH2022$114,230$0$6,670$0
 2021$109,150$0$6,180$0
HQL2022$115,180$0$6,670$0
 2021$108,270$0$6,180$0
THQ2022$72,930$0$6,670$0
 2021$70,030$0$6,180$0
THW2022$72,930$0$14,170$0
 2021$70,030$0$11,955$0

All of the services described in the table above were approved by each Audit Committee pursuant to its pre-approval policies and procedures (the "Pre-Approval“Pre-Approval Policies and Procedures"Procedures”) which are summarized below to the extent that such services were required to be pre-approved by each Audit Committee.

The aggregate non-audit fees billed by Deloitte & Touche LLP for services rendered to each Fund and to the Adviser, or an affiliate thereof that provides ongoing services to each Fund, amounted to $4,650 for the fiscal years ended September 30, 2015 and 2014 for HQH, HQL and THQ and $4,650 for the fiscal year ended September 30, 2015 for THW.

Each Fund'sFund’s Audit Committee has adopted Pre-Approval Policies and Procedures pursuant to which the Committee pre-approves all audit and non-audit services provided by the Fund'sFund’s independent auditor (the "Auditor"“Auditor”) and any non-audit services provided by the Auditor to the Fund'sFund’s investment adviser and service affiliates ("(“Service Affiliates"Affiliates”) during the period of the Auditor'sAuditor’s engagement to provide audit services to the Fund, if those services directly impact the Fund'sFund’s operations and financial reporting. Audit services include those typically associated with the annual audit such as evaluation of internal controls. Non-Audit services include certain services that are audit-related, such as consultations regarding financial accounting and reporting standards and tax services. Certain services may not be provided by the Auditor to the Fund'sFunds or the Fund'sFunds’ Service Affiliates without jeopardizing the Auditor'sAuditor’s independence. These services are deemed prohibited services and include certain management functions; human resources services; broker-dealer, investment adviser or investment banking services; legal services; and expert services unrelated to the audit. Other services are conditionally prohibited and may be provided, if the Audit Committee reasonably concludes that the results of the services will not be subject to audit procedures during an audit of the Fund'sFunds’ financial statements. These types of services include bookkeeping; financial information systems design and implementation; appraisal or valuation services; actuarial services; and internal audit outsourcing services.

The Pre-Approval Policies and Procedures of each Fund'sFund’s Audit Committee require Audit Committee approval of the engagement of the Auditor for each fiscal year and approval of the engagement by at least a majority of the Fund'sFund’s Independent Trustees. In determining whether to engage the Auditor for its audit services, each Fund'sFund’s Audit Committee will consider the Auditor'sAuditor’s proposed fees for the engagement, in light of the scope and nature of the audit services that the Fund will receive.

The Pre-Approval Policies and Procedures also permit each Fund'sFund’s Audit Committee to pre-approve the provisions of types or categories of permissible non-audit services for the Fund and its Service Affiliates on an annual basis at the time of the Auditor'sAuditor’s engagement and on a project-by-project basis. At the time of the annual engagement of each Fund'sFund’s Auditor, each Audit Committee is to receive a list of the categories of expected non-audit services with a description and an estimated budget of fees. In their pre-approval, each Audit Committee should determine that the provision of the service is consistent with, and will not impair, the ongoing independence of the Auditor and set any limits on fees or other conditions they find appropriate. Non-audit services may also be approved on a project-by-project basis by each Audit Committee consistent with the same standards for determination and information.

25


Each Audit Committee may also appoint a member of each Committee to pre-approve non-audit services that have not been pre-approved or material changes in the nature or cost of any non-audit services previously pre-approved. The member may not pre-approve any project the estimated budget (or budgeted range) of fees of which exceed or may exceed $15,000. Any actions by the member are to be ratified by the Audit Committee by the time of its next scheduled meeting. Each Fund'sFund’s Pre-Approval Policies and Procedures are reviewed annually by the Fund'sFund’s Audit Committee, and the Fund maintains a record of the decisions made by the Committee pursuant to these procedures.

Required Vote

The selection of Deloitte & Touche LLP as each Fund's independent public accountants for the fiscal year ending September 30, 2016 is submitted to shareholders for ratification and requires approval by a majority of each Fund's shares voting at the Joint Annual Meeting. The Trustees recommend a vote FOR the selection of Deloitte & Touche LLP as the independent registered public accountants of each Fund.

Proposal 3
CHANGE THE SUBCLASSIFICATION OF HQH
FROM DIVERSIFIED TO NON-DIVERSIFIED AND
ELIMINATE THE RELATED FUNDAMENTAL INVESTMENT RESTRICTION

The Board has unanimously approved, and recommends that shareholders of HQH approve, changing the subclassification of HQH from a "diversified" fund to a "non-diversified" fund, as such terms are defined in the 1940 Act. Section 13(a)(1) of the 1940 Act provides that shareholder approval is required for a fund to change its subclassification from diversified to non-diversified. If shareholders approve the proposal, HQH would become classified as a "non-diversified" fund under the 1940 Act and in this connection its fundamental investment restriction concerning diversification, set forth below, would be eliminated. Changing the subclassification of HQH from a "diversified" fund to a "non-diversified" fund means that HQH may invest a higher percentage of its assets in any one issuer and thus in a smaller number of companies overall, and may also invest in a greater percentage of the outstanding voting securities of any one issuer. Thus, such a fund may have more risks than a diversified fund, as described below.

As a 1940 Act diversified fund, HQH must invest at least 75% of its total assets so that: (i) no more than 5% of its total assets is invested in the securities of any issuer, and (ii) it holds no more than 10% of the outstanding voting securities of any issuer. With respect to the remaining 25% of its total assets, there is no limit on the amount of assets HQH may invest in the securities of a single issuer. These 1940 Act limits do not apply to securities issued or guaranteed by the U.S. Government, its agencies or instrumentalities or repurchase agreements collateralized by any of such obligations. These limits apply at the time HQH purchases a security; HQH may exceed these limits if positions it already holds increase in value relative to the rest of HQH's holdings. A 1940 Act non-diversified fund is not subject to these requirements, but as described further below, HQH would still be subject to the more liberal diversification requirements under the Internal Revenue Code of 1986, as amended (the "Code"), as a non-diversified fund.


The following sets forth both the current and proposed fundamental restriction on diversification, as well as the diversification restriction under the Code. Regardless of whether shareholders approve the change in diversification classification and the elimination of the fundamental restriction, HQH will remain subject to the more liberal diversification restriction under the Code.

Current Fundamental RestrictionProposed Fundamental
Restriction
Internal Revenue Code of 1986
Diversification Restriction

With respect to 75% of its total assets, invest in securities of any one issuer if immediately after and as a result of such investment more than 5% of the total assets of the Trust, taken at market value, would be invested in the securities of such issuer. This restriction does not apply to investments in U.S. Government Securities.

None.

With respect to 50% of its total assets, HQH must invest so that no more than 5% of its total assets is invested in the securities of any one issuer, and so that it holds no more than 10% of the outstanding voting securities of any one issuer. With respect to the remaining 50% of its total assets, HQH may invest up to 25% in the securities of a single issuer.

The Adviser believes that the requirements under the 1940 Act for diversified funds may, at times, hinder HQH's ability to invest in attractive securities that are suitable for it, particularly given its investment focus on healthcare companies and in venture companies in this sector. Additionally, the increased flexibility would enable the Adviser to invest HQH's assets more effectively. The Adviser believes the flexibility to acquire more than 10% of the voting securities of any one issuer would be particularly useful in connection with HQH's venture investments, which are typically small companies. The Adviser believes the 10% limit can constrain such venture investments. Additionally, the Adviser believes that its ability to manage HQH's portfolio in a changing regulatory and investment environment will be enhanced by this change.

As a general matter, the Board believes that changing HQH from a diversified fund to a non-diversified fund may give the Adviser more flexibility in implementing HQH's investment strategies.

It should also be noted that many industry and sector focused funds, such as HQH, operate as non-diversified funds in order to utilize the same flexibility the proposed changes would afford HQH.

Risks. Shareholder approval of the proposal would enable HQH to operate as a non-diversified fund, which means that it would not be limited by the 1940 Act in the proportion of its assets that may be invested in the obligations of a single issuer or the percentage of an issuer's voting securities it may acquire. As a result, HQH may hold a smaller number of issuers than if it were diversified. Investing in a non-diversified fund could involve more risk than investing in a fund that holds a broader range of securities because HQH's net asset value may be more vulnerable to changes in the market value of a single issuer or group of issuers and may be relatively more susceptible to adverse effects from any single corporate, industry, economic, market, political or regulatory occurrence.

The Board believes that this increased investment flexibility may provide opportunities to enhance HQH's performance, although investing a larger percentage of HQH's assets in any one issuer or a greater percentage of the voting securities of any one issuer could increase HQH's risk of loss and its share price volatility because the value of its shares would be more susceptible to adverse events affecting that issuer. If HQH takes a larger position in an issuer that subsequently has an adverse return, HQH may have a greater loss than it would have had if it had more diversified investments. The Adviser may use this increased investment flexibility for HQH to take larger positions in the securities of a single issuer or a greater percentage of the voting securities of any one issuer when it believes the investment opportunity may justify the risks involved.


As described earlier, the limits applicable to a diversified fund's holdings apply only at the time a fund purchases a security. As a result, it is currently possible for HQH, as a diversified fund, to have holdings that significantly exceed the diversification limits, provided that this is the result of market movements, such as the appreciation of a particular security or, conversely, the depreciation of other securities in HQH's portfolio, and not as the result of a purchase transaction. If holdings exceed a limit due to market movements, no action is required by HQH to bring the relevant position back below the limit. In these situations, HQH is exposed to the same risks relating to exposure to a particular issuer as is a non-diversified fund. However, unlike a non-diversified fund, HQH is unable to take advantage of investment opportunities through subsequent purchases.

For example, consider the situation where HQH exceeds the diversification limits in the securities of a particular issuer as a result of market movements (e.g., the appreciation of the security relative to HQH's other holdings). Assume that the company subsequently appears to the Adviser to be on the verge of a major scientific breakthrough. In such a case, HQH would be prohibited from purchasing additional shares of such security to take advantage of this perceived opportunity.

Additionally, the time of purchase aspect of the diversification limits would even prevent HQH from reestablishing a position in excess of a limit that it previously held but more recently reduced.

Although operating as a non-diversified fund would make HQH subject to the risks described above, it would also provide HQH and the Adviser with the ability to take advantage of market opportunities that may be present and that would otherwise be unavailable if HQH remained as a diversified fund.

Ability To Use Or Not Use Such Flexibility. If HQH's shareholders approve this proposal, HQH may operate as non-diversified or it may not, depending on the investment opportunities available to HQH. The flexibility to take larger positions in the securities of a single issuer (whether as a percentage of HQH's assets or as a percentage of the outstanding voting securities of an issuer) may not be used immediately upon shareholder approval, and may be implemented over time depending on market conditions. The Adviser intends to operate HQH as non-diversified when it believes it would be in shareholders' best interests to do so.

Similar But More Liberal Limits Under Internal Revenue Code. HQH's current intention, however, is to continue to qualify as a regulated investment company under the Code and be subject to its diversification rules. Although the Code's diversification limits provide a fund with relatively more investment flexibility than the diversification limits of the 1940 Act, qualifying as a regulated investment company under the Code will prevent HQH from fully realizing the investment flexibility from the conversion from diversified to non-diversified under the 1940 Act. The Code's diversification rules provide that, to maintain favorable tax treatment, HQH must invest at least 50% of its total assets so that no more than 5% of its total assets is invested in the securities of any issuer, and so that it holds no more than 10% of the outstanding voting securities of any issuer. With respect to the remaining 50% of its total assets, HQH is limited to investing 25% in the securities of a single issuer. These limits apply only as of the end of each quarter of HQH's fiscal year, so HQH may actually have a higher concentration in an issuer during periods between the ends of its fiscal quarters. Like the 1940 Act limits, the Code limits do not apply to securities issued or guaranteed by the U.S. Government, its agencies or instrumentalities, or repurchase agreements collateralized by any of such obligations.

Required Vote

Changing HQH from a diversified fund to a non-diversified fund requires approval of the holders of a majority of HQH's outstanding voting securities. A "majority of HQH's outstanding voting securities" for this purpose and under the 1940 Act means the lesser of (1) 67% or more of HQH's shares present


at a meeting if more than 50% of the outstanding shares of HQH are present and represented by proxy, or (2) more than 50% of the outstanding shares of HQH (a "1940 Act Majority"). The Trustees recommend a vote FOR changing HQH from a diversified fund to a non-diversified fund.

Proposal 4
CHANGE THE SUBCLASSIFICATION OF HQL
FROM DIVERSIFIED TO NON-DIVERSIFIED AND
ELIMINATE THE RELATED FUNDAMENTAL INVESTMENT RESTRICTION

The Board has unanimously approved, and recommends that shareholders of HQL approve, changing the subclassification of HQL from a "diversified" fund to a "non-diversified" fund, as such terms are defined in the 1940 Act. Section 13(a)(1) of the 1940 Act provides that shareholder approval is required for a fund to change its subclassification from diversified to non-diversified. If shareholders approve the proposal, HQL would become classified as a "non-diversified" fund under the 1940 Act and in this connection its fundamental investment restriction concerning diversification, set forth below, would be eliminated. Changing the subclassification of HQL from a "diversified" fund to a "non-diversified" fund means that HQL may invest a higher percentage of its assets in any one issuer and thus in a smaller number of companies overall, and may also invest in a greater percentage of the outstanding voting securities of any one issuer. Thus, such a fund may have more risks than a diversified fund, as described below.

As a 1940 Act diversified fund, HQL must invest at least 75% of its total assets so that: (i) no more than 5% of its total assets is invested in the securities of any issuer, and (ii) it holds no more than 10% of the outstanding voting securities of any issuer. With respect to the remaining 25% of its total assets, there is no limit on the amount of assets HQL may invest in the securities of a single issuer. These 1940 Act limits do not apply to securities issued or guaranteed by the U.S. Government, its agencies or instrumentalities or repurchase agreements collateralized by any of such obligations. These limits apply at the time HQL purchases a security; HQL may exceed these limits if positions it already holds increase in value relative to the rest of HQL's holdings. A 1940 Act non-diversified fund is not subject to these requirements, but as described further below, HQL would still be subject to the more liberal diversification requirements under the Code as a non-diversified fund.

The following sets forth both the current and proposed fundamental restriction on diversification, as well as the diversification restriction under the Code. Regardless of whether shareholders approve the change in diversification classification and the elimination of the fundamental restriction, HQL will remain subject to the more liberal diversification restriction under the Code.

Current Fundamental RestrictionProposed Fundamental
Restriction
Internal Revenue Code of 1986
Diversification Restriction

With respect to 75% of its total assets, invest in securities of any one issuer if immediately after and as a result of such investment more than 5% of the total assets of the Trust, taken at market value, would be invested in the securities of such issuer. This restriction does not apply to investments in U.S. Government Securities.

None.

With respect to 50% of its total assets, HQL must invest so that no more than 5% of its total assets is invested in the securities of any one issuer, and so that it holds no more than 10% of the outstanding voting securities of any one issuer. With respect to the remaining 50% of its total assets, HQL may invest up to 25% in the securities of a single issuer.


The Adviser believes that the requirements under the 1940 Act for diversified funds may, at times, hinder HQL's ability to invest in attractive securities that are suitable for it, particularly given its investment focus on life sciences companies and in venture companies in this sector. Additionally, the increased flexibility would enable the Adviser to invest HQL's assets more effectively. The Adviser believes the flexibility to acquire more than 10% of the voting securities of any one issuer would be particularly useful in connection with HQL's venture investments, which are typically small companies. The Adviser believes the 10% limit can constrain such venture investments. Additionally, the Adviser believes that its ability to manage HQL's portfolio in a changing regulatory and investment environment will be enhanced by this change.

As a general matter, the Board believes that changing HQL from a diversified fund to a non-diversified fund may give the Adviser more flexibility in implementing HQL's investment strategies.

It should also be noted that many industry and sector focused funds, such as HQL, operate as non-diversified funds in order to utilize the same flexibility the proposed changes would afford HQL.

Risks. Shareholder approval of the proposal would enable HQL to operate as a non-diversified fund, which means that it would not be limited by the 1940 Act in the proportion of its assets that may be invested in the obligations of a single issuer or the percentage of an issuer's voting securities it may acquire. As a result, HQL may hold a smaller number of issuers than if it were diversified. Investing in a non-diversified fund could involve more risk than investing in a fund that holds a broader range of securities because HQL's net asset value may be more vulnerable to changes in the market value of a single issuer or group of issuers and may be relatively more susceptible to adverse effects from any single corporate, industry, economic, market, political or regulatory occurrence.

The Board believes that this increased investment flexibility may provide opportunities to enhance HQL's performance, although investing a larger percentage of HQL's assets in any one issuer or a greater percentage of the voting securities of any one issuer could increase HQL's risk of loss and its share price volatility because the value of its shares would be more susceptible to adverse events affecting that issuer. If HQL takes a larger position in an issuer that subsequently has an adverse return, HQL may have a greater loss than it would have had if it had more diversified investments. The Adviser may use this increased investment flexibility for HQL to take larger positions in the securities of a single issuer or a greater percentage of the voting securities of any one issuer when it believes the investment opportunity may justify the risks involved.

As described earlier, the limits applicable to a diversified fund's holdings apply only at the time a fund purchases a security. As a result, it is currently possible for HQL, as a diversified fund, to have holdings that significantly exceed the diversification limits, provided that this is the result of market movements, such as the appreciation of a particular security or, conversely, the depreciation of other securities in HQL's portfolio, and not as the result of a purchase transaction. If holdings exceed a limit due to market movements, no action is required by HQL to bring the relevant position back below the limit. In these situations, HQL is exposed to the same risks relating to exposure to a particular issuer as is a non-diversified fund. However, unlike a non-diversified fund, HQL is unable to take advantage of investment opportunities through subsequent purchases.

For example, consider the situation where HQL exceeds the diversification limits in the securities of a particular issuer as a result of market movements (e.g., the appreciation of the security relative to HQL's other holdings). Assume that the company subsequently appears to the Adviser to be on the verge of a major scientific breakthrough. In such a case, HQL would be prohibited from purchasing additional shares of such security to take advantage of this perceived opportunity.


Additionally, the time of purchase aspect of the diversification limits would even prevent HQL from reestablishing a position in excess of a limit that it previously held but more recently reduced.

Although operating as a non-diversified fund would make HQL subject to the risks described above, it would also provide HQL and the Adviser with the ability to take advantage of market opportunities that may be present and that would otherwise be unavailable if HQL remained as a diversified fund.

Ability To Use Or Not Use Such Flexibility. If HQL's shareholders approve this proposal, HQL may operate as non-diversified or it may not, depending on the investment opportunities available to HQL. The flexibility to take larger positions in the securities of a single issuer (whether as a percentage of HQL's assets or as a percentage of the outstanding voting securities of an issuer) may not be used immediately upon shareholder approval, and may be implemented over time depending on market conditions. The Adviser intends to operate HQL as non-diversified when it believes it would be in shareholders' best interests to do so.

Similar But More Liberal Limits Under Internal Revenue Code. HQL's current intention, however, is to continue to qualify as a regulated investment company under the Code and be subject to its diversification rules. Although the Code's diversification limits provide a fund with relatively more investment flexibility than the diversification limits of the 1940 Act, qualifying as a regulated investment company under the Code will prevent HQL from fully realizing the investment flexibility from the conversion from diversified to non-diversified under the 1940 Act. The Code's diversification rules provide that, to maintain favorable tax treatment, HQL must invest at least 50% of its total assets so that no more than 5% of its total assets is invested in the securities of any issuer, and so that it holds no more than 10% of the outstanding voting securities of any issuer. With respect to the remaining 50% of its total assets, HQL is limited to investing 25% in the securities of a single issuer. These limits apply only as of the end of each quarter of HQL's fiscal year, so HQL may actually have a higher concentration in an issuer during periods between the ends of its fiscal quarters. Like the 1940 Act limits, the Code limits do not apply to securities issued or guaranteed by the U.S. Government, its agencies or instrumentalities, or repurchase agreements collateralized by any of such obligations.

Required Vote

Changing HQL from a diversified fund to a non-diversified fund requires approval of the holders of a 1940 Act Majority of HQL's outstanding voting securities. The Trustees recommend a vote FOR changing HQL from a diversified fund to a non-diversified fund.

Proposal 5
APPROVAL TO AMEND OR ELIMINATE CERTAIN FUNDAMENTAL INVESTMENT
RESTRICTIONS OF HQH AND HQL

Proposal 5 relates to proposed changes to certain of the fundamental investment restrictions of HQH and HQL. Currently, some of HQH's and HQL's fundamental investment policies are antiquated or more restrictive than current law requires. Proposal 5 is intended to simplify and modernize HQH's and HQL's investment policies to reflect current law and to increase each Fund's investment flexibility to be able to adapt over time.

The 1940 Act requires HQH and HQL to have certain fundamental policies and restrictions. Fundamental policies and restrictions can be changed only by a shareholder vote. The proposed changes to the fundamental investment restrictions would continue to satisfy current regulatory requirements and are proposed to provide HQH and HQL with the flexibility to respond to future legal, regulatory and market changes. Clarifying and modernizing these investment restrictions


generally would allow HQH and HQL to operate more efficiently within the limits of the 1940 Act and rules and related guidance by the SEC and its staff. These revisions are expected to give HQH and HQL greater flexibility to take advantage of, and react to, changes in financial markets and new investment vehicles. It is possible that as the financial markets continue to evolve over time, the 1940 Act and the related rules and guidance may be amended or evolve to address changed situations and new investment opportunities. The Adviser believes that its ability to manage HQH's and HQL's portfolios in a changing regulatory or investment environment will be enhanced by these changes. In addition, by eliminating those fundamental restrictions that are not required by the 1940 Act to be fundamental, HQH and HQL may be able to avoid the costs and delay associated with a shareholder meeting should the desire or need arise suddenly to change such a restriction in the future.

The Board has authorized the submission to HQH's and HQL's shareholders for their approval, and the Board recommends that shareholders approve the proposed amendments to, or elimination of, certain HQH's and HQL's fundamental restrictions as outlined herein. Set forth below is a discussion of each of the proposed changes to HQH's and HQL's fundamental investment restrictions, including the language of each proposed fundamental investment restriction.

Proposal 5.A — Senior Securities — HQH and HQL only

The current and proposed fundamental investment restriction regarding issuing senior securities for HQH is the following:

Current Fundamental Investment Restriction

Proposed Fundamental Investment Restriction

[The Fund may not] issue senior securities or borrow amounts in excess of 10% of its net assets at the time of borrowing, and then only from banks as a temporary measure for extraordinary or emergency purposes or for the repurchase of its securities. The Trust will not repurchase its securities during periods when it has outstanding borrowings in excess of 5% of its net assets. The Trust will not borrow for investment purposes.

The Fund may issue senior securities to the extent permitted under the 1940 Act and the rules and regulations thereunder.

The current and proposed fundamental investment restriction regarding issuing senior securities for HQL is the following:

Current Fundamental Investment Restriction

Proposed Fundamental Investment Restriction

[The Fund may not] issue senior securities or borrow amounts in excess of 10% of its net assets at the time of borrowing, and then only from banks (except in the case of reverse repurchase agreements) as a temporary measure for extraordinary or emergency purposes or for the repurchase of its securities. The Trust will not repurchase its securities during periods when it has outstanding borrowings in excess of 5% of its net assets. The Trust will not borrow for investment purposes.

The Fund may issue senior securities to the extent permitted under the 1940 Act and the rules and regulations thereunder.

The existing fundamental investment restriction regarding issuing senior securities for HQH and HQL imposes limitations that are in excess of those imposed by the 1940 Act for a closed-end fund. The 1940 Act prohibits investment companies from issuing "senior securities," except for borrowings where certain conditions are met. In addition, under the 1940 Act, certain types of transactions entered into by a fund, including borrowings, reverse repurchase agreements, short sales, and when-issued and delayed delivery transactions, may be considered forms of indebtedness having priority over


shareholders to fund assets in liquidation and, therefore, may be considered to be senior securities. Currently, these activities or investments are permissible under the 1940 Act so long as certain collateral asset coverage requirements designed to protect shareholders are met.

To the extent HQH or HQL engages in transactions that may be interpreted as resulting in the issuance of senior securities, HQH or HQL would be subject to the risks associated with leveraging. Leveraging, including borrowing, may magnify investment losses and may generally cause HQH or HQL to be more volatile than if HQH or HQL had not been leveraged. This is because leverage tends to increase a fund's exposure to market risk or other risks by, in effect, increasing assets available for investment. The use of leverage may also cause HQH or HQL to be required to liquidate portfolio positions when it may not be advantageous to do so.

Proposal 5.B — Investments in Other Investment Companies — HQH and HQL only

The current and proposed fundamental investment restriction regarding investments in other investment companies for HQH is the following:

Current Fundamental Investment Restriction

Proposed Fundamental Investment Restriction

[The Fund may not] purchase securities of other investment companies except in connection with a merger, consolidation, acquisition or reorganization, if (a) more than 10% of its total assets would be invested in securities of other investment companies, (b) more than 5% of its total assets would be invested in the securities of any one investment company, or (c) the Trust would own more than 3% of any other investment company's securities.

None.

The current and proposed fundamental investment restriction regarding investments in other investment companies for HQL is the following:

Current Fundamental Investment Restriction

Proposed Fundamental Investment Restriction

[The Fund may not] purchase securities of other investment companies, if (a) more than 10% of its total assets would be invested in securities of other investment companies, (b) more than 5% of its total assets would be invested in the securities of any one investment company, or (c) the Trust would own more than 3% of any other investment company's securities.

None.

Each of HQH and HQL has a fundamental investment restriction set forth above that limits the extent to which it may invest in other investment companies, including exchange traded funds. This restriction is more restrictive than the rules and regulations under the 1940 Act and applicable exemptive relief by the SEC. The 1940 Act also does not require a fund to adopt such a provision as a fundamental investment policy. If the proposal is approved by shareholders, HQH and HQL would remain subject to the limitations on investments in other investment companies imposed on all investment companies under the 1940 Act and related rules and SEC exemptive relief.

From time to time, each of HQH and HQL makes certain investments in other investment companies, particularly exchange traded funds, in order to gain exposure to the market or a particular market segment. Such investments may be made as a means to invest cash quickly and efficiently when a market opportunity arises until the Adviser conducts diligence on individual issuers that will replace the investment company holding.


Most exchange traded funds have obtained exemptive relief from the SEC that permits other funds, such as HQH and HQL, to acquire their shares in amounts in excess of the 1940 Act limits, subject to certain conditions. Because the 1940 Act limits are expressly set forth in HQH's and HQL's fundamental investment restrictions, however, HQH and HQL are separately bound to these limits and cannot take advantage of this relief available to other investing funds.

Investments in other investment companies in excess of the amounts currently set forth in the restriction would generally be temporary. To the extent HQH and HQL invest in securities of other investment companies, HQH and HQL may incur duplication of advisory fees and certain other expenses. By investing in another investment company, HQH or HQL, like any other investors becomes a shareholder of that investment company. As a result, HQH's and HQL's own shareholders indirectly would bear the underlying fund's proportionate share of the fees and expenses paid by all shareholders of the other investment company, in addition to the fees and expenses HQH's and HQL's shareholders directly bear in connection with HQH's and HQL's own operations.

Similarly, to the extent it takes advantage of this flexibility to make investments in other investment companies to a greater degree, HQH and HQL may become subject, to a greater degree, to the risks associated with investments in other investment companies. As such other investment companies are typically broadly diversified by issuer holdings, however, to some extent such investments may actually diversify risks.

Proposal 5.C — Securities on Margin and Short Sales — HQH only

The current and proposed fundamental restriction regarding purchasing securities on margin and short sales for HQH is the following:

Current Fundamental Investment Restriction

Proposed Fundamental Investment Restriction

[The Fund may not] purchase any securities on margin or make short sales of securities, except for short-term credit necessary for the clearance of portfolio transactions.

None.

HQH has a current fundamental investment restriction that prohibits the Fund from purchasing securities on margin or engaging in short sales of securities. This restriction is more prohibitive than the rules and regulations under the 1940 Act and related guidance by the SEC and its staff applicable to closed-end funds. Further, the 1940 Act and guidance also do not require a fund to adopt such a provision as a fundamental investment policy. Both the Adviser and the Board believe that the current fundamental investment restriction is unduly restrictive.

There are certain risks associated with purchasing securities on margin and short sales. The risks associated with purchasing securities on margin generally are the same as those involved in borrowing. Borrowing money creates leverage. The use of leverage has the potential to increase returns to shareholders, but also involves additional risks. Leverage increases the volatility of an investment portfolio and could result in larger losses than if it were not used. HQH would typically pay interest or incur other borrowing costs in connection with leverage transactions. Short sales likewise may enhance returns, but also involve risk. A short sale refers to the practice of selling a security a fund does not own. In order to deliver the security to the buyer, the seller (here HQH) would "borrow" the security from a third party pursuant to a promise to replace it at a later time, regardless of its value at that time. To replace it, HQH would need to go into the market place to acquire the security for delivery. The difference between the original short sale price and the replacement price (each adjusted for transactions costs) is the profit or loss on the transaction. If HQH sells a security short, it will make


money if the security's price goes down (in an amount greater than any transaction costs) and will lose money if the security's price goes up. For the same reason, there is no limit theoretically on the amount of money HQH may lose on a short sale. HQH may not be able to close out a short sale when it might wish to do so, or may do so only at an unfavorable price.

This proposed change in policy may allow for added flexibility to purchase securities on margin when the Adviser believes it to be advantageous. Likewise, the 1940 Act generally allows a fund to engage in short sales of securities, consistent with applicable law and the fund's investment objective and policies. If the current investment restriction is removed, HQH would be able to engage in short sales of securities, consistent with applicable law and HQH's investment objective and policies. The removal of the current investment restriction may afford HQH added flexibility in the future in pursuing its investment objective and strategy.

Required Vote

Changing or removing certain of HQH's and HQL's fundamental investment restrictions requires approval of the holders of a 1940 Act Majority of HQH and HQL, respectively.

INFORMATION PERTAINING TO THE CUSTODIAN AND ADMINISTRATOR AND
TRANSFER AGENT, DIVIDEND DISBURSING AGENT AND REGISTRAR

Each Fund's securities and cash are held under a custodian contract by State Street Bank and Trust Company ("State Street"), whose principal business address is One Lincoln Street, Boston, MA 02111. State Street is also the Administrator of each Fund and also performs certain accounting related functions for each Fund, including calculation of net asset value and net income.

Computershare Inc. serves as Dividend Disbursing Agent. Computershare Trust Company, N.A., a fully owned subsidiary of Computershare Inc., serves as (1) the Plan Agent for each Fund's Dividend Reinvestment Plan and (2) the Transfer Agent and Registrar for Shares of each Fund. Computershare Trust Company, N.A. and Computershare Inc. have their principal business at 250 Royall Street, Canton, MA 02021.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Exchange Act and Section 30(j) of the 1940 Act, as applied to each Fund, require the Fund'sFund’s officers and trustees,Trustees, investment manager,adviser, affiliates of the investment manager,adviser, and persons who beneficially own more than ten percent of a registered class of the Fund'sFund’s outstanding securities ("(“Reporting Persons"Persons”) to file reports of ownership of the Fund'sFund’s securities and changes in such ownership with the SEC and the NYSE. Such persons are required by SEC regulations to furnish the Fund with copies of all such filings.

Based solely upon its review of the copies of such forms received by it, and written representations from certain Reporting Persons that no year-end reports were required for those persons, each Fund believes that during the fiscal year ended September 30, 2015,2022, its Reporting Persons complied with all applicable filing requirements.


OTHER BUSINESS

As of the date of this Joint Proxy Statement, the Board of each Fund is not aware that any matters are to be presented for action at the Joint Annual MeetingSpecial Meetings other than those described above. Should other business properly be brought before the Annual Meeting,Special Meetings, it is intended that the accompanying Proxy will be voted thereon in accordance with the judgment of the persons named as proxies.

PROXIES AND VOTING AT THE ANNUAL MEETINGSPECIAL MEETINGS

Shareholders who execute proxies may revoke them at any time before they are voted by written notice to the Secretary of the FundFunds at 100 Federal Street, 19th Floor, Boston, MA 02110, or by casting a vote at the Joint Annual Meeting.Special Meetings. Instructions on how to attend the meeting and vote in person can be obtained by calling (617) 772-8500.617-772-8500. All valid proxies received prior to the Joint Annual Meeting,Special Meetings, or any adjournment(s) or postponements(s) thereof, will be voted at the Joint Annual MeetingSpecial Meetings and any adjournments or postponements thereof.

The representation in person or by proxy

Shareholders of each Fund are being asked to approve the Proposals. Approval of the First Meeting Proposal with respect to each Fund will require the affirmative vote of a majority“majority of the outstanding voting securities” of the Fund as defined in the 1940 Act. This means the lesser of (1) 67% or more of the shares of the Fund present at the First Meeting if more than 50% of the outstanding shares of the Fund are present or represented by proxy, or (2) more than 50% of the outstanding shares of the Fund.

26

Shareholders of each Fund is necessaryare also being asked to constitute a quorum for transacting business atapprove the Joint Annual Meeting. For purposesSecond Meeting Proposal. The election of determiningStephen Bird, Rose DiMartino, C. William Maher, and Todd Reit will require the presence of a quorum, abstentions and broker "non-votes" will be treated as shares that are present. Broker non-votes are proxies received by each Fund from brokers or nominees when the broker or nominee has neither received instructions from the beneficial owner or other persons entitled toaffirmative vote nor has discretionary power to vote on a particular matter. Proposals 1 and 2 to be voted upon by the shareholders involve matters that the NYSE considers to be routine and within the discretion of brokers to vote if no customer instructions are received.

Proposal 1 requires the approval of a plurality of shares of the respective Fund voting at the Joint AnnualSecond Meeting.

If the First Meeting (i.e.,Proposal is not approved by shareholders of all four of the Funds, none of the nominees for election receivingin the greatest numberSecond Meeting Proposal will serve as Trustees of votes will be elected).

the Funds, even if elected by shareholders. In such an event, the Current Trustees would continue to serve. Similarly, if the Second Meeting Proposal 2 requiresis not approved by the approval of a majorityshareholders of all votes validly cast atfour of the Funds, the New Advisory Agreements will not go into effect and Tekla will remain the Funds’ investment adviser, even if shareholders approve the New Advisory Agreements, unless the parties agree to waive or modify certain conditions of the Purchase Agreement. The completion of the Asset Transfer described in this Joint Annual Meeting.

Proxy Statement is contingent upon both the First Meeting Proposal 3,and Second Meeting Proposal 4being approved by shareholders of all four of the Funds and Proposal 5 require the approvalsatisfaction or waiver of a 1940 Act Majority forcertain other conditions. If either of the applicable Fund.

Abstentions and broker non-votes will be considered shares presentProposals are not approved by shareholders of one or represented by a proxy butmore Funds or the conditions of the Purchase Agreement are not satisfied or waived, the Asset Transfer will not be considered shares voted. As a result, they will: (i) have no effect on Proposals 1 or 2;completed, Tekla will continue to serve as the Funds’ investment adviser and (ii) have the effectCurrent Trustees will continue to serve as Trustees of votes against Proposals 3, 4 and 5.the Funds.

Matters on which a choice has been provided will be voted as indicated on the proxy card and, if no instruction is given, the persons named as proxies will vote the shares represented thereby FOR all nominees for election as Trustee, FOR Proposal 2, FOR Proposal 3, FOR Proposal 4 and FOR Proposal 5. and will use their best judgment in connection with the transaction of such other business as may properly come before the Joint Annual Meeting or any adjournment(s) or postponement(s) thereof.

In the event that sufficient votes in accordance with the Trustees'Trustees’ recommendations on anythe First Meeting Proposal or Second Meeting Proposal are not received by June[August 14, 2016] 2023 or the necessary quorum has not been obtained for such Special Meeting, or if other matters arise requiring shareholder attention, the persons named as proxies on the enclosed proxy cardProxy Cards may propose one or more adjournments of the Joint AnnualFirst Meeting or Second Meeting or both Special Meetings (as applicable) to permit further solicitation. Any such adjournment will require approvalA Special Meeting may be adjourned by a majoritythe chairman of the votes validly cast on the mattermeeting whether or not a quorum is present. Any business that would have been transacted at the session of the Joint Annuala Special Meeting tomay be adjourned. When voting ontransacted at any adjourned meeting. If a proposed adjournment, the persons named as proxies will vote FOR the proposed adjournment all shares that they are entitled to votequorum is present at a Special Meeting with respect to each item, unless directedany one or more proposals, the chairman of the meeting may, but shall not be required to, cause a vote AGAINST an item, in which case such shares willto be voted AGAINST the proposed adjournmenttaken with respect to that item. A


shareholderany such proposal or proposals which vote maycan be taken on one or more items prior to suchcertified as final and effective notwithstanding the adjournment if sufficient votes have been received and it is otherwise appropriate. Abstentions and broker non-votes will be disregarded for purposes of voting on adjournment.

As of April 19, 2016, there were:

HQH

HQL

THQ

THW

Shares of beneficial interest

OPEN

OPEN

OPEN

OPEN

Shareholders of each Fund will be entitled to one vote for each share held. Only shareholders of record at the close of business on April 19, 2016, the record date, will be entitled to vote at the Joint Annual Meeting. As of March 31, 2016, the Trustees and officers of each Fund individually and as a group beneficially owned less than 1% of the outstanding voting securities of the Fund. To the best of each Fund's knowledge, based upon filings made with the SEC, as of April 13, 2016, the below persons or groups beneficially owned more than 5% of the voting securities of the Fund:

(1) Title of class

(2) Name and address of
beneficial owner
(3) Amount and nature of
beneficial ownership

(4) Percent of class

HQH Common
Stock
Morgan Stanley
Morgan Stanley Smith Barney LLC
1858 Broadway
New York, NY 10036

3,565,032 shares*

12.9

%

HQL Common
Stock
First Trust Portfolios L.P.
First Trust Advisors L.P.
The Charger Corporation
120 East Liberty Drive, Suite 400
Wheaton, IL 60187
1,583,591**
1,668,375**
1,668,375**

8.64

%

HQL Common
Stock
Morgan Stanley
Morgan Stanley Smith Barney LLC
1858 Broadway
New York, NY 10036

666,491***

5.5

%

THQ Common
Stock
Morgan Stanley
Morgan Stanley Smith Barney LLC
1858 Broadway
New York, NY 10036

1,915,940****

6.4

%

  *  Morgan Stanley and/or certain of its operating units (including Morgan Stanley Smith Barney LLC) have shared dispositive powerSpecial Meeting with respect to 3,565,032 shares and shared voting power with respect to 4,677,491 shares.any other proposal or proposals.

 **  First Trust Portfolios L.P., First Trust Advisors L.P. and The Charger Corporation have shared dispositive power with respect to 1,583,591, 1,668,375, and 1,668,375 shares, respectively, and shared voting power with respect to 0, 84,784, and 84,784 shares, respectively.

  ***  Morgan Stanley and/or certain operating units (including Morgan Stanley Smith Barney LLC) have shared dispositive power with respect to 666,491 shares, sole voting power with respect to 902 shares and shared voting power with respect to 1,057,507.

  ****  Morgan Stanley and/or certain operating units (including Morgan Stanley Smith Barney LLC) have shared dispositive power with respect to 1,915,940 shares and shared voting power with respect to 2,680,439.


PROPOSALS FOR 20172024 ANNUAL MEETING

Shareholder proposals for each Fund's 2017 JointFund’s 2024 Annual Meeting must be received by U.S. mail, a private courier service, or hand delivery and be addressed to the Fund’s Secretary at the Fund'sFund’s executive offices at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110 no later than January 1, 2017December 18, 2023 for inclusion in the Fund's 2017Fund’s 2024 proxy statement and form of proxy, unless the meeting date is more than 30 days before or after June 14, 2017,8, 2024, in which case the proposal must be submitted a reasonable time before the time the Fund begins to print and send its proxy materials for the 2017 annual meeting.2024 Annual Meeting. Submission of such proposals does not insureensure that they will be included in the Fund's 2017Fund’s 2024 proxy statement or submitted for a vote at the Fund's 2017 annual meeting.

Fund’s 2024 Annual Meeting. In addition, shareholder proposals for each Fund's 2017 annual meeting of shareholdersFund’s 2024 Annual Meeting (other than proposals submitted for inclusion in the Fund's 2017Fund’s 2024 proxy statement) must be submitted to the Fund'sFund’s Secretary between February 9, 20172024 and March 11, 2017,10, 2024, unless the meeting date is more than 30 days before or after June 4, 2017,8, 2024, in which case the proposal must be submitted by the later of the close of business on (1) the date 90 days prior to the 2017 annual meeting2024 Annual Meeting date or (2) the tenth business day following the date on which the 2017 annual meeting2024 Annual Meeting date is first publicly announced or disclosed.

GENERAL

Each FundGENERAL

Tekla and abrdn Inc. will pay the cost of preparing, printing and mailing the enclosed proxy card(s)Proxy Cards and Joint Proxy Statement and all other costs incurred in connection with the solicitation of proxies, including any additional solicitation made by letter, Internet,internet, telephone or telegraph. The solicitation of proxies will be largely by mail. In addition, certain officers of the FundFunds and certain employees of the Adviser,Tekla, who will receive no compensation for their services other than their regular salaries, may solicit the return of proxies personally or by telephone or facsimile. Banks, brokerage houses, nominees and other fiduciaries will be requested to forward the proxy soliciting materials to the beneficial owners of the shares of each Fund. Each Fund may reimburse brokerage houses, nominees and other fiduciaries for postage and reasonable expenses incurred by them in forwarding of proxy material to beneficial owners.

A number of banks, brokers and financial institutions have instituted "householding".“householding.” Under this practice, only one Joint Proxy Statement may be delivered to multiple shareholders who share the same address and satisfy other conditions. Each Fund will deliver promptly a separate copy of this Joint Proxy Statement to a shareholder at a shared address upon request. To request a separate copy of this Joint Proxy Statement, write or call the FundFunds at the address and phone number set forth above.

27

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY
MATERIALS

FOR THE SHAREHOLDER MEETING TO BE HELD ON JUNEAUGUST 14, 20162023

The Joint Proxy Statement for the Joint Annual MeetingSpecial Meetings of Shareholders of TeklaHQH, HQL, THQ and THW and forms of proxy cards are available at www.OkapiPartners.com/TeklaSpecial.

TEKLA HEALTHCARE INVESTORS

TEKLA LIFE SCIENCES INVESTORS

TEKLA HEALTHCARE OPPORTUNITIES FUND

TEKLA WORLD HEALTHCARE FUND

[ ], 2023

28

EXHIBIT A

FORM OF NEW INVESTMENT ADVISORY AGREEMENTS

ABRDN HEALTHCARE INVESTORS

INVESTMENT ADVISORY AGREEMENT

THIS INVESTMENT ADVISORY AGREEMENT, dated as of [ ], 20[ ] between ABRDN HEALTHCARE INVESTORS (FORMERLY, TEKLA HEALTHCARE INVESTORS), a Massachusetts business trust (the “Fund”), and ABRDN INC., a Delaware corporation (the “Investment Adviser”),

W I T N E S S E T H:

That in consideration of the mutual covenants herein contained, it is agreed as follows:

1.Services To Be Rendered by the Investment Adviser to the Fund.

Subject to the supervision and direction of the Board of Trustees of the Fund, the Investment Adviser will:

a.          act in strict conformity with the Fund’s Declaration of Trust, the Investment Company Act of 1940 (the “1940 Act”) and the Investment Advisers Act of 1940, as the same may from time to time be amended;

b.          manage the portfolio in accordance with the Fund’s investment objective and policies as stated in the Fund’s Prospectus;

c.          make investment decisions for the Fund;

d.          place purchase and sale orders for portfolio transactions for the Fund;

e.          supply the Fund with office facilities (which may be in the Investment Adviser’s own offices), statistical and research data, data processing services, clerical, internal executive and administrative services, and stationery and office supplies;

f.           supply or direct and supervise a third party administrator and/or custodian in the provision to the Fund of accounting and bookkeeping services, the calculation of the net asset value of shares of the Fund, and the management of the Fund’s administrative affairs; and

g.          prepare or supervise and direct a third party administrator and/or custodian in the preparation of reports to shareholders of the Fund, tax returns and reports to and filings with the Securities and Exchange Commission (“SEC”) and state Blue Sky authorities.

In providing these services, the Investment Adviser will provide investment research and supervision of the Fund’s investments and conduct a continual program of investment, evaluation and, if appropriate, sale and reinvestment of the Fund’s assets.  In addition, the Investment Adviser will furnish the Fund with whatever statistical information the Fund may reasonably request with respect to the securities that the Fund may hold or contemplate purchasing.

2.Brokerage.

In executing transactions for the Fund and selecting brokers or dealers (which brokers or dealers may include any affiliate of the Investment Adviser to the extent permitted by the 1940 Act) the Investment Adviser will use its best efforts to obtain the best price and execution for the Fund.  In assessing the best price and execution available for any portfolio transaction, the Investment Adviser will consider all factors it deems relevant


including, but not limited to, price (including any applicable brokerage commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm involved and the firm’s risk in positioning a block of securities.  In selecting brokers or dealers to execute a particular transaction and in evaluating the best price and execution available, the Investment Adviser may consider the brokerage and research services (as those terms are defined in Section 28(e) of the Securities Exchange Act of 1934 (the “Exchange Act”)) provided to the Fund and/or other accounts over which the Investment Adviser exercises investment discretion.  It is understood that such services may be useful to the Investment Adviser in connection with its services to other clients.

On occasions when the Investment Adviser deems the purchase or sale of a security to be in the best interest of the Fund as well as other clients, the Investment Adviser, to the extent permitted by applicable laws and regulations, may, but shall be under no obligation to, aggregate the securities to be sold or purchased in order to obtain the most favorable price or lower brokerage commissions and efficient execution.  In such event, allocation of the securities so purchased or sold, as well as the expenses incurred in the transaction, will be made by the Investment Adviser in the manner it considers to be the most equitable and consistent with its fiduciary obligations to the Fund and to such other clients.

3.Other Agreements; Use of Name, Etc.

It is understood that any of the shareholders, Trustees, officers, agents and employees of the Fund may be a shareholder, director, officer, agent or employee of or be otherwise interested in the Investment Adviser and in any affiliate thereof with the Investment Adviser and that the Investment Adviser and any affiliate thereof with the Investment Adviser may have an interest in the Fund.  It is also understood that the Investment Adviser and persons affiliated with the Investment Adviser have and may have advisory, management, service or other contracts with other organizations and persons, and may have other interests and businesses and that the Fund shall have no interest in the profits or opportunities derived from the same, that the Investment Adviser may give advice and take action in the performance of its duties with respect to such other clients that may differ from advice given on the timing or nature of action taken with respect to the Fund.  Nothing in this Agreement shall be deemed to confer upon the Investment Adviser any obligation to acquire for the account of the Fund a position in any security that the Investment Adviser or any affiliate thereof may acquire for its own account or for the account of any other client, if in the sole and absolute discretion of the Investment Adviser it is not for any reason practical or desirable to acquire a position in such security for the Fund’s account.

The Investment Adviser shall authorize and permit any of its officers, directors and employees who may be elected as Trustees or officers of the Fund to serve in the capacities in which they are elected.  Services to be furnished by the Investment Adviser under this Agreement may be furnished through the medium of any of such officers, directors or employees.

4.Compensation.

The Fund will pay to the Investment Adviser as compensation for the Investment Adviser’s services rendered a fee, computed monthly, equal when annualized to (1) 2.5% of the average net assets for such month of its venture capital and other restricted securities constituting up to 25% of net assets and (2) the percentage that corresponds to the fee table below of the average net assets for such month of all other assets (“Other Assets”); provided that in no event shall such monthly fee when annualized exceed 1.36% of the average net assets of the Fund for such month.

Annualized
Value of Other AssetsFee Rate
$250,000,000 or less0.98%
$250,000,001 to $500,000,0000.88%
$500,000,001 to $1,000,000,0000.80%
In excess of $1,000,000,0000.7%


For purposes of this section, “average net assets” for any month shall be equal to the average of the net asset value of the appropriate assets at the last business day of such month and the net asset value of the appropriate assets at the last business day of the prior month.  In determining average net assets for purposes of clauses (1) and (2) above, liabilities and expenses of the Fund shall be allocated pro rata based on the ratio that the assets referred to in each clause bear to the total assets of the Fund.  Such fee shall be payable for each month within five business days after the end of such month.

For purposes of this Section 4, “venture capital and other restricted securities” shall be securities of issuers for which no market quotations are readily available and securities of companies for which market quotations are readily available but which are subject to legal or contractual restrictions on resale.  Securities of companies for which public information is available but as to sale of which the safe harbor provided by Rule 144(k) is not available shall be considered to be subject to legal or contractual restrictions on resale.

In the event that expenses of the Fund for any fiscal year should exceed the expense limitation on investment company expenses imposed by any statute or regulatory authority of any jurisdiction in which shares of the Fund are qualified for offer and sale, the compensation due the Investment Adviser for such fiscal year shall be reduced by the amount of such excess by a reduction or refund thereof.  In the event that the expenses of the Fund exceed any expense limitation which the Investment Adviser may, by written notice to the Fund, voluntarily declare to be effective subject to such terms and conditions as the Investment Adviser may prescribe in such notice, the compensation due the Investment Adviser shall be reduced and if necessary the Investment Adviser shall assume expenses of the Fund, to the extent required by such expense limitation.  In no event shall the provisions of this Section 4 require the Investment Adviser to reduce its fee if not so required by an applicable statute or regulatory authority.

If the Investment Adviser shall serve for less than the whole of a month, the foregoing compensation shall be pro rated.

5.Expenses.

The Investment Adviser will bear all expenses in connection with the performance of its services under this Agreement, including compensation of and office space for officers and employees of the Fund connected with investment and economic research, trading and investment management of the Fund, as well as the fees of all Trustees of the Fund who are “affiliated persons” of the Investment Adviser, as that term is defined in the 1940 Act, or any of its “affiliated persons”.

The Fund shall pay (or, in the event that such expenses are paid by the Investment Adviser, shall reimburse the Investment Adviser for) all other expenses incurred in the organization and operation of the Fund including, among other things, expenses for legal and auditing services, costs of printing proxy statements, prospectuses, stock certificates and shareholder reports, charges of the custodian, any sub-custodian and transfer agent, expenses in connection with the Dividend Reinvestment and Cash Purchase Plan, SEC and Financial Industry Regulatory Authority (“FINRA”) fees, fees and expenses of the Trustees who are not “affiliated persons” of the Investment Adviser or any of its “affiliated persons”, accounting and valuation costs, administrator’s fees, membership fees in trade associations, fidelity bond coverage for the Fund’s officers and employees, errors and omissions insurance coverage for Trustees and officers, interest, brokerage costs, taxes, stock exchange listing fees and expenses, expenses of qualifying the Fund’s shares for sale in various states, expenses associated with personnel performing exclusively shareholder servicing functions, certain other organization expenses, litigation and other extraordinary or non-recurring expenses, and other expenses properly payable by the Fund.

6.Assignment Terminates This Agreement; Amendments of This Agreement.

This Agreement shall automatically terminate, without the payment of any penalty in the event of its assignment, and this Agreement shall not be amended unless such amendment is approved at a meeting by the affirmative vote of a majority of the outstanding shares of the Fund, and by vote cast in person at a meeting called for the purpose of voting on such approval, of a majority of the Trustees of the Fund who are not interested persons of the Fund or of the Investment Adviser.


7.Effective Period and Termination of This Agreement.

This Agreement shall become effective as of the date first written above and shall remain in full force and effect for an initial two-year term and continuously thereafter so long as such continuance is specifically approved at least annually (a) by the vote of a majority of the Trustees who are not parties to this Agreement or interested persons of any such party, cast in person at a meeting called for the purpose of voting on such approval, and (b) by the Board of Trustees of the Fund or by vote of a majority of the outstanding voting securities of the Fund.  This Agreement shall automatically terminate, without the payment of any penalty, in the event of its assignment.

Either party hereto may at any time terminate this Agreement without the payment of any penalty by not less than thirty (30) days’ nor more than sixty (60) days’ written notice delivered or mailed by registered mail, postage prepaid, to the other party.  Action by the Fund to terminate this Agreement may be taken either by (i) vote of a majority of its Trustees, or (ii) by the affirmative vote of a majority of the outstanding shares of the Fund.

8.Certain Definitions.

For the purposes of this Agreement, the “affirmative vote of a majority of outstanding shares of the Fund” means the affirmative vote, at a duly called and held meeting of shareholders of the Fund, (a) of the holders of 67% or more of the shares of the Fund present (in person or by proxy) and entitled to vote at such meeting, if the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting are present in person or by proxy, or (b) of the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting, whichever is less.

For the purposes of this Agreement, the terms “affiliated person”, “control”, “interested person” and “assignment” shall have their respective meanings as defined in the 1940 Act and the Rules and Regulations thereunder, subject, however to such exemptions as may be granted by the SEC under said Act; the term “specifically approve at least annually” shall be construed in a manner consistent with the 1940 Act and the Rules and Regulations thereunder; and the term “brokerage and research services” shall have the meaning given in the Exchange Act and the Rules and Regulations thereunder.

9.Non-liability of the Investment Adviser.

The Investment Adviser shall not be held responsible for any loss incurred by any act or omission of any broker.  The Investment Adviser also shall not be liable to the Fund or to any shareholder of the Fund for any error or judgment or for any loss suffered by the Fund in connection with rendering services hereunder except (a) a loss resulting from a breach of fiduciary duty with respect to the receipt of compensation for services (in which case any award of damages shall be limited to the period and the amount set forth in Section 36(b)(3) of the 1940 Act) or (b) a loss resulting from willful misfeasance, bad faith or gross negligence on the part of the Investment Adviser, or reckless disregard of its obligations and duties hereunder.  Subject to the foregoing, the Fund also shall indemnify the Investment Adviser, and any officer, director and employee thereof to the maximum extent permitted by Article V of the Fund’s Declaration of Trust.

10.Limitation of Liability of the Trustees and Shareholders.

A copy of the Declaration of Trust of the Fund is on file with the Secretary of the Commonwealth of Massachusetts, and notice is hereby given that this instrument is executed on behalf of the Trustees of the Fund as Trustees and not individually and that the obligations of this instrument are not binding upon any of the Trustees or shareholders individually but are binding only upon the assets and property of the Fund.

11.Furnishing of Materials.

During the term of this Agreement, the Fund agrees to furnish the Investment Adviser at its principal executive office all prospectuses, proxy statements, report to shareholders, sales literature, or other material prepared for distribution to shareholders of the Fund or the public, which refer to the Investment Adviser in any way, prior to use thereof and not to use such material if the Investment Adviser reasonably objects in writing within five


business days (or such other time as may be mutually agreed) after receipt thereof.  In the event of termination of this Agreement, the Fund will continue to furnish to the Investment Adviser copies of any of the above-mentioned materials which refer in any way to the Investment Adviser.  The Fund shall furnish or otherwise make available to the Investment Adviser such other information relating to the business affairs of the Fund as the Investment Adviser at any time, or from time to time, reasonably requests in order to discharge its obligations hereunder.

12.Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts.

[Remainder of page intentionally left blank]


N WITNESS WHEREOF, abrdn Healthcare Investors Teklaand the Investment Adviser have each caused this instrument to be signed in duplicate on its behalf by its President or other officer thereunto duly authorized, all as of the date first hereinabove written.

ABRDN HEALTHCARE INVESTORS
By:
Title:
ABRDN INC.
By:
Title:


ABRDN LIFE SCIENCES INVESTORS

INVESTMENT ADVISORY AGREEMENT

THIS INVESTMENT ADVISORY AGREEMENT, dated as of [ ], 20[ ] between ABRDN LIFE SCIENCES INVESTORS (formerly, TEKLA LIFE SCIENCES INVESTORS), a Massachusetts business trust (the “Fund”), and ABRDN INC., a Delaware corporation (the “Investment Adviser”),

W I T N E S S E T H:

That in consideration of the mutual covenants herein contained, it is agreed as follows:

1.            Services To Be Rendered by the Investment Adviser to the Fund.

Subject to the supervision and direction of the Board of Trustees of the Fund, the Investment Adviser will:

a.          act in strict conformity with the Fund’s Declaration of Trust, the Investment Company Act of 1940 (the “1940 Act”) and the Investment Advisers Act of 1940, as the same may from time to time be amended;

b.          manage the portfolio in accordance with the Fund’s investment objective and policies as stated in the Fund’s Prospectus;

c.          make investment decisions for the Fund;

d.          place purchase and sale orders for portfolio transactions for the Fund;

e.          supply the Fund with office facilities (which may be in the Investment Adviser’s own offices), statistical and research data, data processing services, clerical, internal executive and administrative services, and stationery and office supplies;

f.           supply or direct and supervise a third party administrator and/or custodian in the provision to the Fund of accounting and bookkeeping services, the calculation of the net asset value of shares of the Fund, and the management of the Fund’s administrative affairs; and

g.          prepare or supervise and direct a third party administrator and/or custodian in the preparation of reports to shareholders of the Fund, tax returns and reports to and filings with the Securities and Exchange Commission (“SEC”) and state Blue Sky authorities.

In providing these services, the Investment Adviser will provide investment research and supervision of the Fund’s investments and conduct a continual program of investment, evaluation and, if appropriate, sale and reinvestment of the Fund’s assets.  In addition, the Investment Adviser will furnish the Fund with whatever statistical information the Fund may reasonably request with respect to the securities that the Fund may hold or contemplate purchasing.

2.             Brokerage.

In executing transactions for the Fund and selecting brokers or dealers (which brokers or dealers may include any affiliate of the Investment Adviser to the extent permitted by the 1940 Act) the Investment Adviser will use its best efforts to obtain the best price and execution for the Fund.  In assessing the best price and execution available for any portfolio transaction, the Investment Adviser will consider all factors it deems relevant including, but not limited to, price (including any applicable brokerage commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm involved and the firm’s risk in positioning a block of securities.  In selecting brokers or dealers to execute a particular transaction and in evaluating the best price and execution available, the Investment Adviser may consider the brokerage and research services (as those terms are defined in Section 28(e) of the Securities Exchange Act of 1934 (the “Exchange Act”)) provided to the Fund and/or other accounts over which the Investment Adviser exercises investment discretion.  It is


understood that such services may be useful to the Investment Adviser in connection with its services to other clients.

On occasions when the Investment Adviser deems the purchase or sale of a security to be in the best interest of the Fund as well as other clients, the Investment Adviser, to the extent permitted by applicable laws and regulations, may, but shall be under no obligation to, aggregate the securities to be sold or purchased in order to obtain the most favorable price or lower brokerage commissions and efficient execution.  In such event, allocation of the securities so purchased or sold, as well as the expenses incurred in the transaction, will be made by the Investment Adviser in the manner it considers to be the most equitable and consistent with its fiduciary obligations to the Fund and to such other clients.

3.             Other Agreements; Use of Name, Etc.

It is understood that any of the shareholders, Trustees, officers, agents and employees of the Fund may be a shareholder, director, officer, agent or employee of or be otherwise interested in the Investment Adviser and in any affiliate thereof with the Investment Adviser and that the Investment Adviser and any affiliate thereof with the Investment Adviser may have an interest in the Fund.  It is also understood that the Investment Adviser and persons affiliated with the Investment Adviser have and may have advisory, management, service or other contracts with other organizations and persons, and may have other interests and businesses and that the Fund shall have no interest in the profits or opportunities derived from the same, that the Investment Adviser may give advice and take action in the performance of its duties with respect to such other clients that may differ from advice given on the timing or nature of action taken with respect to the Fund.  Nothing in this Agreement shall be deemed to confer upon the Investment Adviser any obligation to acquire for the account of the Fund a position in any security that the Investment Adviser or any affiliate thereof may acquire for its own account or for the account of any other client, if in the sole and absolute discretion of the Investment Adviser it is not for any reason practical or desirable to acquire a position in such security for the Fund’s account.

The Investment Adviser shall authorize and permit any of its officers, directors and employees who may be elected as Trustees or officers of the Fund to serve in the capacities in which they are elected.  Services to be furnished by the Investment Adviser under this Agreement may be furnished through the medium of any of such officers, directors or employees.

4.             Compensation.

The Fund will pay to the Investment Adviser as compensation for the Investment Adviser’s services rendered a fee, computed monthly, equal when annualized to (1) 2.5% of the average net assets for such month of its venture capital and other restricted securities constituting up to 25% of net assets and (2) the percentage that corresponds to the fee table below of the average net assets for such month of all other assets (“Other Assets”); provided that in no event shall such monthly fee when annualized exceed 1.36% of the average net assets of the Fund for such month.

Annualized
Value of Other AssetsFee Rate
$250,000,000 or less0.98%
$250,000,001 to $500,000,0000.88%
$500,000,001 to $1,000,000,0000.80%
In excess of $1,000,000,0000.7%

For purposes of this section, “average net assets” for any month shall be equal to the average of the net asset value of the appropriate assets at the last business day of such month and the net asset value of the appropriate assets at the last business day of the prior month.  In determining average net assets for purposes of clauses (1) and (2) above, liabilities and expenses of the Fund shall be allocated pro rata based on the ratio that the assets referred to in each clause bear to the total assets of the Fund.  Such fee shall be payable for each month within five business days after the end of such month.


For purposes of this Section 4, “venture capital and other restricted securities” shall be securities of issuers for which no market quotations are readily available and securities of companies for which market quotations are readily available but which are subject to legal or contractual restrictions on resale.  Securities of companies for which public information is available but as to sale of which the safe harbor provided by Rule 144(k) is not available shall be considered to be subject to legal or contractual restrictions on resale.

In the event that expenses of the Fund for any fiscal year should exceed the expense limitation on investment company expenses imposed by any statute or regulatory authority of any jurisdiction in which shares of the Fund are qualified for offer and sale, the compensation due the Investment Adviser for such fiscal year shall be reduced by the amount of such excess by a reduction or refund thereof.  In the event that the expenses of the Fund exceed any expense limitation which the Investment Adviser may, by written notice to the Fund, voluntarily declare to be effective subject to such terms and conditions as the Investment Adviser may prescribe in such notice, the compensation due the Investment Adviser shall be reduced and if necessary the Investment Adviser shall assume expenses of the Fund, to the extent required by such expense limitation.  In no event shall the provisions of this Section 4 require the Investment Adviser to reduce its fee if not so required by an applicable statute or regulatory authority.

If the Investment Adviser shall serve for less than the whole of a month, the foregoing compensation shall be pro rated.

5.             Expenses.

The Investment Adviser will bear all expenses in connection with the performance of its services under this Agreement, including compensation of and office space for officers and employees of the Fund connected with investment and economic research, trading and investment management of the Fund, as well as the fees of all Trustees of the Fund who are “affiliated persons” of the Investment Adviser, as that term is defined in the 1940 Act, or any of its “affiliated persons”.

The Fund shall pay (or, in the event that such expenses are paid by the Investment Adviser, shall reimburse the Investment Adviser for) all other expenses incurred in the organization and operation of the Fund including, among other things, expenses for legal and auditing services, costs of printing proxy statements, prospectuses, stock certificates and shareholder reports, charges of the custodian, any sub-custodian and transfer agent, expenses in connection with the Dividend Reinvestment and Cash Purchase Plan, SEC and Financial Industry Regulatory Authority (“FINRA”) fees, fees and expenses of the Trustees who are not “affiliated persons” of the Investment Adviser or any of its “affiliated persons”, accounting and valuation costs, administrator’s fees, membership fees in trade associations, fidelity bond coverage for the Fund’s officers and employees, errors and omissions insurance coverage for Trustees and officers, interest, brokerage costs, taxes, stock exchange listing fees and expenses, expenses of qualifying the Fund’s shares for sale in various states, expenses associated with personnel performing exclusively shareholder servicing functions, certain other organization expenses, litigation and other extraordinary or non-recurring expenses, and other expenses properly payable by the Fund.

6.             Assignment Terminates This Agreement; Amendments of This Agreement.

This Agreement shall automatically terminate, without the payment of any penalty in the event of its assignment, and this Agreement shall not be amended unless such amendment is approved at a meeting by the affirmative vote of a majority of the outstanding shares of the Fund, and by vote cast in person at a meeting called for the purpose of voting on such approval, of a majority of the Trustees of the Fund who are not interested persons of the Fund or of the Investment Adviser.

7.             Effective Period and Termination of This Agreement.

This Agreement shall become effective as of the date first written above and shall remain in full force and effect for an initial two-year term and continuously thereafter so long as such continuance is specifically approved at least annually (a) by the vote of a majority of the Trustees who are not parties to this Agreement or interested persons of any such party, cast in person at a meeting called for the purpose of voting on such approval, and (b) by


the Board of Trustees of the Fund or by vote of a majority of the outstanding voting securities of the Fund.  This Agreement shall automatically terminate, without the payment of any penalty, in the event of its assignment.

Either party hereto may at any time terminate this Agreement without the payment of any penalty by not less than thirty (30) days’ nor more than sixty (60) days’ written notice delivered or mailed by registered mail, postage prepaid, to the other party.  Action by the Fund to terminate this Agreement may be taken either by (i) vote of a majority of its Trustees, or (ii) by the affirmative vote of a majority of the outstanding shares of the Fund.

8.             Certain Definitions.

For the purposes of this Agreement, the “affirmative vote of a majority of outstanding shares of the Fund” means the affirmative vote, at a duly called and held meeting of shareholders of the Fund, (a) of the holders of 67% or more of the shares of the Fund present (in person or by proxy) and entitled to vote at such meeting, if the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting are present in person or by proxy, or (b) of the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting, whichever is less.

For the purposes of this Agreement, the terms “affiliated person”, “control”, “interested person” and “assignment” shall have their respective meanings as defined in the 1940 Act and the Rules and Regulations thereunder, subject, however to such exemptions as may be granted by the SEC under said Act; the term “specifically approve at least annually” shall be construed in a manner consistent with the 1940 Act and the Rules and Regulations thereunder; and the term “brokerage and research services” shall have the meaning given in the Exchange Act and the Rules and Regulations thereunder.

9.             Non-liability of the Investment Adviser.

The Investment Adviser shall not be held responsible for any loss incurred by any act or omission of any broker.  The Investment Adviser also shall not be liable to the Fund or to any shareholder of the Fund for any error or judgment or for any loss suffered by the Fund in connection with rendering services hereunder except (a) a loss resulting from a breach of fiduciary duty with respect to the receipt of compensation for services (in which case any award of damages shall be limited to the period and the amount set forth in Section 36(b)(3) of the 1940 Act) or (b) a loss resulting from willful misfeasance, bad faith or gross negligence on the part of the Investment Adviser, or reckless disregard of its obligations and duties hereunder.  Subject to the foregoing, the Fund also shall indemnify the Investment Adviser, and any officer, director and employee thereof to the maximum extent permitted by Article V of the Fund’s Declaration of Trust.

10.          Limitation of Liability of the Trustees and Shareholders.

A copy of the Declaration of Trust of the Fund is on file with the Secretary of the Commonwealth of Massachusetts, and notice is hereby given that this instrument is executed on behalf of the Trustees of the Fund as Trustees and not individually and that the obligations of this instrument are not binding upon any of the Trustees or shareholders individually but are binding only upon the assets and property of the Fund.

11.          Furnishing of Materials.

During the term of this Agreement, the Fund agrees to furnish the Investment Adviser at its principal executive office all prospectuses, proxy statements, report to shareholders, sales literature, or other material prepared for distribution to shareholders of the Fund or the public, which refer to the Investment Adviser in any way, prior to use thereof and not to use such material if the Investment Adviser reasonably objects in writing within five business days (or such other time as may be mutually agreed) after receipt thereof.  In the event of termination of this Agreement, the Fund will continue to furnish to the Investment Adviser copies of any of the above-mentioned materials which refer in any way to the Investment Adviser.  The Fund shall furnish or otherwise make available to the Investment Adviser such other information relating to the business affairs of the Fund as the Investment Adviser at any time, or from time to time, reasonably requests in order to discharge its obligations hereunder.


12.          Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts.

[Remainder of page intentionally left blank]


IN WITNESS WHEREOF, abrdn Life Sciences Investors Teklaand the Investment Adviser have each caused this instrument to be signed in duplicate on its behalf by its President or other officer thereunto duly authorized, all as of the date first hereinabove written.

ABRDN LIFE SCIENCES INVESTORS
By:
Title:
ABRDN INC.
By:
Title:


ABRDN HEALTHCARE OPPORTUNITIES FUND

INVESTMENT ADVISORY AGREEMENT

THIS INVESTMENT ADVISORY AGREEMENT, dated as of [  ], 20[ ] between ABRDN HEALTHCARE OPPORTUNITIES FUND, a Massachusetts business trust (the “Fund”), and ABRDN INC., a Delaware corporation (the “Investment Adviser”),

W I T N E S S E T H:

That in consideration of the mutual covenants herein contained, it is agreed as follows:

1.Services To Be Rendered by the Investment Adviser to the Fund.

Subject to the supervision and direction of the Board of Trustees of the Fund, the Investment Adviser will:

a.          act in strict conformity with the Fund’s Declaration of Trust, the Investment Company Act of 1940 (the “1940 Act”) and the Investment Advisers Act of 1940, as the same may from time to time be amended

b.          manage the portfolio in accordance with the Fund’s investment objective and policies as stated in the Fund’s Prospectus;

c.           make investment decisions for the Fund;

d.          place purchase and sale orders for portfolio transactions for the Fund;

e.          supply the Fund with office facilities (which may be in the Investment Adviser’s own offices), statistical and research data, data processing services, clerical, internal executive and administrative services, and stationery and office supplies;

f.           supply or direct and supervise a third party administrator and/or custodian in the provision to the Fund of accounting and bookkeeping services, the calculation of the net asset value of shares of the Fund, and the management of the Fund’s administrative affairs; and

g.          prepare or supervise and direct a third party administrator and/or custodian in the preparation of reports to shareholders of the Fund, tax returns and reports to and filings with the Securities and Exchange Commission (“SEC”) and state Blue Sky authorities.

In providing these services, the Investment Adviser will provide investment research and supervision of the Fund’s investments and conduct a continual program of investment, evaluation and, if appropriate, sale and reinvestment of the Fund’s assets. In addition, the Investment Adviser will furnish the Fund with whatever statistical information the Fund may reasonably request with respect to the securities that the Fund may hold or contemplate purchasing.

2.Brokerage.

In executing transactions for the Fund and selecting brokers or dealers (which brokers or dealers may include any affiliate of the Investment Adviser to the extent permitted by the 1940 Act) the Investment Adviser will use its best efforts to obtain the best price and execution for the Fund. In assessing the best price and execution available for any portfolio transaction, the Investment Adviser will consider all factors it deems relevant including, but not limited to, price (including any applicable brokerage commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm involved and the firm’s risk in positioning a block of securities. In selecting brokers or dealers to execute a particular transaction and in evaluating the best price and execution available, the Investment Adviser may consider the brokerage and research services (as those terms are defined in Section 28(e) of the Securities Exchange Act of 1934 (the “Exchange Act”)) provided to the Fund and/or other


accounts over which the Investment Adviser exercises investment discretion. It is understood that such services may be useful to the Investment Adviser in connection with its services to other clients.

On occasions when the Investment Adviser deems the purchase or sale of a security to be in the best interest of the Fund as well as other clients, the Investment Adviser, to the extent permitted by applicable laws and regulations, may, but shall be under no obligation to, aggregate the securities to be sold or purchased in order to obtain the most favorable price or lower brokerage commissions and efficient execution. In such event, allocation of the securities so purchased or sold, as well as the expenses incurred in the transaction, will be made by the Investment Adviser in the manner it considers to be the most equitable and consistent with its fiduciary obligations to the Fund and to such other clients.

3.Other Agreements; Use of Name Etc.

It is understood that any of the shareholders, Trustees, officers, agents and employees of the Fund may be a shareholder, director, officer, agent or employee of or be otherwise interested in the Investment Adviser and in any affiliate thereof with the Investment Adviser and that the Investment Adviser and any affiliate thereof with the Investment Adviser may have an interest in the Fund. It is also understood that the Investment Adviser and persons affiliated with the Investment Adviser have and may have advisory, management, service or other contracts with other organizations and persons, and may have other interests and businesses and that the Fund shall have no interest in the profits or opportunities derived from the same, that the Investment Adviser may give advice and take action in the performance of its duties with respect to such other clients that may differ from advice given on the timing or nature of action taken with respect to the Fund. Nothing in this Agreement shall be deemed to confer upon the Investment Adviser any obligation to acquire for the account of the Fund a position in any security that the Investment Adviser or any affiliate thereof may acquire for its own account or for the account of any other client, if in the sole and absolute discretion of the Investment Adviser it is not for any reason practical or desirable to acquire a position in such security for the Fund’s account.

The Investment Adviser shall authorize and permit any of its officers, directors and employees who may be elected as Trustees or officers of the Fund to serve in the capacities in which they are elected. Services to be furnished by the Investment Adviser under this Agreement may be furnished through the medium of any of such officers, directors or employees.

4.Compensation.

The Fund will pay to the Investment Adviser as compensation for the Investment Adviser’s services rendered a fee, computed and payable monthly, equal when annualized to 1.00% of the average daily value of the Trust’s managed assets.  For purposes of this section, “managed assets” for any month shall be equal to the total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund’s accrued liabilities (other than liabilities representing borrowings for investment purposes).  Borrowings for investment purposes include any form or combination of financial leverage instruments, such as borrowings from banks or other financial institutions (i.e., a credit facility), margin facilities, the issuance of preferred shares or notes and leverage attributable to reverse repurchase agreements, dollar rolls or similar transactions.  Such fee shall be payable for each month within five business days after the end of such month.

In the event that the expenses of the Fund exceed any expense limitation which the Investment Adviser may, by written notice to the Fund, voluntarily declare to be effective subject to such terms and conditions as the Investment Adviser may prescribe in such notice, the compensation due the Investment Adviser shall be reduced and if necessary the Investment Adviser shall assume expenses of the Fund, to the extent required by such expense limitation.

If the Investment Adviser shall serve for less than the whole of a month, the foregoing compensation shall be pro rated.


5.Expenses.

The Investment Adviser will bear all expenses in connection with the performance of its services under this Agreement, including compensation of and office space for officers and employees of the Fund connected with investment and economic research, trading and investment management of the Fund, as well as the fees of all Trustees of the Fund who are “affiliated persons” of the Investment Adviser, as that term is defined in the 1940 Act, or any of its “affiliated persons”.

The Fund shall pay (or, in the event that such expenses are paid by the Investment Adviser, shall reimburse the Investment Adviser for) all other expenses incurred in the operation of the Fund including, among other things, expenses for legal and auditing services, costs of printing proxy statements, prospectuses, stock certificates and shareholder reports, charges of the custodian, any sub-custodian and transfer agent, expenses in connection with the Dividend Reinvestment and Stock Purchase Plan, SEC and Financial Industry Regulatory Authority (“FINRA”) fees, fees and expenses of the Trustees who are not “affiliated persons” of the Investment Adviser or any of its “affiliated persons”, accounting and valuation costs, administrator’s fees, membership fees in trade associations, fidelity bond coverage for the Fund’s officers and employees, errors and omissions insurance coverage for Trustees and officers, interest, brokerage costs, taxes, stock exchange listing fees and expenses, expenses of qualifying the Fund’s shares for sale in various states, expenses associated with personnel performing exclusively shareholder servicing functions, litigation and other extraordinary or non-recurring expenses, and other expenses properly payable by the Fund.

6.Amendments of This Agreement.

This Agreement shall not be amended unless such amendment is approved at a meeting by the affirmative vote of a majority of the outstanding shares of the Fund, and by vote cast in person at a meeting called for the purpose of voting on such approval, of a majority of the Trustees of the Fund who are not interested persons of the Fund or of the Investment Adviser.

7.Effective Period and Termination of This Agreement.

This Agreement shall become effective as of the date first written above and shall remain in full force and effect for an initial two-year term and continuously thereafter so long as such continuance is specifically approved at least annually (a) by the vote of a majority of the Trustees who are not parties to this Agreement or interested persons of any such party, cast in person at a meeting called for the purpose of voting on such approval, and (b) by the Board of Trustees of the Fund or by vote of a majority of the outstanding voting securities of the Fund.  This Agreement shall automatically terminate, without the payment of any penalty, in the event of its assignment.

Either party hereto may at any time terminate this Agreement without the payment of any penalty by not less than thirty (30) days’ nor more than sixty (60) days’ written notice delivered or mailed by registered mail, postage prepaid, to the other party.  Action by the Fund to terminate this Agreement may be taken either by (i) vote of a majority of its Trustees, or (ii) by the affirmative vote of a majority of the outstanding shares of the Fund.

8.Certain Definitions.

For the purposes of this Agreement, the “affirmative vote of a majority of outstanding shares of the Fund” means the affirmative vote, at a duly called and held meeting of shareholders of the Fund, (a) of the holders of 67% or more of the shares of the Fund present (in person or by proxy) and entitled to vote at such meeting, if the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting are present in person or by proxy, or (b) of the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting, whichever is less.

For the purposes of this Agreement, the terms “affiliated person”, “control”, “interested person” and “assignment” shall have their respective meanings as defined in the 1940 Act and the Rules and Regulations thereunder, subject, however to such exemptions as may be granted by the SEC under said Act; the term “specifically approve at least annually” shall be construed in a manner consistent with the 1940 Act and the


Rules and Regulations thereunder; and the term “brokerage and research services” shall have the meaning given in the Exchange Act and the Rules and Regulations thereunder.

9.Non-Liability of the Investment Adviser.

The Investment Adviser shall not be held responsible for any loss incurred by any act or omission of any broker. The Investment Adviser also shall not be liable to the Fund or to any shareholder of the Fund for any error or judgment or for any loss suffered by the Fund in connection with rendering services hereunder except (a) a loss resulting from a breach of fiduciary duty with respect to the receipt of compensation for services (in which case any award of damages shall be limited to the period and the amount set forth in Section 36(b)(3) of the 1940 Act) or (b) a loss resulting from willful misfeasance, bad faith or gross negligence on the part of the Investment Adviser, or reckless disregard of its obligations and duties hereunder. Subject to the foregoing, the Fund also shall indemnify the Investment Adviser, and any officer, director and employee thereof to the maximum extent permitted by Article V of the Fund’s Declaration of Trust.

10.Limitation of Liability of the Trustees and Shareholders.

A copy of the Declaration of Trust of the Fund is on file with the Secretary of the Commonwealth of Massachusetts, and notice is hereby given that this instrument is executed on behalf of the Trustees of the Fund as Trustees and not individually and that the obligations of this instrument are not binding upon any of the Trustees or shareholders individually but are binding only upon the assets and property of the Fund.

11.Furnishing of Materials.

During the term of this Agreement, the Fund agrees to furnish the Investment Adviser at its principal executive office all prospectuses, proxy statements, report to shareholders, sales literature, or other material prepared for distribution to shareholders of the Fund or the public, which refer to the Investment Adviser in any way, prior to use thereof and not to use such material if the Investment Adviser reasonably objects in writing within five business days (or such other time as may be mutually agreed) after receipt thereof. In the event of termination of this Agreement, the Fund will continue to furnish to the Investment Adviser copies of any of the above-mentioned materials which refer in any way to the Investment Adviser. The Fund shall furnish or otherwise make available to the Investment Adviser such other information relating to the business affairs of the Fund as the Investment Adviser at any time, or from time to time, reasonably requests in order to discharge its obligations hereunder.

12.Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts.

[Remainder of page intentionally left blank]


IN WITNESS WHEREOF, abrdn Healthcare Opportunities Fund and Teklathe Investment Adviser have each caused this instrument to be signed in duplicate on its behalf by its President or other officer thereunto duly authorized, all as of the date first hereinabove written.

ABRDN HEALTHCARE OPPORTUNITIES FUND
By:
Title:
ABRDN INC.
By:
Title:


ABRDN WORLD HEALTHCARE FUND

INVESTMENT ADVISORY AGREEMENT

THIS INVESTMENT ADVISORY AGREEMENT, dated as of [  ], 20[ ] between ABRDN WORLD HEALTHCARE FUND, a Massachusetts business trust (the “Fund”), and ABRDN INC., a Delaware corporation (the “Investment Adviser”),

W I T N E S S E T H:

That in consideration of the mutual covenants herein contained, it is agreed as follows:

1.Services To Be Rendered by the Investment Adviser to the Fund.

Subject to the supervision and direction of the Board of Trustees of the Fund, the Investment Adviser will:

a.          act in strict conformity with the Fund’s Declaration of Trust, the Investment Company Act of 1940 (the “1940 Act”) and the Investment Advisers Act of 1940, as the same may from time to time be amended

b.          manage the portfolio in accordance with the Fund’s investment objective and policies as stated in the Fund’s Prospectus;

c.           make investment decisions for the Fund;

d.          place purchase and sale orders for portfolio transactions for the Fund;

e.           supply the Fund with office facilities (which may be in the Investment Adviser’s own offices), statistical and research data, data processing services, clerical, internal executive and administrative services, and stationery and office supplies;

f.            supply or direct and supervise a third party administrator and/or custodian in the provision to the Fund of accounting and bookkeeping services, the calculation of the net asset value of shares of the Fund, and the management of the Fund’s administrative affairs; and

g.           prepare or supervise and direct a third party administrator and/or custodian in the preparation of reports to shareholders of the Fund, tax returns and reports to and filings with the Securities and Exchange Commission (“SEC”) and state Blue Sky authorities.

In providing these services, the Investment Adviser will provide investment research and supervision of the Fund’s investments and conduct a continual program of investment, evaluation and, if appropriate, sale and reinvestment of the Fund’s assets. In addition, the Investment Adviser will furnish the Fund with whatever statistical information the Fund may reasonably request with respect to the securities that the Fund may hold or contemplate purchasing.

2.Brokerage.

In executing transactions for the Fund and selecting brokers or dealers (which brokers or dealers may include any affiliate of the Investment Adviser to the extent permitted by the 1940 Act) the Investment Adviser will use its best efforts to obtain the best price and execution for the Fund. In assessing the best price and execution available for any portfolio transaction, the Investment Adviser will consider all factors it deems relevant including, but not limited to, price (including any applicable brokerage commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm involved and the firm’s risk in positioning a block of securities. In selecting brokers or dealers to execute a particular transaction and in evaluating the best price and execution available, the Investment Adviser may consider the brokerage and research services (as those terms are defined in Section 28(e) of the Securities Exchange Act of 1934 (the “Exchange Act”)) provided to the Fund and/or other


accounts over which the Investment Adviser exercises investment discretion. It is understood that such services may be useful to the Investment Adviser in connection with its services to other clients.

On occasions when the Investment Adviser deems the purchase or sale of a security to be in the best interest of the Fund as well as other clients, the Investment Adviser, to the extent permitted by applicable laws and regulations, may, but shall be under no obligation to, aggregate the securities to be sold or purchased in order to obtain the most favorable price or lower brokerage commissions and efficient execution. In such event, allocation of the securities so purchased or sold, as well as the expenses incurred in the transaction, will be made by the Investment Adviser in the manner it considers to be the most equitable and consistent with its fiduciary obligations to the Fund and to such other clients.

3.Other Agreements; Use of Name Etc.

It is understood that any of the shareholders, Trustees, officers, agents and employees of the Fund may be a shareholder, director, officer, agent or employee of or be otherwise interested in the Investment Adviser and in any affiliate thereof with the Investment Adviser and that the Investment Adviser and any affiliate thereof with the Investment Adviser may have an interest in the Fund. It is also understood that the Investment Adviser and persons affiliated with the Investment Adviser have and may have advisory, management, service or other contracts with other organizations and persons, and may have other interests and businesses and that the Fund shall have no interest in the profits or opportunities derived from the same, that the Investment Adviser may give advice and take action in the performance of its duties with respect to such other clients that may differ from advice given on the timing or nature of action taken with respect to the Fund. Nothing in this Agreement shall be deemed to confer upon the Investment Adviser any obligation to acquire for the account of the Fund a position in any security that the Investment Adviser or any affiliate thereof may acquire for its own account or for the account of any other client, if in the sole and absolute discretion of the Investment Adviser it is not for any reason practical or desirable to acquire a position in such security for the Fund’s account.

The Investment Adviser shall authorize and permit any of its officers, directors and employees who may be elected as Trustees or officers of the Fund to serve in the capacities in which they are elected. Services to be furnished by the Investment Adviser under this Agreement may be furnished through the medium of any of such officers, directors or employees.

4.Compensation.

The Fund will pay to the Investment Adviser as compensation for the Investment Adviser’s services rendered a fee, computed and payable monthly, equal when annualized to 1.00% of the average daily value of the Trust’s managed assets.  For purposes of this section, “managed assets” for any month shall be equal to the total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund’s accrued liabilities (other than liabilities representing borrowings for investment purposes).  Borrowings for investment purposes include any form or combination of financial leverage instruments, such as borrowings from banks or other financial institutions (i.e., a credit facility), margin facilities, the issuance of preferred shares or notes and leverage attributable to reverse repurchase agreements, dollar rolls or similar transactions.  Such fee shall be payable for each month within five business days after the end of such month.

In the event that the expenses of the Fund exceed any expense limitation which the Investment Adviser may, by written notice to the Fund, voluntarily declare to be effective subject to such terms and conditions as the Investment Adviser may prescribe in such notice, the compensation due the Investment Adviser shall be reduced and if necessary the Investment Adviser shall assume expenses of the Fund, to the extent required by such expense limitation.

If the Investment Adviser shall serve for less than the whole of a month, the foregoing compensation shall be pro rated.


5.Expenses.

The Investment Adviser will bear all expenses in connection with the performance of its services under this Agreement, including compensation of and office space for officers and employees of the Fund connected with investment and economic research, trading and investment management of the Fund, as well as the fees of all Trustees of the Fund who are “affiliated persons” of the Investment Adviser, as that term is defined in the 1940 Act, or any of its “affiliated persons”.

The Fund shall pay (or, in the event that such expenses are paid by the Investment Adviser, shall reimburse the Investment Adviser for) all other expenses incurred in the operation of the Fund including, among other things, expenses for legal and auditing services, costs of printing proxy statements, prospectuses, stock certificates and shareholder reports, charges of the custodian, any sub-custodian and transfer agent, expenses in connection with the Dividend Reinvestment and Stock Purchase Plan, SEC and Financial Industry Regulatory Authority (“FINRA”) fees, fees and expenses of the Trustees who are not “affiliated persons” of the Investment Adviser or any of its “affiliated persons”, accounting and valuation costs, administrator’s fees, membership fees in trade associations, fidelity bond coverage for the Fund’s officers and employees, errors and omissions insurance coverage for Trustees and officers, interest, brokerage costs, taxes, stock exchange listing fees and expenses, expenses of qualifying the Fund’s shares for sale in various states, expenses associated with personnel performing exclusively shareholder servicing functions, litigation and other extraordinary or non-recurring expenses, and other expenses properly payable by the Fund.

6.Amendments of This Agreement.

This Agreement shall not be amended unless such amendment is approved at a meeting by the affirmative vote of a majority of the outstanding shares of the Fund, and by vote cast in person at a meeting called for the purpose of voting on such approval, of a majority of the Trustees of the Fund who are not interested persons of the Fund or of the Investment Adviser.

7.Effective Period and Termination of This Agreement.

This Agreement shall become effective as of the date first written above and shall remain in full force and effect for an initial two-year term and continuously thereafter so long as such continuance is specifically approved at least annually (a) by the vote of a majority of the Trustees who are not parties to this Agreement or interested persons of any such party, cast in person at a meeting called for the purpose of voting on such approval, and (b) by the Board of Trustees of the Fund or by vote of a majority of the outstanding voting securities of the Fund.  This Agreement shall automatically terminate, without the payment of any penalty, in the event of its assignment.

Either party hereto may at any time terminate this Agreement without the payment of any penalty by not less than thirty (30) days’ nor more than sixty (60) days’ written notice delivered or mailed by registered mail, postage prepaid, to the other party.  Action by the Fund to terminate this Agreement may be taken either by (i) vote of a majority of its Trustees, or (ii) by the affirmative vote of a majority of the outstanding shares of the Fund.

8.Certain Definitions.

For the purposes of this Agreement, the “affirmative vote of a majority of outstanding shares of the Fund” means the affirmative vote, at a duly called and held meeting of shareholders of the Fund, (a) of the holders of 67% or more of the shares of the Fund present (in person or by proxy) and entitled to vote at such meeting, if the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting are present in person or by proxy, or (b) of the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting, whichever is less.

For the purposes of this Agreement, the terms “affiliated person”, “control”, “interested person” and “assignment” shall have their respective meanings as defined in the 1940 Act and the Rules and Regulations thereunder, subject, however to such exemptions as may be granted by the SEC under said Act; the term “specifically approve at least annually” shall be construed in a manner consistent with the 1940 Act and the


Rules and Regulations thereunder; and the term “brokerage and research services” shall have the meaning given in the Exchange Act and the Rules and Regulations thereunder.

9.Non-Liability of the Investment Adviser.

The Investment Adviser shall not be held responsible for any loss incurred by any act or omission of any broker. The Investment Adviser also shall not be liable to the Fund or to any shareholder of the Fund for any error or judgment or for any loss suffered by the Fund in connection with rendering services hereunder except (a) a loss resulting from a breach of fiduciary duty with respect to the receipt of compensation for services (in which case any award of damages shall be limited to the period and the amount set forth in Section 36(b)(3) of the 1940 Act) or (b) a loss resulting from willful misfeasance, bad faith or gross negligence on the part of the Investment Adviser, or reckless disregard of its obligations and duties hereunder. Subject to the foregoing, the Fund also shall indemnify the Investment Adviser, and any officer, director and employee thereof to the maximum extent permitted by Article V of the Fund’s Declaration of Trust.

10.Limitation of Liability of the Trustees and Shareholders.

A copy of the Declaration of Trust of the Fund is on file with the Secretary of the Commonwealth of Massachusetts, and notice is hereby given that this instrument is executed on behalf of the Trustees of the Fund as Trustees and not individually and that the obligations of this instrument are not binding upon any of the Trustees or shareholders individually but are binding only upon the assets and property of the Fund.

11.Furnishing of Materials.

During the term of this Agreement, the Fund agrees to furnish the Investment Adviser at its principal executive office all prospectuses, proxy statements, report to shareholders, sales literature, or other material prepared for distribution to shareholders of the Fund or the public, which refer to the Investment Adviser in any way, prior to use thereof and not to use such material if the Investment Adviser reasonably objects in writing within five business days (or such other time as may be mutually agreed) after receipt thereof. In the event of termination of this Agreement, the Fund will continue to furnish to the Investment Adviser copies of any of the above-mentioned materials which refer in any way to the Investment Adviser. The Fund shall furnish or otherwise make available to the Investment Adviser such other information relating to the business affairs of the Fund as the Investment Adviser at any time, or from time to time, reasonably requests in order to discharge its obligations hereunder.

12.Governing Law; No Third-Party Beneficiaries.

This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. There are no third-party beneficiaries of this Agreement.

[Remainder of page intentionally left blank]


IN WITNESS WHEREOF, abrdn World Healthcare Fund and formthe Investment Adviser have each caused this instrument to be signed in duplicate on its behalf by its President or other officer thereunto duly authorized, all as of proxythe date first hereinabove written.

ABRDN WORLD HEALTHCARE FUND
By:
Title:
ABRDN INC.
By:
Title:


SCHEDULE 1

OUTSTANDING SHARES AS OF RECORD DATE (JUNE 16, 2023)

As of June 16, 2023 there were:

  HQHHQLTHQTHW

Shares of beneficial interest issued and outstanding

 48,351,111.026,212,047.041,356,057.737,998,415.6


SCHEDULE 2

SHAREHOLDERS OWNING 5% OR MORE OF EACH FUND

To the best of each Fund’s knowledge, based upon filings made with the SEC, as of June 16, 2023, no persons or groups beneficially owned more than 5% of the voting securities of HQL, THQ or THW.

To the best of each Fund’s knowledge, based upon filings made with the SEC, as of June 16, 2023, the below persons or groups beneficially owned more than 5% of the voting securities of the HQH:

(1) Title of class(2) Name and address of
beneficial owner
(3) Amount and nature
of

beneficial ownership
(4) Percent of
class
HQH Common
Stock
Morgan Stanley Smith Barney LLC
1585 Broadway
New York, NY 10036
3,118,800 shares6.6%


SCHEDULE 3

CURRENT EXECUTIVE OFFICERS OF THE FUNDS

The Boards and the senior management of the Funds appoint officers each year, and from time to time as necessary. Listed below are available at www.proxy-direct.com/TKL-27713.the executive officers, their years of birth and addresses, positions and length of service with the Funds, and principal occupations during the past five years. Each executive officer is also an officer of Tekla, the investment adviser of the Funds, and considered to be an “interested person” of the Funds under the 1940 Act.

TEKLA HEALTHCARE INVESTORS
TEKLA LIFE SCIENCES INVESTORS
TEKLA HEALTHCARE OPPORTUNITIES FUND
TEKLA WORLD HEALTHCARE FUND

Name, Address
and Year of Birth
Position(s) Held
With the Fund
Length of
Time Served
Principal Occupation(s) During the Past Five
Years

Dr. Daniel R. Omstead

c/o Tekla Capital Management LLC, 100 Federal Street, 19th Floor, Boston, Massachusetts, 02110

Year of Birth: 1953

PresidentSince 2001President of HQH (since 2001), of Tekla Life Sciences Investors (“HQL”) (since 2001), of THQ (since 2014), of THW (since 2015); President, Chief Executive Officer and Managing Member of Tekla Capital Management LLC (Since 2002); Director: Hotspot Therapeutics, Inc. (since 2021); IlluminOss Medical, Inc. (2011-2020); Veniti, Inc. (2015-2018); Joslin Diabetes Center (2016-2019); Decipher Biosciences Inc. (2016-2018).

Laura Woodward

c/o Tekla Capital Management LLC, 100 Federal Street, 19th Floor, Boston, Massachusetts, 02110

Year of Birth:1968

Chief Compliance Officer, Secretary and TreasurerSince 2009Chief Compliance Officer of HQH, HQL and Tekla Capital Management LLC (since 2009), of THQ (since 2014) and of THW (since 2015); Secretary and Treasurer, HQH and HQL (since 2009), of THQ (since 2014) and of THW (since 2015); Senior Manager, PricewaterhouseCoopers LLP (prior to 2009).

April 20, 2016


SCHEDULE 4

PROPOSED OFFICERS OF THE FUNDS

Certain biographical and other information relating to the new slate of officers expected to be elected into office by the New Boards is set forth below:

Name, Address,
and Year of Birth
Expected Position(s) to
be Held with the Funds
Principal Occupation(s) Held During the Past
Five Years and Other Relevant Experience

Christian Pittard

c/o abrdn Inc.

1900 Market Street,

Suite 200,

Philadelphia, PA
19103

Year of Birth: 1973

PresidentCurrently, Group Head of Product Opportunities and a Director of abrdn plc since 2010. Mr. Pittard joined abrdn from KPMG in 1999.

Dr. Daniel R. Omstead

c/o abrdn Inc.

1900 Market Street,

Suite 200,

Philadelphia, PA
19103

Year of Birth: 1953

Vice PresidentPresident of HQH (since 2001), of Tekla Life Sciences Investors (“HQL”) (since 2001), of THQ (since 2014), of THW (since 2015); President, Chief Executive Officer and Managing Member of Tekla Capital Management LLC (since 2002)1; Director: Hotspot Therapeutics, Inc. (since 2021); IlluminOss Medical, Inc. (2011-2020); Veniti, Inc. (2015-2018); Joslin Diabetes Center (2016-2019); Decipher Biosciences Inc. (2016-2018).

Laura Woodward

c/o abrdn Inc.

1900 Market Street,

Suite 200,

Philadelphia, PA
19103

Year of Birth: 1968

Vice PresidentChief Compliance Officer of HQH, HQL and Tekla Capital Management LLC (since 2009), of THQ (since 2014) and of THW (since 2015); Secretary and Treasurer, HQH and HQL (since 2009), of THQ (since 2014) and of THW (since 2015); Senior Manager, PricewaterhouseCoopers LLP (prior to 2009).

Alan Goodson

c/o abrdn Inc.,

1900 Market St,

Suite 200

Philadelphia, PA
19103

Year of Birth: 1974

Vice PresidentCurrently, Executive Director, Product & Client Solutions—Americas for abrdn Inc, overseeing Product Management and Governance, Product Development and Client Solutions for registered and unregistered investment companies in the U.S., Brazil and Canada. Mr. Goodson is Director and Vice President of abrdn Inc. and joined abrdn Inc. in 2000.

Lucia Sitar

c/o abrdn Inc.

1900 Market Street,

Vice President, Chief Legal OfficerCurrently, Vice President and Head of Product Management and Governance for abrdn Inc. since 2020. Previously, Ms. Sitar was Managing

1 Following completion of the Asset Transfer, Dr. Omstead and Ms. Woodward will be employed by abrdn Inc.


Suite 200,
Philadelphia, PA
19103

Year of Birth: 1971

U.S. Counsel for abrdn Inc. Ms. Sitar joined abrdn Inc. as U.S. Counsel in July 2007.

Meghan Kennedy

c/o abrdn Inc.

1900 Market Street,

Suite 200,

Philadelphia, PA
19103

Year of Birth: 1974

SecretaryCurrently, Senior Director, Product Governance for abrdn Inc. Ms. Kennedy joined abrdn Inc. as a Senior Fund Administrator in 2005.

Sharon Ferrari

c/o abrdn Inc.

1900 Market Street,

Suite 200,

Philadelphia, PA
19103

Year of Birth: 1977 

Treasurer and Chief Financial OfficerCurrently, Director Product Management for abrdn Inc. Ms. Ferrari joined abrdn Inc. as a Senior Fund Administrator in 2008.

Joseph Andolina

c/o abrdn Inc.

1900 Market Street,

Suite 200,

Philadelphia, PA
19103

Year of Birth: 1978

Chief Compliance OfficerCurrently, Chief Risk Officer—Americas and serves as the Chief Compliance Officer for abrdn Inc. Prior to joining the Risk and Compliance Department, he was a member of abrdn Inc.’s Legal Department, where he served as US Counsel since 2012.


EXHIBIT AB

FORMS OF PROXY CARDS


FORM OF PROXYFORM OF PROXY

TEKLA CAPITAL MANAGEMENT LLC

SPECIAL MEETING OF SHAREHOLDERS TO BE HELD AUGUST 14, 2023

100 Federal Street, 19th Floor, Boston, Massachusetts 02110

[INSERT FUND NAME]

GovernanceTHIS PROXY IS BEING SOLICITED BY THE BOARD OF TRUSTEES. The undersigned shareholder(s) of the above-mentioned Fund (the “Fund”), hereby appoints [XXXXXXX], or any one of them, true and Nominating Committee Charterlawful attorneys with power of substitution of each, to vote all shares of the Fund which the undersigned is entitled to vote, at the Special Meeting of Shareholders to be held on August 14, 2023 at [          ]., Eastern Time, at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110, and at any or all adjournments or postponements thereof. In their discretion, the proxy holders named above are authorized to vote upon such other matters as may properly come before the meeting or any adjournments or postponements.

Receipt of the Notice of the Special Meeting and the accompanying Proxy Statement is hereby acknowledged. THIS PROXY CARD WILL BE VOTED AS INSTRUCTED. IF NO SPECIFICATION IS MADE AND THE PROXY CARD IS EXECUTED, THE PROXY CARD WILL BE VOTED “FOR” THE PROPOSAL SET FORTH ON THE REVERSE.

   CONTROL #:

SHARES:
Note: Please date and sign exactly as the name appears on this proxy card. When shares are held by joint owners/tenants, at least one holder should sign. When signing in a fiduciary capacity, such as executor, administrator, trustee, attorney, guardian etc., please so indicate. Corporate and partnership proxies should be signed by an authorized person.
Signature(s) (Title(s), if applicable)
Date

PLEASE VOTE VIA THE INTERNET OR TELEPHONE OR MARK, SIGN, DATE AND RETURN THIS PROXY USING THE ENCLOSED ENVELOPE

CONTINUED ON THE REVERSE SIDE

EVERY SHAREHOLDER’S VOTE IS IMPORTANT!

VOTE THIS PROXY CARD TODAY!

THE BOARD OF TRUSTEES RECOMMENDS A VOTE “FOR” THE PROPOSAL

FORAGAINSTABSTAIN
1.To approve a new investment advisory agreement (each a “New Advisory Agreement” and collectively, the “New Advisory Agreements”) between the Fund and abrdn Inc.¨¨¨

You may have received more than one proxy card due to multiple investments in the Funds.

PLEASE REMEMBER TO VOTE ALL OF YOUR PROXY CARDS!

PLEASE FOLD ALONG THE PERFORATION, DETACH AND RETURN THE UPPER PORTION IN THE ENCLOSED ENVELOPE.

CONTINUED AND TO BE SIGNED ON REVERSE SIDE

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE

SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 14, 2023

THE PROXY STATEMENT AND THE NOTICE OF SPECIAL MEETING OF SHAREHOLDERS FOR THIS MEETING

ARE AVAILABLE AT: WWW.OKAPIVOTE.COM/TEKLASPECIAL

FORM OF PROXYFORM OF PROXY

TEKLA CAPITAL MANAGEMENT LLC

SPECIAL MEETING OF SHAREHOLDERS TO BE HELD AUGUST 14, 2023

100 Federal Street, 19th Floor, Boston, Massachusetts 02110

[INSERT FUND NAME]

THIS PROXY IS BEING SOLICITED BY THE BOARD OF TRUSTEES. The undersigned shareholder(s) of the above-mentioned Fund (the “Fund”), hereby appoints [ XXXXXXX], or any one of them, true and lawful attorneys with power of substitution of each, to vote all shares of the Fund which the undersigned is entitled to vote, at the Special Meeting of Shareholders to be held on August 14, 2023 at [          ]., Eastern Time, at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110, and at any or all adjournments or postponements thereof. In their discretion, the proxy holders named above are authorized to vote upon such other matters as may properly come before the meeting or any adjournments or postponements.

Receipt of the Notice of the Special Meeting and the accompanying Proxy Statement is hereby acknowledged. THIS PROXY CARD WILL BE VOTED AS INSTRUCTED. IF NO SPECIFICATION IS MADE AND THE PROXY CARD IS EXECUTED, THE PROXY CARD WILL BE VOTED “FOR” THE PROPOSAL SET FORTH ON THE REVERSE.

   CONTROL #:

SHARES:
Note: Please date and sign exactly as the name appears on this proxy card. When shares are held by joint owners/tenants, at least one holder should sign. When signing in a fiduciary capacity, such as executor, administrator, trustee, attorney, guardian etc., please so indicate. Corporate and partnership proxies should be signed by an authorized person.
Signature(s) (Title(s), if applicable)
Date

PLEASE VOTE VIA THE INTERNET OR TELEPHONE OR MARK, SIGN, DATE AND RETURN THIS PROXY USING THE ENCLOSED ENVELOPE

CONTINUED ON THE REVERSE SIDE

EVERY SHAREHOLDER’S VOTE IS IMPORTANT!

VOTE THIS PROXY CARD TODAY!

THE BOARD OF TRUSTEES RECOMMENDS A VOTE “FOR” EACH OF THE BELOW NOMINEES

ELECTION OF FOUR TRUSTEES TO THE BOARD OF TRUSTEES TO THE CLASS SPECIFIED IN THE PROXY STATEMENT

FORWITHHOLD
1a. Stephen Bird¨¨
1b. Rose DiMartino¨¨
1c. C. William Maher¨¨
1d. Todd Reit¨¨

You may have received more than one proxy card due to multiple investments in the Funds.

PLEASE REMEMBER TO VOTE ALL OF YOUR PROXY CARDS!

PLEASE FOLD ALONG THE PERFORATION, DETACH AND RETURN THE UPPER PORTION IN THE ENCLOSED ENVELOPE.

CONTINUED AND TO BE SIGNED ON REVERSE SIDE

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE

SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 14, 2023

THE PROXY STATEMENT AND THE NOTICE OF SPECIAL MEETING OF SHAREHOLDERS FOR THIS MEETING

ARE AVAILABLE AT: WWW.OKAPIVOTE.COM/TEKLASPECIAL

EXHIBIT C

GOVERNANCE AND NOMINATING COMMITTEE CHARTER

For convenience, this Charter refers to the Funds and their respective Boards of Trustees (each the "Board"“Board”), and their respective Governance and Nominating Committees (each the "Committee"“Committee” or the "Governance“Governance and Nominating Committee"Committee”) in the singular. However, this Charter applies to each Fund, its Board and its Committee independently.

Committee Membership

The Committee shall consist entirely of trustees of the Fund who (1) are not "interested“interested persons," as that term is defined in the Investment Company Act of 1940, as amended (the "1940 Act"“1940 Act”), of the Fund or the Fund'sFund’s investment adviser and (2) are "independent"“independent” as defined in the New York Stock Exchange ("NYSE"(“NYSE”) Listing Standards ("(“Independent Trustees"Trustees”). The President of the Fund, although not a member of the Committee, will cooperate with the Committee by assisting the Committee to discharge its responsibilities, including by recommending candidates and recruiting them for the Board or to serve as executive officers of the Fund.

Missions

The principal missions of the Committee are (i) to review, evaluate, and enhance the effectiveness of the Board in its role in governing the Fund and overseeing the management of the Fund and (ii) to promote the effective participation of qualified individuals on the Board, on committees of the Board, and as executive officers of the Fund. The Committee shall consider the Corporate Governance Guidelines attached to this Charter as Appendix A in fulfilling its missions.

Governance Function

The Committee shall review, discuss, and make recommendations to the Board relating to those issues that pertain to the effectiveness of the Board in carrying out its responsibilities in governing the Fund and overseeing the management of the Fund. These may include, but are not limited to, issues relating to:

1.  the selection of the Fund's investment adviser (the "Adviser") and approval of the Fund's

1.the selection of the Fund’s investment adviser (the “Adviser”) and approval of the Fund’s investment advisory contract;

2.the selection and approval of the Fund’s outside counsel (“Fund Counsel”);

3.the composition of the Board, including:

(a)the size of the Board and the qualifications and representative areas of expertise of the members of the Board; and

(b)retirement and succession policies relating to members of the Board;

4.the members of the Board, including:

(a)guidelines relating to ownership of shares of the Fund by members of the Board;

(b)whether members of the Board may not serve in a similar capacity on the board of a registered investment company (i) which is not sponsored or advised by the Adviser or its


2.  the selection and approval of the Fund's outside counsel ("Fund Counsel");

3.  the composition of the Board, including:

(a)  the size of the Board and the qualifications and representative areas of expertise of the members of the Board; and

(b)  retirement and succession policies relating to members of the Board;

4.  the members of the Board, including:

(a)  guidelines relating to ownership of shares of the Fund by members of the Board;

(b)  whether members of the Board may not serve in a similar capacity on the board of a registered investment company (i) which is not sponsored or advised by the Adviser or its affiliates and (ii) which the Committee in its discretion has determined to be competitive with the Fund taking into account such registered investment company'scompany’s investment mandate;


(c)  

(c)continuing education of members of the Board; and

(d)identification of best practices for members of the Board;

5.the meetings of the Board, including:

(a)coordination with the Chairman of the Board in developing the agenda for the meetings of the Board, with the assistance of the Adviser and Fund Counsel;

(b)frequency of meetings of the Board; and

(c)Board meeting attendance policies;

6.the role of the Independent Trustees, including:

(a)limitations on the ability of Independent Trustees to act and function independently of the Board and the Adviser; and

(b)the quality of information received by the Independent Trustees;

7.compensation for Independent Trustees;

8.the role of the committees of the Board, including:

(a)number and type of committees; and

(b)periodic approval of the charter and scope of the responsibilities of each committee;

9.the relationship between the Board and management, including:

(a)oversight of and communication with management;

(b)coordination with management to ensure that management has developed an appropriate plan to deal with succession and potential crisis management situations; and

10.Board self-evaluation.

(d)  identification of best practices for members of the Board;

5.  the meetings of the Board, including:

(a)  coordination with the Chairman of the Board in developing the agenda for the meetings of the Board, with the assistance of the Adviser and Fund Counsel;

(b)  frequency of meetings of the Board; and

(c)  Board meeting attendance policies;

6.  the role of the Independent Trustees, including:

(a)  limitations on the ability of Independent Trustees to act and function independently of the Board and the Adviser; and

(b)  the quality of information received by the Independent Trustees;

7.  compensation for Independent Trustees;

8.  the role of the committees of the Board, including:

(a)  number and type of committees; and

(b)  periodic approval of the charter and scope of the responsibilities of each committee;

9.  the relationship between the Board and management, including:

(a)  oversight of and communication with management;

(b)  coordination with management to ensure that management has developed an appropriate plan to deal with succession and potential crisis management situations; and

10.  Board self-evaluation.

Nominating Function – Board

1.  The Committee shall make nominations for trustees and officers of the Fund and submit such nominations to the full Board. The Committee shall evaluate candidates' qualifications for such positions and, in the case of candidates for election to the Board, whether they would qualify as Independent Trustees. The Committee shall also consider the effect of any relationships beyond those delineated in the 1940 Act that might impair independence (e.g. business, financial or family relationships with the Adviser). In determining candidates' qualifications for Board membership, the Committee shall consider factors which may be delineated in this Charter or the Fund's By-Laws

1.The Committee shall make nominations for trustees and officers of the Fund and submit such nominations to the full Board. The Committee shall evaluate candidates’ qualifications for such positions and, in the case of candidates for election to the Board, whether they would qualify as Independent Trustees. The Committee shall also consider the effect of any relationships beyond those delineated in the 1940 Act that might impair independence (e.g. business, financial or family relationships with the Adviser). In determining candidates’ qualifications for Board membership, the Committee shall consider factors which may be delineated in this Charter or the Fund’s By-


Laws and may consider such other factors as it may determine to be relevant to fulfilling the role of being a member of the Board.

2.  The Committee may consider potential trustee candidates recommended by shareholders, provided that the proposed candidates: (i) satisfy any minimum qualifications of the Fund for its trustees; and (ii) qualify as Independent Trustees. In order for the Committee to evaluate any nominee recommended by a shareholder or shareholder group, potential trustee candidates and nominating shareholders or shareholder groups must satisfy the requirements provided in Appendix B to this Charter. The Committee shall not otherwise evaluate shareholder trustee nominees in a different manner than other nominees, and the standard of the Committee is to treat all equally qualified


nominees in the same manner. Once a nomination has been timely received in proper form, the nominee will be asked to complete an eligibility questionnaire to assist the Committee in assessing the nominee's
2.The Committee may consider potential trustee candidates recommended by shareholders, provided that the proposed candidates: (i) satisfy any minimum qualifications of the Fund for its trustees; and (ii) qualify as Independent Trustees. In order for the Committee to evaluate any nominee recommended by a shareholder or shareholder group, potential trustee candidates and nominating shareholders or shareholder groups must satisfy the requirements provided in Appendix B to this Charter. The Committee shall not otherwise evaluate shareholder trustee nominees in a different manner than other nominees, and the standard of the Committee is to treat all equally qualified nominees in the same manner. Once a nomination has been timely received in proper form, the nominee will be asked to complete an eligibility questionnaire to assist the Committee in assessing the nominee’s qualifications as a potential Independent Trustee. The Committee will make such determinations in its sole discretion and such determinations shall be final.

3.The Committee may identify prospective trustees from any reasonable source, including, but not limited to, the consultation of third-party trustee search services.

4.The Committee requires that each prospective trustee have a college degree or equivalent business experience. In addition to the requirements delineated in the Fund’s By-Laws, the Committee may take into account a wide variety of factors in considering prospective trustees, including (but not limited to): (i) availability and commitment of a candidate to attend meetings and perform his or her responsibilities on the Board; (ii) relevant industry and related experience; (iii) educational background; (iv) financial expertise; (v) the candidate’s ability, judgment and expertise; and (vi) overall diversity of the Board’s composition.

5.The Committee shall evaluate the participation and contribution of each trustee coming to the end of his or her term before deciding whether to recommend reelection. The Committee may seek the views of other trustees to assist them in this evaluation.

3.  The Committee may identify prospective trustees from any reasonable source, including, but not limited to, the consultation of third-party trustee search services.

4.  The Committee requires that each prospective trustee have a college degree or equivalent business experience. In addition to the requirements delineated in the Fund's By-Laws, the Committee may take into account a wide variety of factors in considering prospective trustees, including (but not limited to): (i) availability and commitment of a candidate to attend meetings and perform his or her responsibilities on the Board; (ii) relevant industry and related experience; (iii) educational background; (iv) financial expertise; (v) the candidate's ability, judgment and expertise; and (vi) overall diversity of the Board's composition.

6.  The Committee shall evaluate the participation and contribution of each trustee coming to the end of his or her term before deciding whether to recommend reelection. The Committee may seek the views of other trustees to assist them in this evaluation.

Nominating Function – Committees

The Committee shall make nominations for membership on all committees of the Board and submit such nominations to the full Board and shall review committee assignments as necessary.

Other Powers and Responsibilities

1.  The Committee shall meet at least annually so it can carry out its review of the investment advisory agreement, recommend the selection of an Adviser, and consider Board and Committee nominations. The Committee shall meet at such other time or times as the Committee or the Board may determine appropriate or necessary and is empowered to hold special meetings as circumstances require.

1.The Committee shall meet at least annually so it can carry out its review of the investment advisory agreement, recommend the selection of an Adviser, and consider Board and Committee nominations. The Committee shall meet at such other time or times as the Committee or the Board may determine appropriate or necessary and is empowered to hold special meetings as circumstances require.

2.  The Committee shall have the resources and authority appropriate to discharge its responsibilities, including authority to utilize Fund Counsel and to retain experts or other persons with specific competence at the expense of the Fund.

2.The Committee shall have the resources and authority appropriate to discharge its responsibilities, including authority to utilize Fund Counsel and to retain experts or other persons with specific competence at the expense of the Fund.

3.  The Committee shall review this Charter periodically and recommend any changes to the Board.

3.The Committee shall review this Charter periodically and recommend any changes to the Board.


APPENDIX A

Corporate Governance Guidelines

1. General

The intent is that the Board shall, wherever possible, comply in its structure and operations with the guidelines issued by the NYSE and the Securities and Exchange Commission ("SEC"(“SEC”).

2. Board Composition

(a)  The Fund's Declaration of Trust, as amended, provides that the Trustees shall be at least three and not more than fifteen in number, as fixed by the Trustees, and the number of Trustees is currently fixed at seven.

(a)The Fund’s Declaration of Trust, as amended, provides that the Trustees shall be at least three and not more than fifteen in number, as fixed by the Trustees, and the number of Trustees is currently fixed at seven.

(b)  Independent Trustees shall represent at least 75% of Board membership.

(b)Independent Trustees shall represent at least 75% of Board membership.

(c)  The President of the Adviser, and such other officers of the Adviser as the Board may designate, shall be included among those nominated for Board membership, but they shall not be considered as Independent Trustees.

(c)The President of the Adviser, and such other officers of the Adviser as the Board may designate, shall be included among those nominated for Board membership, but they shall not be considered as Independent Trustees.

(d)  

(d)The Board shall seek to be broadly representative of the various skills and experience deemed necessary to ensure sound oversight of the Fund.

3. Selection of Chairman of the Board

The Board shall annually elect its own Chairman from among those Independent Trustees elected by the shareholders. This election shall take place at the first Board meeting following the annual meeting of shareholders or upon the initiative of a two-thirds majority of the trustees.

4. General Expectations

(a)  In serving as a trustee, each trustee must exercise duties of care and loyalty to the Fund.

(a)In serving as a trustee, each trustee must exercise duties of care and loyalty to the Fund.

(b)  Each Independent Trustee is expected to be knowledgeable about Fund business and financial operations through Board and Board committee meetings and personal inquiry and observation, and to contribute to the Board's oversight of the Fund's investment performance.

(b)Each Independent Trustee is expected to be knowledgeable about Fund business and financial operations through Board and Board committee meetings and personal inquiry and observation, and to contribute to the Board’s oversight of the Fund’s investment performance.

(c)  Each trustee is expected to devote sufficient time and attention to carrying out his or her duties and responsibilities as a trustee of the Fund and to ensure that other commitments or responsibilities do not materially interfere with his or her duties and responsibilities to the Fund.

(c)Each trustee is expected to devote sufficient time and attention to carrying out his or her duties and responsibilities as a trustee of the Fund and to ensure that other commitments or responsibilities do not materially interfere with his or her duties and responsibilities to the Fund.

(d)  

(d)The criteria to be used to evaluate candidates to serve as trustees, which will be reviewed from time to time by the Board or the Governance and Nominating Committee, will stress personal and professional integrity, sound judgment, relevant experience, a proven record of professional accomplishment, and a commitment to devote sufficient time and attention to Fund matters, among other relevant factors. In the case of a candidate to serve as an Independent Trustee, independence will be required in terms of both the letter and spirit of applicable law.

5. Retirement of Trustees

Trustees shall serve for a three-year term upon nomination by the Committee and election by the shareholders. No person may be nominated for election to the Board, if that person is 75 years of age or older at the time of consideration, unless such nomination is approved by at least 662/3% 2/3% of the Independent Trustees.


6. Independent Trustee Sessions

Independent Trustees are expected to meet in separate session at least once each quarter, typically in conjunction with the regularly scheduled Board meeting for that quarter. In such sessions, Independent Trustees are expected to engage in candid discussions about Fund management performance and other sensitive matters deemed appropriate.


7. Independent Trustee Authority to Hire Staff

Independent Trustees may hire their own staff to the extent deemed necessary to help Independent Trustees deal with matters on which they deem outside assistance to be necessary.

8. Committees of the Board

(a)  The Board shall have four Committees:

(a)The Board shall have four Committees:

(i)  an Audit Committee;

(i)an Audit Committee;

(ii)  a Valuation Committee;

(ii)a Valuation Committee;

(iii)  a Governance and Nominating Committee; and

(iii)a Governance and Nominating Committee; and

(iv)  a Qualified Legal Compliance Committee.

(iv)a Qualified Legal Compliance Committee.

(b)  A Compensation Committee, generally required by SEC and NYSE guidelines, is not deemed necessary as personnel of the Adviser serve as the Fund's officers, and the compensation of such personnel is determined and payable by the Adviser (with the exception of the Fund's Chief Compliance Officer). Oversight of the Adviser's budget, including compensation, shall be a factor in the Board's approval of the Adviser's investment advisory contract.

(b)A Compensation Committee, generally required by SEC and NYSE guidelines, is not deemed necessary as personnel of the Adviser serve as the Fund’s officers, and the compensation of such personnel is determined and payable by the Adviser (with the exception of the Fund’s Chief Compliance Officer). Oversight of the Adviser’s budget, including compensation, shall be a factor in the Board’s approval of the Adviser’s investment advisory contract.

(c)  Each of the Board's committees shall have a charter (or policies and procedures), which shall have been approved by the Board. The Governance and Nominating Committee shall review periodically each such charter and recommend any changes to the Board. The Audit Committee shall review its charter annually to comply with NYSE Listing Standards and recommend any changes to the Board.

(c)Each of the Board’s committees shall have a charter (or policies and procedures), which shall have been approved by the Board. The Governance and Nominating Committee shall review periodically each such charter and recommend any changes to the Board. The Audit Committee shall review its charter annually to comply with NYSE Listing Standards and recommend any changes to the Board.

(d)  Committee Chairman and members shall be nominated by the Governance and Nominating Committee and approved by the Board.

(d)Committee Chairman and members shall be nominated by the Governance and Nominating Committee and approved by the Board.

(e)  

(e)The Audit Committee, Governance and Nominating Committee and Qualified Legal Compliance Committee shall each consist solely of Independent Trustees.

9. Board Meetings

(a)  The Board is expected to meet no less than four times per year, including one meeting which coincides with the annual meeting of shareholders.

(a)The Board is expected to meet no less than four times per year, including one meeting which coincides with the annual meeting of shareholders.

(b)  Trustees are expected to attend all Board meetings in person. Where conflicts prevent attendance in person, trustees may attend by telephone or video conference. It is expected that, during their term, trustees shall attend no fewer than 50% of Board meetings in person and no less than 75% of meetings where a majority of Independent Trustees must be present in person.

(b)Trustees are expected to attend all Board meetings in person. Where conflicts prevent attendance in person, trustees may attend by telephone or video conference. It is expected that, during their term, trustees shall attend no fewer than 50% of Board meetings in person and no less than 75% of meetings where a majority of Independent Trustees must be present in person.

(c)  Agendas for Board meetings shall be proposed by the Adviser and Fund Counsel and approved by the Chairman of the Board at least two weeks in advance of each Board meeting and one month in advance of the annual meeting of shareholders.

(c)Agendas for Board meetings shall be proposed by the Adviser and Fund Counsel and approved by the Chairman of the Board at least two weeks in advance of each Board meeting and one month in advance of the annual meeting of shareholders.

(d)Minutes for each Board meeting shall be prepared and circulated within a reasonable period of time following each Board meeting and shall highlight items on which follow-up action is required.


(d)  Minutes for each Board meeting shall be prepared and circulated within six weeks of each Board meeting and shall highlight items on which follow-up action is required.

(e)In their role as trustees, all trustees owe a duty of loyalty to the shareholders and to the Fund. This duty of loyalty mandates that the best interests of the shareholders and the Fund take precedence over any interests possessed by a trustee. In the event of any conflict of interests, a trustee shall promptly disclose such conflict to the Chairman of the Board and Fund Counsel and recuse him or herself from any discussions or votes involving the conflict.

(e)  In their role as trustees, all trustees owe a duty of loyalty to the shareholders and to the Fund. This duty of loyalty mandates that the best interests of the shareholders and the Fund take precedence over any interests possessed by a trustee. In the event of any conflict of interests, a trustee shall promptly disclose such conflict to the Chairman of the Board and Fund Counsel and recuse him or herself from any discussions or votes involving the conflict.

(f)  
(f)The proceedings of the Board and its committees are confidential. Each trustee shall maintain the confidentiality of information received as part of his or her duty as a trustee.

10. Board Access to Senior Management and Key Service Providers

Trustees must have reasonable access to Fund management and senior management of the Adviser. Trustees must have reasonable access to Fund Counsel, auditors, and other key service providers. Independent Trustees must have reasonable access to independent legal counsel. The Chairman of the Board is responsible for fostering constructive interaction between Fund management and the Board. The chairman of each committee is responsible for fostering constructive interaction between Fund management and the committee.

11. Trustee Education

(a)  New trustees will review background materials and participate in an orientation program that includes discussions with incumbent trustees and senior management. Topics covered will include investment operations, compliance practices and operations, financial operations, and organizational structure.

(a)New trustees will review background materials and participate in an orientation program that includes discussions with incumbent trustees and senior management. Topics covered will include investment operations, compliance practices and operations, financial operations, and organizational structure.

(b)  

(b)Continuing trustee education will be a standing agenda item for each regularly scheduled meeting to cover timely topics based on industry developments and Fund operations.

12. Review of Strategic Planning

The Board will periodically review the continued organizational strength of the Fund, Fund management, and the Adviser to ensure the Fund'sFund’s continued short-term and long-term viability. At least biannually, the Board will review the Fund'sFund’s annual and longer term strategic business plans and management development and succession plan.

13. Board Compensation

The Independent Trustees will establish and periodically review their compensation.

14. Insurance Coverage and Indemnification

The Fund will maintain directors'directors’ and officers'officers’/errors and omissions insurance coverage and/or indemnification that is adequate to ensure the independence and effectiveness of the Independent Trustees. The Independent Trustees will periodically review the effectiveness of such insurance coverage and/or indemnification.

15. Board Evaluation

The Governance and Nominating Committee shall prepare a Board self-evaluation instrument that each trustee shall complete annually.


Appendix B

Procedures and Eligibility Requirements for

Shareholder Submission of Nominee Candidates21

A. Nominee Requirements

Trustee nominees recommended by shareholders must fulfill the following requirements:

1.  The nominee may not be the nominating shareholder, a member of the nominating shareholder group, or a member of the immediate family of the nominating shareholder or any member of the nominating shareholder group.

1.The nominee may not be the nominating shareholder, a member of the nominating shareholder group, or a member of the immediate family of the nominating shareholder or any member of the nominating shareholder group.

2.  Neither the nominee nor any member of the nominee's immediate family may be currently employed or employed within the last year by any nominating shareholder entity or entity in a nominating shareholder group.

2.Neither the nominee nor any member of the nominee’s immediate family may be currently employed or employed within the last year by any nominating shareholder entity or entity in a nominating shareholder group.

3.  Neither the nominee nor any immediate family member of the nominee is permitted to have accepted directly or indirectly, during the year of the election for which the nominee's name was submitted, during the immediately preceding calendar year, or during the year when the nominee's name was submitted, any consulting, advisory, or other compensatory fee from the nominating shareholder or any member of a nominating shareholder group.

3.Neither the nominee nor any immediate family member of the nominee is permitted to have accepted directly or indirectly, during the year of the election for which the nominee’s name was submitted, during the immediately preceding calendar year, or during the year when the nominee’s name was submitted, any consulting, advisory, or other compensatory fee from the nominating shareholder or any member of a nominating shareholder group.

4.  The nominee may not be an executive officer, director (or person performing similar functions) of the nominating shareholder or any member of the nominating shareholder group, or of an affiliate of the nominating shareholder or any such member of the nominating shareholder group.

4.The nominee may not be an executive officer, director (or person performing similar functions) of the nominating shareholder or any member of the nominating shareholder group, or of an affiliate of the nominating shareholder or any such member of the nominating shareholder group.

5.  The nominee may not control (as "control"

5.The nominee may not control (as “control” is defined in the 1940 Act) the nominating shareholder or any member of the nominating shareholder group (or in the case of a holder or member that is a fund, an interested person of such holder or member as defined by Section 2(a)(19) of the 1940 Act).

B. Nominating Shareholder or Shareholder Group Requirements

The nominating shareholder or shareholder group must meet the following requirements:

1.  Any shareholder or shareholder group submitting a proposed nominee must beneficially own, either individually or in the aggregate, more than 5% of the Fund's securities that are eligible to vote at the time of submission of the nominee and at the time of the meeting where the nominee may be elected. Each of the securities used for purposes of calculating the required ownership must have been held continuously for at least two years as of the date of the nomination. In addition, such securities must continue to be held through the date of the meeting. The nominating shareholder or shareholder group must also bear the economic risk of the investment, and the securities used for purposes of calculating the required ownership cannot be held "short."

1.Any shareholder or shareholder group submitting a proposed nominee must beneficially own, either individually or in the aggregate, more than 5% of the Fund’s securities that are eligible to vote at the time of submission of the nominee and at the time of the meeting where the nominee may be elected. Each of the securities used for purposes of calculating the required ownership must have been held continuously for at least two years as of the date of the nomination. In addition, such securities must continue to be held through the date of the meeting. The nominating shareholder or shareholder group must also bear the economic risk of the investment, and the securities used for purposes of calculating the required ownership cannot be held “short.”

2.The nominating shareholder or shareholder group must also submit a certification which provides the number of shares which the person or group has (i) sole power to vote or direct the vote; (ii)

2.  The nominating shareholder or shareholder group must also submit a certification which provides the number of shares which the person or group has (i) sole power to vote or direct the vote; (ii)

2Appendix B applies only to trustee nominee recommendations made by shareholders to the Governance and Nominating Committee. Refer to the Fund’s By-laws regarding submission of shareholder proposals for the election of trustees. Unless otherwise specified herein, please refer to the Securities Exchange Act of 1934 and regulations thereunder for interpretations of terms used in this Appendix B.


shared power to vote or direct the vote; (iii) sole power to dispose or direct the disposition of such shares; and (iv) shared power to dispose or direct the disposition of such shares. In addition, the certification shall provide that the shares have been held continuously for at least 2 years.

1  Appendix B applies only to trustee nominee recommendations made by shareholders to the Governance and Nominating Committee. Refer to the Fund's By-laws regarding submission of shareholder proposals for the election of trustees. Unless otherwise specified herein, please refer to the Securities Exchange Act of 1934 and regulations thereunder for interpretations of terms used in this Appendix B.


C. Deadlines and Limitations

1.  A nominating shareholder or shareholder group may not submit more than one nominee per year.

1.A nominating shareholder or shareholder group may not submit more than one nominee per year.

2.  All nominee submissions must be received by the Fund by the deadline for submission of any shareholder proposals which would be included in the Fund's

2.All nominee submissions must be received by the Fund by the deadline for submission of any shareholder proposals which would be included in the Fund’s proxy statement for the next annual meeting of the Fund.

D. Making a Submission

Shareholders recommending potential trustee candidates must substantiate compliance with these requirements at the time of submitting their proposed trustee candidate to the attention of the Fund'sFund’s Secretary. Notice to the Fund'sFund’s Secretary should include: (i) the shareholder'sshareholder’s contact information; (ii) the trustee candidate'scandidate’s contact information and the number of Fund shares owned by the proposed candidate; (iii) all information regarding the candidate that would be required to be disclosed in solicitations of proxies for elections of trustees required by Regulation 14A of the 1934 Act; and (iv) a notarized letter executed by the trustee candidate, stating his or her intention to stand for election and be named in the Fund'sFund’s proxy statement, if nominated by the Board, and to serve as a trustee, if so elected.



EVERY SHAREHOLDER’S VOTE IS IMPORTANT

EASY VOTING OPTIONS:

VOTE ON THE INTERNET

Log on to:

www.proxy-direct.com

or scan the QR code

Follow the on-screen instructions

available 24 hours

VOTE BY PHONE

Call 1-800-337-3503

Follow the recorded instructions

available 24 hours

VOTE BY MAIL

Vote, sign and date this Proxy

Card and return in the

postage-paid envelope

VOTE IN PERSON

Attend Shareholder Meeting

100 Federal Street, 19th Floor

Boston, MA 02110

on June 14, 2016

at 10:00 A.M. Eastern Time

Please detach at perforation before mailing.

PROXY

TEKLA HEALTHCARE INVESTORS

PROXY

JOINT ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD JUNE 14, 2016

This Proxy is Being Solicited on Behalf of the Board of Trustees. The undersigned hereby appoints Daniel R. Omstead, Ph.D., Oleg M. Pohotsky and Michael W. Bonney and each of them, proxies of the undersigned, with full powers of substitution, to vote at the Joint Annual Meeting of Shareholders of TEKLA HEALTHCARE INVESTORS (the “Fund”) to be held on June 14, 2016 at 10:00 a.m., at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110, and at any adjournment(s) or postponement(s) thereof, all the shares of the Fund outstanding in the name of the undersigned as follows on the reverse of this card.

THIS PROXY WILL BE VOTED AS SPECIFIED.  IF NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR ALL PROPOSALS.

VOTE VIA THE INTERNET:  www.proxy-direct.com

VOTE VIA THE TELEPHONE:  1-800-337-3503

Note:  Please sign this proxy exactly as your name appears on the books of the Fund.  Joint owners should each sign personally.  Trustees and other fiduciaries should indicate the capacity in which they sign, and where more than one name appears, a majority must sign.  If a corporation, this signature should be that of an authorized officer who should state his or her title.

Signature

Signature (if held jointly)

Date

HQH_27713_033116

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.

 




EVERY SHAREHOLDER’S VOTE IS IMPORTANT

Important Notice Regarding the Availability of Proxy Materials for the

Joint Annual Shareholder Meeting to Be Held on June 14, 2016.

The Joint Proxy Statement and Proxy Card for this meeting are available at:

https://www.proxy-direct.com/TKL-27713

IF YOU VOTE ON THE INTERNET OR BY TELEPHONE,

YOU NEED NOT RETURN THIS PROXY CARD

Please detach at perforation before mailing.

The Board of Trustees recommends a vote FOR all the nominees listed and FOR Proposals 2, 3, 5A, 5B and 5C.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK.  Example: 

1.

The election of three Class C Trustees:

FOR
ALL

WITHHOLD
ALL

FOR ALL
EXCEPT

01.     Michael W. Bonney         02.     Oleg M. Pohotsky         03.     William S. Reardon, CPA

o

o

o

INSTRUCTIONS:  To withhold authority to vote for any individual nominee(s), mark the box “FOR ALL EXCEPT” and write the nominee’s number on the line provided below.

FOR

AGAINST

ABSTAIN

2.

The ratification or rejection of the selection of Deloitte & Touche LLP as the independent registered public accountants of the Fund for the fiscal year ending September 30, 2016.

o

o

o

3.

Change the subclassification of HQH from “diversified” to “non-diversified” and eliminate the related fundamental investment restriction.

o

o

o

4.

Not Applicable

5A.

Amend HQH’s fundamental investment restriction regarding issuing senior securities.

o

o

o

5B.

Remove HQH’s fundamental investment restriction regarding investments in other investment companies.

o

o

o

5C.

Remove HQH’s fundamental investment restriction regarding short sales and purchasing securities on margin.

o

o

o

6.

The transaction of such other business as may properly come before the Annual Meeting and any adjournment(s) or postponement(s) thereof.

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.

HQH_27713_033116



EVERY SHAREHOLDER’S VOTE IS IMPORTANT

EASY VOTING OPTIONS:

VOTE ON THE INTERNET

Log on to:

www.proxy-direct.com

or scan the QR code

Follow the on-screen instructions

available 24 hours

VOTE BY PHONE

Call 1-800-337-3503

Follow the recorded instructions

available 24 hours

VOTE BY MAIL

Vote, sign and date this Proxy

Card and return in the

postage-paid envelope

VOTE IN PERSON

Attend Shareholder Meeting

100 Federal Street, 19th Floor

Boston, MA 02110

on June 14, 2016

at 10:00 A.M. Eastern Time

Please detach at perforation before mailing.

PROXY

TEKLA LIFE SCIENCES INVESTORS

PROXY

JOINT ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD JUNE 14, 2016

This Proxy is Being Solicited on Behalf of the Board of Trustees. The undersigned hereby appoints Daniel R. Omstead, Ph.D., Oleg M. Pohotsky and Michael W. Bonney and each of them, proxies of the undersigned, with full powers of substitution, to vote at the Joint Annual Meeting of Shareholders of TEKLA LIFE SCIENCES INVESTORS (the “Fund”) to be held on June 14, 2016 at 10:00 a.m., at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110, and at any adjournment(s) or postponement(s) thereof, all the shares of the Fund outstanding in the name of the undersigned as follows on the reverse of this card.

THIS PROXY WILL BE VOTED AS SPECIFIED.  IF NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR ALL PROPOSALS.

VOTE VIA THE INTERNET:  www.proxy-direct.com

VOTE VIA THE TELEPHONE:  1-800-337-3503

Note:  Please sign this proxy exactly as your name appears on the books of the Fund.  Joint owners should each sign personally.  Trustees and other fiduciaries should indicate the capacity in which they sign, and where more than one name appears, a majority must sign.  If a corporation, this signature should be that of an authorized officer who should state his or her title.

Signature

Signature (if held jointly)

Date

HQL_27713_033116

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.



EVERY SHAREHOLDER’S VOTE IS IMPORTANT

Important Notice Regarding the Availability of Proxy Materials for the

Joint Annual Shareholder Meeting to Be Held on June 14, 2016.

The Joint Proxy Statement and Proxy Card for this meeting are available at:

https://www.proxy-direct.com/TKL-27713

IF YOU VOTE ON THE INTERNET OR BY TELEPHONE,

YOU NEED NOT RETURN THIS PROXY CARD

Please detach at perforation before mailing.

The Board of Trustees recommends a vote FOR the nominees listed and FOR Proposals 2, 4, 5A and 5B.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK.  Example: 

1.

The election of three Class C Trustees:

FOR
ALL

WITHHOLD
ALL

FOR ALL
EXCEPT

01.     Michael W. Bonney         02.     Rakesh K. Jain, Ph.D.         03.     Uwe E. Reinhardt, Ph.D.

o

o

o

INSTRUCTIONS:  To withhold authority to vote for any individual nominee(s), mark the box “FOR ALL EXCEPT” and write the nominee’s number on the line provided below.

FOR

AGAINST

ABSTAIN

2.

The ratification or rejection of the selection of Deloitte & Touche LLP as the independent registered public accountants of the Fund for the fiscal year ending September 30, 2016.

o

o

o

3.

Not Applicable

4.

Change the subclassification of HQL from “diversified” to “non-diversified” and eliminate the related fundamental investment restriction.

o

o

o

5A.

Amend HQL’s fundamental investment restriction regarding issuing senior securities.

o

o

o

5B.

Remove HQL’s fundamental investment restriction regarding investments in other investment companies.

o

o

o

5C.

Not Applicable

6.

The transaction of such other business as may properly come before the Annual Meeting and any adjournment(s) or postponement(s) thereof.

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.

HQL_27713_033116



EVERY SHAREHOLDER’S VOTE IS IMPORTANT

EASY VOTING OPTIONS:

VOTE ON THE INTERNET

Log on to:

www.proxy-direct.com

or scan the QR code

Follow the on-screen instructions

available 24 hours

VOTE BY PHONE

Call 1-800-337-3503

Follow the recorded instructions

available 24 hours

VOTE BY MAIL

Vote, sign and date this Proxy

Card and return in the

postage-paid envelope

VOTE IN PERSON

Attend Shareholder Meeting

100 Federal Street, 19th Floor

Boston, MA 02110

on June 14, 2016

at 10:00 A.M. Eastern Time

Please detach at perforation before mailing.

PROXY

TEKLA HEALTHCARE OPPORTUNITIES FUND

PROXY

JOINT ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD JUNE 14, 2016

This Proxy is Being Solicited on Behalf of the Board of Trustees. The undersigned hereby appoints Daniel R. Omstead, Ph.D., Oleg M. Pohotsky and Michael W. Bonney and each of them, proxies of the undersigned, with full powers of substitution, to vote at the Joint Annual Meeting of Shareholders of TEKLA HEALTHCARE OPPORTUNITIES FUND (the “Fund”) to be held on June 14, 2016 at 10:00 a.m., at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110, and at any adjournment(s) or postponement(s) thereof, all the shares of the Fund outstanding in the name of the undersigned as follows on the reverse of this card.

THIS PROXY WILL BE VOTED AS SPECIFIED.  IF NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR ALL PROPOSALS.

VOTE VIA THE INTERNET:  www.proxy-direct.com

VOTE VIA THE TELEPHONE:  1-800-337-3503

Note:  Please sign this proxy exactly as your name appears on the books of the Fund.  Joint owners should each sign personally.  Trustees and other fiduciaries should indicate the capacity in which they sign, and where more than one name appears, a majority must sign.  If a corporation, this signature should be that of an authorized officer who should state his or her title.

Signature

Signature (if held jointly)

Date

THQ_27713_033116

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.



EVERY SHAREHOLDER’S VOTE IS IMPORTANT

Important Notice Regarding the Availability of Proxy Materials for the

Joint Annual Shareholder Meeting to Be Held on June 14, 2016.

The Joint Proxy Statement and Proxy Card for this meeting are available at:

https://www.proxy-direct.com/TKL-27713

IF YOU VOTE ON THE INTERNET OR BY TELEPHONE,

YOU NEED NOT RETURN THIS PROXY CARD

Please detach at perforation before mailing.

The Board of Trustees recommends a vote FOR the nominees listed and FOR Proposal 2.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK.  Example: 

1.

The election of three Class B Trustees:

FOR
ALL

WITHHOLD
ALL

FOR ALL
EXCEPT

01.   Rakesh K. Jain, Ph.D.     02.   Daniel R. Omstead, Ph.D.     03.   Lucinda H. Stebbins, CPA

o

o

o

INSTRUCTIONS:  To withhold authority to vote for any individual nominee(s), mark the box “FOR ALL EXCEPT” and write the nominee’s number on the line provided below.

FOR

AGAINST

ABSTAIN

2.

The ratification or rejection of the selection of Deloitte & Touche LLP as the independent registered public accountants of the Fund for the fiscal year ending September 30, 2016.

o

o

o

3.

Not Applicable

4.

Not Applicable

5A.

Not Applicable

5B.

Not Applicable

5C.

Not Applicable

6.

The transaction of such other business as may properly come before the Annual Meeting and any adjournment(s) or postponement(s) thereof.

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.

THQ_27713_033116



EVERY SHAREHOLDER’S VOTE IS IMPORTANT

EASY VOTING OPTIONS:

VOTE ON THE INTERNET

Log on to:

www.proxy-direct.com

or scan the QR code

Follow the on-screen instructions

available 24 hours

VOTE BY PHONE

Call 1-800-337-3503

Follow the recorded instructions

available 24 hours

VOTE BY MAIL

Vote, sign and date this Proxy

Card and return in the

postage-paid envelope

VOTE IN PERSON

Attend Shareholder Meeting

100 Federal Street, 19th Floor

Boston, MA 02110

on June 14, 2016

at 10:00 A.M. Eastern Time

Please detach at perforation before mailing.

PROXY

TEKLA WORLD HEALTHCARE FUND

PROXY

JOINT ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD JUNE 14, 2016

This Proxy is Being Solicited on Behalf of the Board of Trustees. The undersigned hereby appoints Daniel R. Omstead, Ph.D., Oleg M. Pohotsky and Michael W. Bonney and each of them, proxies of the undersigned, with full powers of substitution, to vote at the Joint Annual Meeting of Shareholders of TEKLA WORLD HEALTHCARE FUND (the “Fund”) to be held on June 14, 2016 at 10:00 a.m., at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110, and at any adjournment(s) or postponement(s) thereof, all the shares of the Fund outstanding in the name of the undersigned as follows on the reverse of this card.

THIS PROXY WILL BE VOTED AS SPECIFIED.  IF NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR ALL PROPOSALS.

VOTE VIA THE INTERNET:  www.proxy-direct.com

VOTE VIA THE TELEPHONE:  1-800-337-3503

Note:  Please sign this proxy exactly as your name appears on the books of the Fund.  Joint owners should each sign personally.  Trustees and other fiduciaries should indicate the capacity in which they sign, and where more than one name appears, a majority must sign.  If a corporation, this signature should be that of an authorized officer who should state his or her title.

Signature

Signature (if held jointly)

Date

THW_27713_033116

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.



EVERY SHAREHOLDER’S VOTE IS IMPORTANT

Important Notice Regarding the Availability of Proxy Materials for the

Joint Annual Shareholder Meeting to Be Held on June 14, 2016.

The Joint Proxy Statement and Proxy Card for this meeting are available at:

https://www.proxy-direct.com/TKL-27713

IF YOU VOTE ON THE INTERNET OR BY TELEPHONE,

YOU NEED NOT RETURN THIS PROXY CARD

Please detach at perforation before mailing.

The Board of Trustees recommends a vote FOR the nominees listed and FOR Proposal 2.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK.  Example: 

1.

The election of two Class A Trustees:

FOR
ALL

WITHHOLD
ALL

FOR ALL
EXCEPT

01.     Oleg M. Pohotsky         02.     William S. Reardon, CPA

o

o

o

INSTRUCTIONS:  To withhold authority to vote for any individual nominee(s), mark the box “FOR ALL EXCEPT” and write the nominee’s number on the line provided below.

FOR

AGAINST

ABSTAIN

2.

The ratification or rejection of the selection of Deloitte & Touche LLP as the independent registered public accountants of the Fund for the fiscal year ending September 30, 2016.

o

o

o

3.

Not Applicable

4.

Not Applicable

5A.

Not Applicable

5B.

Not Applicable

5C.

Not Applicable

6.

The transaction of such other business as may properly come before the Annual Meeting and any adjournment(s) or postponement(s) thereof.

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.

THW_27713_033116